Page last updated: 2024-12-04

menthol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(+-)-menthol : A racemate comprising equimolar amounts of (+)- and (-)-menthol. Both (+-)- and (-)-menthol are used to relieve symptoms of conditions such as bronchitis and sinusitis. When applied to the skin, menthol dilates the blood vessels, giving a sensation of coldness followed by an analgesic effect that relieves itching. It is therefore used in creams and ointments for the relief of pruritis and urticaria. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

(-)-menthol : A p-menthan-3-ol which has (1R,2S,5R)-stereochemistry. It is the most common naturally occurring enantiomer. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Menthol: A monoterpene cyclohexanol produced from mint oils. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16666
CHEMBL ID470670
CHEBI ID15409
SCHEMBL ID4613
MeSH IDM0013417
PubMed CID1254
CHEMBL ID256087
CHEBI ID25187
SCHEMBL ID4612
MeSH IDM0013417

Synonyms (357)

Synonym
(1r,2s,5s)-2-isopropyl-5-methyl-cyclohexanol
gtpl2430
nsc-2603
menthacamphor
menthol,3,trans-1,4-
cyclohexanol, (1.alpha.,2.beta.,5.alpha.)-
menthomenthol
wln: l6tj ay1&1 bq d1
menthol, (1r,3r,4s)-(-)-
nsc2603 ,
nci-c50000
peppermint camphor
cyclohexanol, 2-isopropyl-5-methyl-
CHEBI:15409 ,
(1alpha,2beta,5alpha)-5-methyl-2(1-methylethyl)cyclohexanol
levomentholum
levomenthol
(1r,3r,4s)-(-)-menthol
(1r-(1-alpha,2-beta,5-alpha))-5-methyl-2-(1-methylethyl)cyclohexanol
(-)-(1r,3r,4s)-menthol
(1r,2s,5r)-5-methyl-2-(propan-2-yl)cyclohexan-1-ol
levomentol
cyclohexanol, 5-methyl-2-(1-methylethyl)-, [1r-(1.alpha.,2.beta.,5.alpha.)]-
KBIO1_000820
DIVK1C_000820
SDCCGMLS-0066659.P001
(1r,2s,5r)-5-methyl-2-(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1r-(1alpha,2beta,5alpha))-
cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1r,3r,4s)-
levomenthol [inn:ban]
einecs 218-690-9
(-)-trans-p-menthan-cis-ol
d-(-)-menthol
levomentholum [inn-latin]
hsdb 5662
nsc 62788
(1r,2s,5r)-2-isopropyl-5-methylcyclohexanol
(-)-menthyl alcohol
ccris 3728
l-menthol (natural)
ai3-52408
menthol, l-
(l)-menthol
(1r)-(-)-menthol
(1r,2s,5r)-5-methyl-2-propan-2-yl-cyclohexan-1-ol
menthol,3r,4s)-(-)-
nsc62788
nsc-62788
wln: l6tj ay1&1 dq d1 -l
u.s.p. menthol
(r)-(-)-menthol
l-(-)-menthol
cyclohexanol, [1r-(1.alpha.,2.beta.,5.alpha.)]-
l-menthol (jp17)
l-menthol (tn)
D00064
5-methyl-2-(1-methylethyl)cyclohexanol, (1alpha,2beta,5alpha)-
d,l-menthol
menthol racemic
menthol (van)
headache crystals
einecs 201-939-0
brn 3194263
racementol [inn-spanish]
SPECTRUM_000305
menthol natural
racementhol [inn:ban]
brn 1902288
ccris 4666
menthol racemique [french]
(+-)-menthol
racementholum [inn-latin]
cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1alpha,2beta,5alpha)-
racementhol
menthol natural, brazilian
tra-kill tracheal mite killer
(+-)-(1r*,3r*,4s*)-menthol
einecs 239-388-3
ccris 375
cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1r,2s,5r)-rel-
IDI1_000820
l-menthol
2216-51-5
(-)-menthol
C00400
(1r,2s,5r)-(-)-menthol, reagentplus(r), 99%
l-menthol, >=99%, fcc, fg
(1r,2s,5r)-(-)-menthol, >=99%, sublimed
l-menthol, natural, >=99%, fcc, fg
DB00825
NCGC00164247-01
KBIOSS_000785
KBIO2_005921
KBIO2_003353
KBIO2_000785
KBIO3_002562
SPECTRUM3_001561
SPECTRUM2_000855
NINDS_000820
SPBIO_000869
SPECTRUM1503134
BSPBIO_003062
cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1r,2s,5r)-
SPECTRUM5_001060
NCGC00164247-02
(-)-menthol, puriss., meets analytical specification of ph. eur., bp, usp, 98.0-102.0%
LMPR0102090001
HMS2092L14
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
inchi=1/c10h20o/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11h,4-6h2,1-3h3/t8-,9+,10-/m1/s1
noolisfmxdjskh-kxucptdwsa-
smr001306785
MLS002207256
(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexan-1-ol
HMS502I22
CHEMBL470670 ,
(-)-p-menthan-3-ol
M0545 ,
HMS1922G13
bdbm50318482
A843308
(1r,2r,5s)-2-isopropyl-5-methyl-cyclohexanol
NCGC00164247-03
racementholum
ys08xha860 ,
2-06-00-00052 (beilstein handbook reference)
ec 201-939-0
4-06-00-00151 (beilstein handbook reference)
menthol racemique
racementol
unii-ys08xha860
thymomenthol
bz1r15mtk7 ,
ec 218-690-9
unii-bz1r15mtk7
tox21_302999
cas-89-78-1
dtxcid802180
dtxsid1022180 ,
cas-2216-51-5
tox21_303028
dtxsid1020805 ,
NCGC00256525-01
NCGC00256561-01
dtxcid101305276
tox21_111620
tox21_201823
NCGC00260156-01
tox21_201919
NCGC00259468-01
tox21_202608
NCGC00259372-01
nsc-758395
nsc758395
pharmakon1600-01503134
S4714
CCG-40300
i-menthol
levomenthol [who-dd]
menthol [mi]
npo-11
fema no. 2665, (-)-
levomenthol [inn]
(-)-trans-p-methan-cis-3-ol
l-mentholum
levomenthol [ii]
(1r,2s,5r)-2-isopropyl-5-methylcyclohexan-1-ol
l-menthol [jan]
1r-menthol
levomenthol [ep monograph]
levomenthol [hsdb]
cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1r-(1.alpha.,2.beta.,5.alpha.))-
(1r,2s,5r)-rel-5-methyl-2-(1-methylethyl)cyclohexanol
dl-menthol [jan]
menthol racemate [mi]
racementhol [hsdb]
racementhol [inn]
(+/-)-(1r*,3r*,4s*)-menthol
menthol, (+/-)-
fema no. 2665, (+/-)-
SCHEMBL4613
1 -menthol
(1r, 2s, 5r)-5-methyl-2-(1-methylethyl)cyclohexyl alcohol
1-menthol
(1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanol
(1r, 2s, 5r-)-(-)-menthol
AKOS016842647
Q-201316
menthol(-)
BS-3863
(1r,2s,5r)-rel-2-isopropyl-5-methylcyclohexanol
(1r-(1-.alpha.,2-.beta.,5-.alpha.))-5-methyl-2-(1-methylethyl)cyclohexanol
2-isopropyl-5-methylcyclohexanol-, (1r,2s,5r)- #
AB00052320_02
SR-05000001936-2
sr-05000001936
(-)-menthol, analytical standard
menthol, united states pharmacopeia (usp) reference standard
(-)-menthol, primary pharmaceutical reference standard
SR-05000001936-1
l-menthol, pharmaceutical secondary standard; certified reference material
(1r,2s,5r)-(-)-menthol, vetec(tm) reagent grade, 98%
(-)-menthol, usp, 97%
levomenthol; (-)-menthol
SBI-0051777.P002
(1r,2s,5r)-(-)-menthol, synthetic pellets
Q407418
l-menthol|levomenthol|menthomenthol|menthacamphor
rel-(1r,2s,5r)-2-isopropyl-5-methylcyclohexanol
114376-98-6
HMS3885J18
D70313
water-soluble menthol
menthol (racemic) 100 microg/ml in methanol
S5868
EN300-92163
l-menthol natural
Z1255438640
menthol
5-methyl-2-(1-methylethyl)cyclohexanol
cyclohexanol, 5-methyl-2-(1-methylethyl)-, [1s-(1.alpha.,2.beta.,5.beta.)]-
cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1.alpha.,2.alpha.,5.beta.)-
(1s, 2s, 5r)-(+)-neomenthol
cyclohexanol, 5-methyl-2-(1-methylethyl)-, [1r-(1.alpha.,2.alpha.,5.beta.)]-
cyclohexanol, 5-methyl-2-(1-methylethyl)-, [1s-(1.alpha.,2.alpha.,5.beta.)]-
robitussin cough drops
einecs 216-074-4
2-isopropyl-5-methylcyclohexanol
ccris 9231
ai3-08161
caswell no. 540
epa pesticide chemical code 051601
menthyl alcohol
dl-menthol
fema no. 2665
menthol, dl-
hsdb 593
cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1.alpha.,2.beta.,5.alpha.)-(.+/-.)-
menthol, (.+/-.)-
cyclohexanol, 5-methyl-2-(1-methylethyl)-
menthol (usp)
fisherman's friend lozenges (tn)
D04849
D04918
1490-04-6
dl-menthol (jp17)
1-methyl-4-isopropyl-3-hydroxycyclohexane
3-p-menthol
4-isopropyl-1-methylcyclohexan-3-ol
dl-menthol, >=95%, fcc, fg
menthol, 99%
NCGC00159382-02
NCGC00159382-03
(+/-)-menthol, racemic, >=98.0% (gc)
meggezone
menthol racemate
chebi:25187 ,
CHEMBL256087
15356-70-4
5-methyl-2-(1-methylethyl)-cyclohexanol
3-hydroxy-p-menthane
2-isopropyl-5-methylcyclohexan-1-ol
1-methyl-4-isopropyl-3-cyclohexanol
FT-0695078
FT-0695077
FT-0695079
M0321 ,
(+/-)-p-menthan-3-ol
5-methyl-2-propan-2-ylcyclohexan-1-ol
STK802468
5-methyl-2-(propan-2-yl)cyclohexanol
AKOS000119740
A808833
2-isopropyl-5-methyl-cyclohexanol
A809442
(2r)-2-isopropyl-5-methyl-cyclohexanol
NCGC00159382-05
NCGC00159382-06
NCGC00159382-04
ec 216-074-4
mentholum
fisherman's friend lozenges
menthol [usp]
therapeutic mineral ice
3623-52-7
mineral ice
cas-1490-04-6
tox21_303464
dtxsid8029650 ,
dtxcid30805
NCGC00257403-01
tox21_200010
NCGC00257564-01
BBL009325
FT-0600039
FT-0625488
FT-0604426
FT-0604430
FT-0604399
FT-0620596
AM81446
SCHEMBL4612
(1s,2r,5r)-2-isopropyl-5-methyl-cyclohexanol
J-500418
(-)menthol
(-) menthol
AKOS016843634
2-isopropyl-5-methylcyclohexanol #
menthol-plus it inverted exclamation markas 3 isomers-1,2,6,6-d4
2-isopropy-5-methylcyclohexanol-1,2,6,6-d4
mfcd00062979
mfcd00001484
mfcd00062983
( inverted exclamation marka)-menthol
unii-l7t10eip3a
menthol, saj special grade, >=98.0%
dl-menthol, analytical standard
menthol, puriss., 99.0%
bdbm248162
SY010603
CS-M3737
(1r,2r,5r)-isomenthol
HY-75161
HY-N1369
5-methyl-2-(propan-2-yl)cyclohexan-1-ol
VS-02042
(1r,2r,5r)-5-methyl-2-(propan-2-yl)cyclohexan-1-ol
Q27109870
menthol 1000 microg/ml in acetonitrile
levomenthol; d-(-)-menthol; (-)-menthol
BCP27552
l-menthol; (-)-menthol; levomenthol; menthomenthol;2-isopropyl-5-methyl-cyclohexanol;menthol
BCP31841
SY004225
AMY3077
HMS3744K19
SB35230
CS-0016777
SB44857
SB44308
menthol crystals; 15356-70-4
E80543
menthol, unspecified form
L7T10EIP3A ,
levomenthol or racementhol
menthol, unspecified
salonpas component menthol
menthol component of salonpas
levorotatory-menthol or racemic-menthol
bohenao
menthol (mart.)
menthol (ii)
menthol (usp monograph)
EN300-19914
SY073200
SY157908

Research Excerpts

Overview

L-Menthol is an effective and safe alternative antiperistaltic medication for EGD in elderly patients with contraindication to HBB. Menthol evokes cold sensations by activating TRPM8 channels in peripheral sensory receptors.

ExcerptReferenceRelevance
"Menthol is a natural compound that evokes cold sensations by activating TRPM8 channels in peripheral sensory receptors. "( Menthol exerts TRPM8-independent antiepileptic effects in prefrontal cortex pyramidal neurons.
Spyrka, A; Szulczyk, B, 2022
)
3.61
"L-Menthol is an effective and safe alternative antiperistaltic medication for EGD in elderly patients with contraindication to HBB."( Antiperistaltic effect and safety of L-menthol for esophagogastroduodenoscopy in the elderly with contraindication to hyoscine-N-butylbromide.
Chen, LK; Chen, PH; Hou, MC; Huang, YH; Lin, MH; Peng, LN; Yang, TC, 2022
)
1.55
"Menthol is a naturally occurring phytochemical, with the formula C10H20O."( Do products containing menthol exacerbate allergic rhinitis? A narrative review.
Azizli, E; Dilber, M, 2022
)
1.75
"Menthol is an anti-inflammatory drug."( Menthol application on healthy and inflamed goat udders changes antimicrobial components in milk.
Isobe, N; Kobayashi, K; Nii, T; Ohno, R; Suzuki, N; Tsugami, Y,
)
2.3
"l-Menthol is a cyclic monoterpene working also as a medical cooling agent."( Factors explaining individual differences in the oral perception of capsaicin, l-menthol, and aluminum ammonium sulfate.
Aisala, H; Hoppu, U; Puputti, S; Roukka, S; Sandell, M; Seppä, L, 2023
)
1.69
"Menthol is a small bioactive compound able to cause several physiological changes and has multiple molecular targets. "( Menthol causes mitochondrial Ca
Acharya, TK; Chang, YT; Goswami, C; Halder, RR; Kumar, S; Mahapatra, P, 2023
)
3.8
"Menthol is a natural compound of low toxicity, used in industries such as cosmetics and gastronomy and generally recognized as safe by the Food and Drug Administration."( Anti-echinococcal activity of menthol and a novel prodrug, menthol-pentanol, against Echinococcus multilocularis.
Clemente, CM; Elissondo, MC; Elissondo, N; Fabbri, J; Gambino, G; Hergert, LY; Palma, SD; Ravetti, S, 2020
)
1.57
"Menthol is a widely used tobacco constituent that has shown to enhance nicotine's reinforcing effects."( Menthol blunts the interoceptive discriminative stimulus effects of nicotine in female but not male rats.
Bevins, RA; Finkner, A; Huynh, YW; Kuck, JD; Raimondi, A; Selleck, C, 2020
)
3.44
"Menthol is an aromatic compound with high antiinflammatory activity. "( The effect of menthol on acute experimental colitis in rats.
Bozorgi, H; Ghasemi-Pirbaluti, M; Motaghi, E, 2017
)
2.26
"Menthol is a commonly used flavorant in tobacco and e-cigarettes, and could contribute to nicotine sensitivity. "( Menthol disrupts nicotine's psychostimulant properties in an age and sex-dependent manner in C57BL/6J mice.
Fait, BW; Jatlow, P; Jordt, SE; Mineur, YS; Mose, TN; Picciotto, MR; Thompson, DC, 2017
)
3.34
"Menthol is a selective transient receptor potential melastatin 8 (TRPM8) channel agonist that induces cutaneous vasodilation in young, normotensive men and women through nitric oxide synthase (NOS)-, endothelium-derived hyperpolarizing factor (EDHF)-, and sensory nerve-mediated mechanisms. "( Menthol-Induced Cutaneous Vasodilation Is Preserved in Essential Hypertensive Men and Women.
Alexander, LM; Craighead, DH, 2017
)
3.34
"Menthol is a selective activator of transient receptor potential melastatin-8 (TRPM8) channels and is also a vasoactive compound. "( The role and mechanism of action of menthol in topical analgesic products.
LeQuang, JA; Pergolizzi, JV; Raffa, RB; Taylor, R, 2018
)
2.2
"Menthol is a compound of plant origin and has recently been used to aid exercise performance in hot, humid environments. "( Menthol Use for Performance in Hot Environments.
Flood, TR, 2018
)
3.37
"Menthol is a natural compound, of which the known effects on human physiology are manifold (a feeling of freshness, decongestant, bowel antispasmodic). "( [Menthol in the control of bladder activity: A review].
Amarenco, G; Charlanes, A; Chesnel, C; Kervinio, F; Le Breton, F; Miget, G; Moutounaïck, M; Teng, M, 2018
)
2.83
"Menthol is a significant flavoring additive in tobacco products. "( Menthol facilitates dopamine-releasing effect of nicotine in rat nucleus accumbens.
Biswas, L; Harrison, E; Liu, X; Tran, T; Zhang, M, 2018
)
3.37
"Menthol is an organic compound with non-thermal cooling properties that has been shown to relieve thermal strain associated with exercise in the heat; however, its effects on performance have not been systematically analysed. "( The effects of menthol on exercise performance and thermal sensation: A meta-analysis.
Jeffries, O; Waldron, M, 2019
)
2.31
"Menthol is an often used skin penetration enhancer because of its high efficiency and relative safety, but the mechanism how it works has not been fully understood up to date. "( Penetration enhancement of menthol on quercetin through skin: insights from atomistic simulation.
Huang, C; Meng, F; Tang, L; Wang, H, 2019
)
2.25
"Menthol (l-menthol) is a naturally-occurring cold receptor agonist commonly used to provide symptomatic relief for upper airway congestion. "( The effect of inhaled menthol on upper airway resistance in humans: a randomized controlled crossover study.
Driver, H; Fitzpatrick, M; Parker, C; Pereira, EJ; Sim, L,
)
1.89
"Menthol is a common compound in pharmaceutical and commercial products and a popular additive to cigarettes. "( Menthol binding and inhibition of α7-nicotinic acetylcholine receptors.
Al Kury, L; Ashoor, A; Howarth, FC; Kabbani, N; Mahgoub, M; Nordman, JC; Oz, M; Sadek, B; Shehu, A; Shuba, Y; Veltri, D; Yang, KH, 2013
)
3.28
"Menthol is a cyclic monoterpene alcohol which possesses well-known cooling characteristics and a residual minty smell of the oil remnants from which it was obtained. "( Menthol: a simple monoterpene with remarkable biological properties.
Kamatou, GP; Lawrence, BM; Vermaak, I; Viljoen, AM, 2013
)
3.28
"Menthol is a widely used penetration enhancer in clinical medicine due to its high efficiency and relative safety. "( Interaction of menthol with mixed-lipid bilayer of stratum corneum: A coarse-grained simulation study.
Dai, X; Qiao, Y; Shi, X; Wan, G; Yin, Q, 2015
)
2.21
"Menthol is an organic compound with diverse medicinal and commercial applications, and is made either synthetically or through extraction from mint oils. "( Phylogenetic Analysis of Selected Menthol-Producing Species Belonging to the Lamiaceae Family.
Bagherian, A; Kazemi Oskuee, R; Masoud Khoi, MJ; Mirzaei, H; Mirzaei, M; Reza Jaafari, M; Reza Mirzaei, H; Sahebkar, A; Salehi, R, 2015
)
2.14
"Menthol is an effective anesthetic for handling of juvenile fat snook at different salinities."( Salinity does not alter the effectiveness of menthol as an anesthetic and sedative during the handling and transport of juvenile fat snook (Centropomus parallelus).
Carvalho, MA; Gomes, LC; Sepulchro, LC, 2016
)
1.42
"Menthol is a significant flavoring additive in tobacco products."( Enhancing effect of menthol on nicotine self-administration in rats.
Avusula, R; Biswas, L; Gong, Y; Harrison, E; Lage, J; Lee, J; Liu, X; Rousselle, T; Zhang, M, 2016
)
1.48
"Menthol is a widely used penetration enhancer in clinical medicine due to its high efficiency and relative safety. "( A Multiscale Study on the Penetration Enhancement Mechanism of Menthol to Osthole.
Dai, X; Guo, S; Qiao, Y; Shi, X; Wan, G; Wang, R; Wu, Z; Yang, S, 2016
)
2.12
"Menthol is a naturally occurring compound, which has three chiral centers that define eight possible optically actives stereoisomers. "( Stereo-selective activity of menthol on GABA(A) receptor.
Corvalán, NA; García, DA; Zygadlo, JA, 2009
)
2.09
"Menthol is a natural herbal compound. "( Impact of menthol inhalation on nasal mucosal temperature and nasal patency.
Konstantinidis, I; Lindemann, J; Scheithauer, MO; Tsakiropoulou, E; Wiesmiller, KM,
)
1.98
"Menthol is a widely-used cooling and flavoring agent derived from mint leaves. "( A-type GABA receptor as a central target of TRPM8 agonist menthol.
Fei, D; Gong, N; Hu, XL; Jiang, P; Xiong, ZQ; Xu, L; Xu, TL; Zhang, XB, 2008
)
2.03
"Menthol is a commonly used additive in tobacco products. "( Chronic menthol attenuates the effect of nicotine on body temperature in adolescent rats.
Anand, R; LaHoste, GJ; Ruskin, DN, 2008
)
2.22
"Menthol is a controversial cigarette additive because its physiologic or pharmacologic effects may possibly increase the risk for cancer and its targeted market is the Black community. "( Effects of menthol on tobacco smoke exposure, nicotine dependence, and NNAL glucuronidation.
Chen, G; Knipe, A; Lazarus, P; Muscat, JE; Richie, JP; Stellman, SD, 2009
)
2.19
"Menthol is a flavored tobacco additive claimed to mask the bitter taste and reduce the harshness of cigarette smoke. "( Effect of menthol on the penetration of tobacco carcinogens and nicotine across porcine oral mucosa ex vivo.
Mantz, MJ; Squier, CA; Wertz, PW, 2010
)
2.21
"Menthol cigarettes are a common choice of cigarettes among young smokers that contribute to the addictive potential of cigarette smoking."( Menthol cigarettes contribute to the appeal and addiction potential of smoking for youth.
Hersey, JC; Homsi, G; Nonnemaker, JM, 2010
)
3.25
"Menthol is a monocyclic terpene alcohol that occurs naturally in plants of the Mentha species lacking anti-S."( Menthol diminishes Staphylococcus aureus virulence-associated extracellular proteins expression.
Deng, X; Deng, Y; Dong, J; Feng, H; Li, H; Luo, M; Qiu, J; Wang, J; Wang, X, 2011
)
2.53
"Menthol is a naturally occurring cyclic monoterpene used in oral hygiene products, confectionary, pharmaceuticals, cosmetics, pesticides, and as a flavoring agent. "( Proteomics indicates modulation of tubulin polymerization by L-menthol inhibiting human epithelial colorectal adenocarcinoma cell proliferation.
Darokar, MP; Dwivedi, UN; Faridi, U; Shasany, AK; Shukla, AK; Shukla, RK; Sisodia, BS, 2011
)
2.05
"Menthol is a prominent design feature used by cigarette manufacturers to attract and retain new, younger smokers."( Menthol cigarettes and smoking initiation: a tobacco industry perspective.
Klausner, K, 2011
)
3.25
"Menthol is an important additive in most tobacco products and is an identifying characteristic of many brands. "( Direct disease-inducing effects of menthol through the eyes of tobacco companies.
Glantz, SA; Salgado, MV, 2011
)
2.09
"Menthol is a cigarette flavoring that makes smoking more appealing to smokers. "( US attitudes about banning menthol in cigarettes: results from a nationally representative survey.
Dempsey, JH; Klein, JD; McMillen, RC; Pearson, JL; Tanski, SE; Vallone, DM; Winickoff, JP, 2011
)
2.11
"Menthol is a natural compound of plant origin known to produce cool sensation via the activation of the TRPM8 channel. "( Menthol pain relief through cumulative inactivation of voltage-gated sodium channels.
Delmas, P; Gabriac, M; Gaudioso, C; Hao, J; Martin-Eauclaire, MF, 2012
)
3.26
"Menthol is a naturally occurring compound, which has been widely used in cosmetics and pharmaceutical products, and also as flavoring in food."( Menthol inhibits the proliferation and motility of prostate cancer DU145 cells.
Chen, D; Meng, Z; Wang, X; Wang, Y; Yang, Z; Zhu, G, 2012
)
2.54
"(-)-Menthol is a widely used flavoring ingredient present in mouthwash, foods, toothpaste, and cigarettes; yet, the pharmacological effects of menthol have not been widely studied. "( Inhibition of human liver microsomal (S)-nicotine oxidation by (-)-menthol and analogues.
Cashman, JR; Fandrick, K; MacDougall, JM; Serafin, SV; Zhang, X, 2003
)
1.11
"Menthol is a cooling compound derived from mint leaves and is extensively used as a flavoring chemical. "( High-throughput random mutagenesis screen reveals TRPM8 residues specifically required for activation by menthol.
Bandell, M; Dubin, AE; Hwang, SW; Mathur, J; Orth, A; Patapoutian, A; Petrus, MJ, 2006
)
1.99
"Menthol is a prominent additive in many tobacco products. "( Menthol and nicotine oppositely modulate body temperature in the rat.
Anand, R; LaHoste, GJ; Ruskin, DN, 2007
)
3.23
"Menthol is a naturally occurring cyclic terpene alcohol of plant origin, which has been used since antiquity for medicinal purposes. "( Menthol: a refreshing look at this ancient compound.
Ishiuji, Y; Patel, T; Yosipovitch, G, 2007
)
3.23
"Menthol is an important cigarette additive that may help explain why some groups have lower quit rates and more smoking-caused disease."( Higher nicotine and carbon monoxide levels in menthol cigarette smokers with and without schizophrenia.
Benowitz, NL; Foulds, J; Gandhi, KK; Steinberg, ML; Williams, JM; Ziedonis, DM, 2007
)
1.32
"Menthol is a commonly used ingredient in many over the counter cough remedies, but there is little objective evidence as to its efficacy."( Effect of inhaled menthol on citric acid induced cough in normal subjects.
Grattan, TJ; Higgins, KS; Marshall, AE; Morice, AH, 1994
)
2.07
"Menthol is an effective antitussive agent in an evoked cough model."( Effect of inhaled menthol on citric acid induced cough in normal subjects.
Grattan, TJ; Higgins, KS; Marshall, AE; Morice, AH, 1994
)
2.07
"Menthol is a common pharmaceutical, food and tobacco flavouring ingredient used for its minty characteristics and cooling effects. "( 13-week inhalation toxicity study of menthol cigarette smoke.
Aranyi, C; Brennecke, LH; Dozier, MM; Gaworski, CL; Gerhart, JM; Heck, JD; Rajendran, N, 1997
)
2.01
"Menthol is a highly valued monoterpene produced by Japanese mint (Mentha arvensis) as a natural product with wide applications in cosmetics, confectionery, flavours, beverages and therapeutics. "( Positive correlation between menthol content and in vitro menthol tolerance in Mentha arvensis L. cultivars.
Dhawan, S; Khanuja, SP; Kumar, S; Shasany, AK, 2000
)
2.04
"Menthol is a major constituent of peppermint oil and is approximately twice as potent as peppermint oil as an inhibitor of K+ depolarization-induced and electrically stimulated responses in ileum and electrically stimulated atrial and papillary muscles."( The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations.
Ferrante, J; Hawthorn, M; Luchowski, E; Rutledge, A; Triggle, DJ; Wei, XY, 1988
)
1.28

Effects

Menthol has a bimodal action on TRPA1, but inhibition may have an analgesic effect. Menthol glucuronide is detectable in urine and serum following menthol use.

Menthol has no effect on objective measures of flow but significantly increases the perception of nasal patency. Menthol exposed BLES has the highest minimum surface tensions across all 20 compression/expansion cycles.

ExcerptReferenceRelevance
"Menthol has a bimodal action on TRPA1, but inhibition may have an analgesic effect."( Modulation of transient receptor potential (TRP) channels by plant derived substances used in over-the-counter cough and cold remedies.
Morice, AH; Sadofsky, LR; Stinson, RJ, 2023
)
1.63
"Menthol has an antimicrobial effect as an active ingredient in Mentha longifolia."( Detection of adeABC efllux pump encoding genes and antimicrobial effect of Mentha longifolia and Menthol on MICs of imipenem and ciprofloxacin in clinical isolates of Acinetobacter baumannii.
Alikhani, MY; Mahmoudi, H; Mohamadi Bardebari, A; Moradkhani, S; Shokoohizadeh, L; Zare Fahim, N, 2020
)
1.5
"Menthol has a half life of 3-6 h and is rapidly metabolized to menthol glucuronide which is detectable in urine and serum following menthol use."( Determination of Menthol in Plasma and Urine by Gas Chromatography/Mass Spectrometry (GC/MS).
Frazee, C; Garg, U; Kearns, G; Peat, J, 2016
)
1.5
"Menthol has a fast-acting, short-lived effect of reducing blood flow. "( Comparison of the effects of ice and 3.5% menthol gel on blood flow and muscle strength of the lower arm.
Jacks, DE; Kaufman, JS; Mink, AM; Topp, R; Winchester, L, 2011
)
2.08
"Menthol has a selective potentiating action on cutaneous cold receptors and shifts the temperature response curve of the bladder cooling reflex towards higher temperatures in animal experiments."( Evidence of cold receptors in the human bladder: effect of menthol on the bladder cooling reflex.
Geirsson, G, 1993
)
1.25
"Menthol use has increased among U.S. "( Menthol Cigarette Use Among Adults Who Smoke Cigarettes, 2008-2020: Rapid Growth and Widening Inequities in the United States.
Delnevo, CD; Ganz, O; Goodwin, RD; Smith, PH; Weinberger, AH; Wyka, K, 2023
)
3.8
"Menthol exposed BLES has the highest minimum surface tensions across all 20 compression/expansion cycles."( E-cigarette aerosol exposure of pulmonary surfactant impairs its surface tension reducing function.
Cao, A; Graham, E; McCaig, L; Shui-Kei Lau, G; Tejura, A; Veldhuizen, R; Zuo, YY, 2022
)
1.44
"Menthol has a bimodal action on TRPA1, but inhibition may have an analgesic effect."( Modulation of transient receptor potential (TRP) channels by plant derived substances used in over-the-counter cough and cold remedies.
Morice, AH; Sadofsky, LR; Stinson, RJ, 2023
)
1.63
"Menthol in cigarettes has been shown to play a role in increasing smoking initiation and making it more difficult to quit smoking."( Perceptions of Use Patterns and Health Consequences Associated With Mentholated Cigarettes Among U.S. Adults.
Barton, A; Glasser, AM; Hair, E; Rath, J; Rose, SW; Simard, B; Vallone, D, 2020
)
1.51
"Menthol has an antimicrobial effect as an active ingredient in Mentha longifolia."( Detection of adeABC efllux pump encoding genes and antimicrobial effect of Mentha longifolia and Menthol on MICs of imipenem and ciprofloxacin in clinical isolates of Acinetobacter baumannii.
Alikhani, MY; Mahmoudi, H; Mohamadi Bardebari, A; Moradkhani, S; Shokoohizadeh, L; Zare Fahim, N, 2020
)
1.5
"Menthol has been shown to contribute to the appeal of tobacco products in humans. "( Impact of menthol on nicotine intake and preference in mice: Concentration, sex, and age differences.
Akinola, LS; Bagdas, D; Carper, M; Chen, RY; Damaj, MI; Jackson, A, 2020
)
2.4
"Menthol has been shown to target similar brain regions and neural receptors as nicotine, yet the association between menthol cigarette use and cognitive performance remains unknown."( Differences in Cognitive Task Performance, Reinforcement Enhancement, and Nicotine Dependence Between Menthol and Nonmenthol Cigarette Smokers.
Hitsman, B; Jao, NC; Levin, ED; Simon, MA, 2021
)
2.28
"Menthol has been hypothesized to ease the harshness of cigarette smoke. "( Differences in Subjective Experiences to First Use of Menthol and Nonmenthol Cigarettes in a National Sample of Young Adult Cigarette Smokers.
Cohn, AM; D'Silva, J; Johnson, AL; Villanti, AC, 2018
)
2.17
"Menthol cigarettes have been historically marketed with messages conveying lower harm than other cigarettes. "( Harm Perceptions of Menthol and Nonmenthol Cigarettes Differ by Brand, Race/Ethnicity, and Gender in US Adult Smokers: Results from PATH Wave 1.
Cohn, AM; Curry, L; Debnam, C; Gray, T; Ilakkuvan, V; Lindblom, E; Mayo, A; Mays, D; Perreras, L; Rose, SW; Tercyak, K; Villanti, AC, 2019
)
2.28
"Menthol has been used as a non-opioid pain reliever since ancient times. "( The role and mechanism of action of menthol in topical analgesic products.
LeQuang, JA; Pergolizzi, JV; Raffa, RB; Taylor, R, 2018
)
2.2
"Menthol has been investigated as an internal and external intervention."( Menthol Use for Performance in Hot Environments.
Flood, TR, 2018
)
2.64
"Menthol cigarette use has continued to be a topic of debate among researchers and policy makers, because of its implications for understanding menthol's contribution to nicotine dependence and smoking persistence, as well as its continued use as a prevalent flavoring in tobacco and nicotine products in the United States and internationally. "( Menthol Cigarettes, Tobacco Dependence, and Smoking Persistence: The Need to Examine Enhanced Cognitive Functioning as a Neuropsychological Mechanism.
Hitsman, B; Jao, NC; Matthews, PA; Schnoll, R; Simon, MA; Tan, MM, 2020
)
3.44
"Menthol in cigarettes has been shown to increase regular cigarette smoking and nicotine dependence, and decrease success in smoking cessation. "( Evaluating a Real World Ban on Menthol Cigarettes: An Interrupted Time-Series Analysis of Sales.
Chaiton, M; Nugent, R; Schwartz, R; Shuldiner, J; Tremblay, G, 2020
)
2.29
"Menthol cigarette use has not typically been evaluated as a predictor of smoking cessation outcomes, but emerging evidence suggests that consumption of menthol may make cessation more difficult. "( Menthol cigarette use predicts treatment outcomes of weight-concerned smokers.
O'Malley, SS; Rojewski, AM; Toll, BA, 2014
)
3.29
"Menthol in cigarettes has been examined for its potential to affect smoking dependence, measured primarily as number of cigarettes smoked per day and time to first cigarette after waking; the ability to quit smoking constitutes an additional measure of dependence. "( Evaluating the association between menthol cigarette use and the likelihood of being a former versus current smoker.
Curtin, GM; Fuller, WG; Ogden, MW; Sulsky, SI; Swauger, JE; Van Landingham, C, 2014
)
2.12
"Menthol cigarettes have been found to influence teen smoking; however, less is known about the association between teen use of other flavored tobacco products, such as cigars and dip, and cigarette smoking."( Teen use of flavored tobacco products in new york city.
Farley, SM; Johns, M; Sacks, R; Seoh, H, 2014
)
1.12
"Menthol has historically been used topically to alleviate various pain conditions. "( Anti-hyperalgesic effects of a novel TRPM8 agonist in neuropathic rats: a comparison with topical menthol.
Brice, NL; Dickenson, AH; Gonçalves, L; Hendrick, A; Leveridge, M; Mack, SR; Patel, R, 2014
)
2.06
"Menthol has shown high anticancer activity against various human cancers, but its effect on skin cancer has never been evaluated."( Chemopreventive efficacy of menthol on carcinogen-induced cutaneous carcinoma through inhibition of inflammation and oxidative stress in mice.
Cao, Y; Chen, C; Fan, F; Lin, C; Liu, Z; Lu, Y; Shan, Y; Shen, C; Sun, L; Tao, Y; Wang, A; Wang, S; Wei, Z; Wu, H; Zheng, S; Zhu, P, 2015
)
1.43
"Menthol has a half life of 3-6 h and is rapidly metabolized to menthol glucuronide which is detectable in urine and serum following menthol use."( Determination of Menthol in Plasma and Urine by Gas Chromatography/Mass Spectrometry (GC/MS).
Frazee, C; Garg, U; Kearns, G; Peat, J, 2016
)
1.5
"l-Menthol has been also linked to the activation of the cold-gated ion channel TRPA1."( Chronic l-menthol-induced browning of white adipose tissue hypothesis: A putative therapeutic regime for combating obesity and improving metabolic health.
Andrade, CM; Boguszewski, C; Carrillo, AE; Flouris, AD; Jamurtas, AZ; Kawashita, NH; Koutedakis, Y; Metsios, GS; Nadolnik, L; Sakellariou, P; Svensson, PA; Valente, A, 2016
)
1.39
"Menthol has been suggested in conditions of psoriasis, in addition to its skin-penetration-enhancing effect on drugs."( Efficacy study of vesicular gel containing methotrexate and menthol combination on parakeratotic rat skin model.
Goyal, AK; Kesarla, R; Murthy, RR; Nagle, A, 2011
)
1.33
"Menthol has recently been added to various cooling products that claim to enhance athletic performance. "( The influence of menthol on thermoregulation and perception during exercise in warm, humid conditions.
Gillis, DJ; House, JR; Tipton, MJ, 2010
)
2.14
"Menthol has long been an important flavorant in tobacco products, and both its historical and present uses are topics of increasing debate. "( The stereoisomers of menthol in selected tobacco products. A brief report.
Chen, C; Gareau, KD; Isabelle, LM; Luo, W; Pankow, JF, 2011
)
2.13
"Menthol has been found to be inversely related to smoking cessation among AA, yet little is known about the factors associated with menthol smoking among AA light smokers."( Factors associated with smoking menthol cigarettes among treatment-seeking African American light smokers.
Ahluwalia, JS; Choi, WS; Cox, LS; Faseru, B; Krebill, R; Mayo, MS; Nollen, NL; Okuyemi, KS, 2011
)
1.37
"Menthol has a fast-acting, short-lived effect of reducing blood flow. "( Comparison of the effects of ice and 3.5% menthol gel on blood flow and muscle strength of the lower arm.
Jacks, DE; Kaufman, JS; Mink, AM; Topp, R; Winchester, L, 2011
)
2.08
"Menthol gels have been used with limited empirical support to relieve pain and improve functioning among individual with OA."( The effect of either topical menthol or a placebo on functioning and knee pain among patients with knee OA.
Brosky, JA; Pieschel, D; Topp, R,
)
1.14
"Menthol in cigarettes has been suggested to inhibit metabolism of nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). "( Metabolism of nicotine and 4-(methylnitrosamino)-l-(3-pyridyl)-lbutanone (NNK) in menthol and non-menthol cigarette smokers.
Liang, Q; Sarkar, M; Wang, J, 2012
)
2.05
"Menthol has previously been suggested as a model for hypersensitivity, but it has not yet been investigated if different levels of neuropathic pain may influence the effects of menthol or if topical application of menthol may act as a model for hypersensitivity in patients with phantom limb pain."( The effects of menthol on cold allodynia and wind-up-like pain in upper limb amputees with different levels of phantom limb pain.
Arendt-Nielsen, L; Jensen, TS; Nikolajsen, L; Svensson, P; Vase, L, 2013
)
1.46
"Menthol has been shown to affect the pharmacokinetics of other drugs by inducing or inhibiting cytochrome P450 isoenzymes and slowing drug absorption."( Possible warfarin interaction with menthol cough drops.
Kassebaum, PJ; Shaw, DL; Tomich, DJ, 2005
)
1.33
"Menthol therefore has selective effects on noxious cold processing."( Psychophysical study of the effects of topical application of menthol in healthy volunteers.
Attal, N; Bouhassira, D; Hatem, S; Willer, JC, 2006
)
1.3
"Mentholation has little effect on other smoke constituents, and no apparent effect on nicotine absorption, airway patency and smoking initiation, dependency or cessation."( Possible effects on smokers of cigarette mentholation: a review of the evidence relating to key research questions.
Coggins, CR; Lee, PN; Werley, MS, 2007
)
1.33
"Menthol has no effect on objective measures of flow but significantly increases the perception of nasal patency. "( Does inhaling menthol affect nasal patency or cough?
Beardsmore, C; Houghton, T; Kenia, P, 2008
)
2.15
"Menthol has a selective potentiating action on cutaneous cold receptors and shifts the temperature response curve of the bladder cooling reflex towards higher temperatures in animal experiments."( Evidence of cold receptors in the human bladder: effect of menthol on the bladder cooling reflex.
Geirsson, G, 1993
)
1.25
"Menthol and borneolum have been used widely in traditional Chinese medicine for the treatment of nasal obstruction, but the mechanism has been still unknown. "( [The effects of menthol, borneolum and moschus on nasal airflow sensation and nasal resistance].
Dong, Z; Wang, Y; Yang, Z, 1997
)
2.09
"Menthol has been shown to stimulate cold receptors in the mouth and nose."( Role of cold receptors and menthol in thirst, the drive to breathe and arousal.
Eccles, R, 2000
)
1.33

Actions

Menthol plays a dual role in the analgesic and anti-inflammatory drugs. It causes cooling and local anesthetic effects and, being a penetration enhancer, it increases the skin permeation of the drug substances. Menthol levels were lower for non-Hispanic black versus all other adolescents in all study years.

ExcerptReferenceRelevance
"Menthol may increase cigarettes appeal for pregnant women. "( Use and perceptions of menthol versus non-menthol cigarettes among pregnant women.
Borba, K; Jao, NC; Scott-Sheldon, LAJ; Sokol, NA; Stroud, LR; Vergara-Lopez, C,
)
1.88
"Menthol levels were lower for non-Hispanic black versus all other adolescents in all study years."( Recent, national trends in US adolescent use of menthol and non-menthol cigarettes.
Johnson, LD; Leventhal, AM; Miech, RA, 2023
)
1.89
"Menthol may blunt the sensory effects of nicotine."( Menthol preference moderates the relationship between cigarette nicotine content choice and reactions in young adults who smoke infrequently.
Denlinger-Apte, RL; Kozink, R; McClernon, FJ; Rubenstein, D; Scroggs, LB; Sweitzer, MM, 2022
)
2.89
"Menthol may increase nicotine exposure, potentially conferring enhanced acute analgesia and driving greater dependence."( Pain and Menthol Use Are Related to Greater Nicotine Dependence Among Black Adults Who Smoke Cigarettes at Wave 5 (2018-2019) of the Population Assessment of Tobacco and Health (PATH) Study.
Deyo, AG; Ditre, JW; Heckman, BW; Powers, JM; Rubenstein, D; Terry, EL; Zale, EL, 2023
)
2.05
"Menthol promotes the expressions of airway inflammationrelated factors IL-1β and TNF-α possibly by activating mTOR to cause the increase of intracellular Ca"( [Role of mammalian target of rapamycin activation in menthol-induced expressions of airway inflammation-related factors in human bronchial epithelial cells
Chen, H; Li, M, 2019
)
2.21
"Does menthol increase the amount of PM? Due to the exposure to secondhand smoke nearly 900,000 people die each year worldwide."( Particulate matter emissions of different brands of mentholated cigarettes.
Bendels, MHK; Braun, M; Gerharz, J; Groneberg, DA; Klingelhöfer, D; Mueller, R, 2018
)
1.19
"Menthol tended to suppress the self-administration of food pellets."( Enhancing effect of menthol on nicotine self-administration in rats.
Avusula, R; Biswas, L; Gong, Y; Harrison, E; Lage, J; Lee, J; Liu, X; Rousselle, T; Zhang, M, 2016
)
1.48
"Menthol plays a dual role in the analgesic and anti-inflammatory drugs: it causes cooling and local anesthetic effects and, being a penetration enhancer, it increases the skin permeation of the drug substances."( Skin disposition of menthol after its application in the presence of drug substances.
Cal, K, 2008
)
1.39
"Menthol does not inhibit the metabolism of nicotine or NNK. "( Metabolism of nicotine and 4-(methylnitrosamino)-l-(3-pyridyl)-lbutanone (NNK) in menthol and non-menthol cigarette smokers.
Liang, Q; Sarkar, M; Wang, J, 2012
)
2.05
"l-Menthol did not inhibit both carrageenin-induced paw edema of rats and the synthesis of prostaglandin E2 in vitro."( [Antinociceptive effects of counterirritants].
Deguchi, Y; Noda, K; Saita, M; Taniguchi, Y, 1994
)
0.85
"The menthol-induced increase in [Ca2+]i was not affected by verapamil but partially inhibited by low Ca2+ medium in the presence of EGTA."( Effect of menthol on cytosolic Ca2+ levels in canine airway epithelium in culture.
Kondo, M; Konno, K; Takeuchi, S; Tamaoki, J, 1994
)
1.17
"The menthol-induced increase in Isc was not altered by pretreatment of the cells with amiloride, indomethacin, or propranolol but was abolished by diphenylamine-2-carboxylate, furosemide or substitution of Cl with iodide in the medium."( Stimulation by menthol of Cl secretion via a Ca(2+)-dependent mechanism in canine airway epithelium.
Chiyotani, A; Isono, K; Kondo, M; Konno, K; Takeuchi, S; Tamaoki, J, 1994
)
1.12

Treatment

Menthol treatment produced aposymbiotic hosts within just 4 weeks. The condition was maintained long after treatment when anemones were held under a standard light:dark cycle. Pretreatment with menthol vapor decreased sensitivity to nasal irritation from acetic acid.

ExcerptReferenceRelevance
"The menthol treated group presented 92% gastroprotection compared to the vehicle-treated group."( The gastroprotective effect of menthol: involvement of anti-apoptotic, antioxidant and anti-inflammatory activities.
Meira de Faria, F; Pellizzon, CH; Rozza, AL; Souza Brito, AR, 2014
)
1.17
"The menthol treatment produced aposymbiotic hosts within just 4 weeks (97-100% symbiont loss), and the condition was maintained long after treatment when anemones were held under a standard light:dark cycle."( Menthol-induced bleaching rapidly and effectively provides experimental aposymbiotic sea anemones (Aiptasia sp.) for symbiosis investigations.
Davy, SK; Grossman, AR; Matthews, JL; Oakley, CA; Sproles, AE; Weis, VM, 2016
)
2.36
"Menthol pretreatment shifted the nicotine dose-response curve to the left."( Enhancing effect of menthol on nicotine self-administration in rats.
Avusula, R; Biswas, L; Gong, Y; Harrison, E; Lage, J; Lee, J; Liu, X; Rousselle, T; Zhang, M, 2016
)
1.48
"Pretreatment with menthol at various doses significantly suppressed tumor formation and growth, and markedly reduced tumor incidence and volume."( Chemopreventive efficacy of menthol on carcinogen-induced cutaneous carcinoma through inhibition of inflammation and oxidative stress in mice.
Cao, Y; Chen, C; Fan, F; Lin, C; Liu, Z; Lu, Y; Shan, Y; Shen, C; Sun, L; Tao, Y; Wang, A; Wang, S; Wei, Z; Wu, H; Zheng, S; Zhu, P, 2015
)
1.03
"Pretreatment with menthol followed by its washout did not affect agonist-induced desensitization, suggesting that menthol must be present during the application of agonist to augment desensitization."( Menthol Enhances the Desensitization of Human α3β4 Nicotinic Acetylcholine Receptors.
Aguilar, BL; Ahern, GP; Kellar, KJ; Olson, TT; Smart, AE; Ton, HT, 2015
)
2.18
"Pretreatment with menthol vapor decreased sensitivity to nasal irritation from acetic acid (participants required higher concentrations to lateralize) but increased sensitivity to allyl isothiocyanate (lower concentrations were required)."( The effect of menthol vapor on nasal sensitivity to chemical irritation.
Eades, J; Preti, G; Wise, PM; Wysocki, CJ, 2011
)
1.06

Toxicity

L-menthol sprayed on the gastric mucosa significantly suppresses peristalsis with minimal adverse drug reactions compared with placebo. Adverse events of a tingling or heat sensation were expected and observed.

ExcerptReferenceRelevance
" Simple dose-toxicity studies of a metabolite will help to elucidate its toxic effect, but it is not possible to quantify its role in the toxicity produced by the parent compound unless the disposition of the preformed and endogenously formed metabolite is taken into account."( Contribution of menthofuran to the hepatotoxicity of pulegone: assessment based on matched area under the curve and on matched time course.
Nelson, SD; Slattery, JT; Thomassen, D, 1988
)
0.27
" One patient died, one received N-acetylcysteine, and two ingested minimally toxic amounts of pennyroyal and were not treated with N-acetylcysteine."( Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature.
Anderson, IB; Blanc, PD; Meeker, JE; Mullen, WH; Nelson, SD; Oishi, S, 1996
)
0.29
" Data on human metabolites may provide new insights into the toxic mechanisms and treatment of pennyroyal poisoning, including the potential role of N-acetylcysteine."( Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature.
Anderson, IB; Blanc, PD; Meeker, JE; Mullen, WH; Nelson, SD; Oishi, S, 1996
)
0.29
" Recently we have shown that false-positive results can still be obtained due to cytotoxicity when loss of membrane integrity is a late event in toxic cell death relative to the induction of endonucleolytic DNA degradation."( Revalidation of the in vitro alkaline elution/rat hepatocyte assay for DNA damage: improved criteria for assessment of cytotoxicity and genotoxicity and results for 81 compounds.
Barnum, JE; DeLuca, JG; Elia, MC; Harmon, LS; Kraynak, AR; McKelvey, TW; Nichols, WW; Storer, RD, 1996
)
0.29
" Aberrations are formed from DNA double-strand breaks, and DSBs are known to be induced by nonmutagenic (Ames test negative) noncarcinogens at toxic levels [Storer et al."( Chromosome aberrations in vitro related to cytotoxicity of nonmutagenic chemicals and metabolic poisons.
Armstrong, MJ; Bradt, CI; Galloway, SM; Greenwood, SK; Hill, RB; Hilliard, CA, 1998
)
0.3
"1-fold more toxic than menthol to the rice weevil."( Fumigant toxicity of volatile natural products from Korean spices and medicinal plants towards the rice weevil, Sitophilus oryzae (L).
Campbell, BC; Choi, WS; Kim, JG; Lee, BH; Lee, SE; Park, BS, 2001
)
0.62
" No serious adverse events were noted."( Efficacy and safety of Ascoril in the management of cough--National Study Group report.
Ainapure, SS; Desai, A; Korde, K, 2001
)
0.31
" Peppermint Oil was minimally toxic in acute oral studies."( Final report on the safety assessment of Mentha Piperita (Peppermint) Oil, Mentha Piperita (Peppermint) Leaf Extract, Mentha Piperita (Peppermint) Leaf, and Mentha Piperita (Peppermint) Leaf Water.
Nair, B, 2001
)
0.31
" Nonalcoholic ingredients of this mouthwash are phenolic compounds (eucalyptol, menthol, and thymol), and large-volume mouthwash ingestion will produce exposure in the reported toxic range of these ingredients."( Fatal large-volume mouthwash ingestion in an adult: a review and the possible role of phenolic compound toxicity.
Dinovo, E; Hinds, RL; Renner, SW; Soo Hoo, GW,
)
0.36
" These compounds, in addition to alcohol, may account for the adverse effects associated with massive mouthwash ingestion."( Fatal large-volume mouthwash ingestion in an adult: a review and the possible role of phenolic compound toxicity.
Dinovo, E; Hinds, RL; Renner, SW; Soo Hoo, GW,
)
0.13
" To solve this problem, synthetic fungicides have been used, although legal restrictions and consumer's concern demand the search of other safe means."( Improvement of table grapes quality and safety by the combination of modified atmosphere packaging (MAP) and eugenol, menthol, or thymol.
Castillo, S; Guillén, F; Martínez-Romero, D; Serrano, M; Valero, D; Valverde, JM, 2005
)
0.54
" Safety data, including adverse events, and secondary efficacy end points were also evaluated."( Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain: a randomized, double-blind, parallel-group, placebo-controlled, multicenter study.
Furuta, K; Higashi, Y; Kiuchi, T, 2010
)
0.6
"GI peristalsis during GI endoscopy commonly requires intravenous or intramuscular injection of antispasmodic agents, which sometimes cause unexpected adverse reactions."( Antiperistaltic effect and safety of L-menthol sprayed on the gastric mucosa for upper GI endoscopy: a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Hiki, N; Hiratsuka, T; Honjo, H; Kaminishi, M; Matsuhashi, N; Nomura, S; Sekine, C; Suzuki, H; Tajiri, H; Uedo, N; Yahagi, N; Yasuda, K, 2011
)
0.64
" The incidence of adverse events did not differ significantly between the groups (P=."( Antiperistaltic effect and safety of L-menthol sprayed on the gastric mucosa for upper GI endoscopy: a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Hiki, N; Hiratsuka, T; Honjo, H; Kaminishi, M; Matsuhashi, N; Nomura, S; Sekine, C; Suzuki, H; Tajiri, H; Uedo, N; Yahagi, N; Yasuda, K, 2011
)
0.64
"During upper GI endoscopy, L-menthol sprayed on the gastric mucosa significantly suppresses peristalsis with minimal adverse drug reactions compared with placebo."( Antiperistaltic effect and safety of L-menthol sprayed on the gastric mucosa for upper GI endoscopy: a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Hiki, N; Hiratsuka, T; Honjo, H; Kaminishi, M; Matsuhashi, N; Nomura, S; Sekine, C; Suzuki, H; Tajiri, H; Uedo, N; Yahagi, N; Yasuda, K, 2011
)
0.93
"55 µg per adult respectively) and was more toxic than menthone (7 day LD(50)=33."( Toxicity of Schizonpeta multifida essential oil and its constituent compounds towards two grain storage insects.
Chu, SS; Jiang, GH; Liu, ZL, 2011
)
0.37
"9 µg cm(-3) ) was the most toxic compound, followed by citronellyl acetate (16."( Fumigant toxicity of lemon eucalyptus oil constituents to acaricide-susceptible and acaricide-resistant Tetranychus urticae.
Ahn, YJ; Choi, BR; Han, J; Kim, SI; Lee, SG, 2011
)
0.37
" In the acute toxicity test, the LD10 and LD50 of free EcEO was 1999 and 2653 mg/kg, respectively, while the LD10 and LD50 of nanoencapsulated EcEO was 1121 and 1681 mg/kg, respectively."( Efficacy of free and nanoencapsulated Eucalyptus citriodora essential oils on sheep gastrointestinal nematodes and toxicity for mice.
Araújo Filho, JV; Bevilaqua, CM; Camurça-Vasconcelos, AL; Macedo, IT; Magalhães, RD; Paula, HC; Ribeiro, JC; Ribeiro, WL; Santos, JM, 2014
)
0.4
" There was no mortality, adverse effects on general conditions or changes in body weight, food consumption and feed conversion efficiency throughout the study in male and female rats."( Safety assessment of essential oil from Minthostachys verticillata (Griseb.) Epling (peperina): 90-days oral subchronic toxicity study in rats.
Bagnis, G; Cariddi, LN; Cavaglieri, LR; Cristofolini, A; Escobar, FM; Gallucci, MN; Mañas, F; Sabini, LI; Sabini, MC, 2015
)
0.42
" The tests carried out also showed that the most toxic were the compounds with 1 and 3 carbon atoms."( The phytotoxicity of ionic liquids from natural pool of (-)-menthol with tetrafluoroborate anion.
Biczak, R; Feder-Kubis, J; Pawłowska, B, 2015
)
0.66
" Sixty volunteers were recruited, of whom 41 had no skin disease; no adverse events were reported in the latter."( Safety and Antipruritic Efficacy of a Menthol-Containing Moisturizing Cream.
Tan, WD; Tay, EY; Tey, HL,
)
0.4
" In the present study, four temporary consolidants, including cyclododecane, menthol, coumarin, and ethyl maltol, at different concentrations were incubated with zebrafish embryos, and their biological toxic effects were firstly evaluated."( Safety evaluation of the temporary consolidant based on a zebrafish embryo model.
Hu, Y; Zhang, BJ; Zhang, L; Zhang, XY, 2018
)
0.71
" Lip volume and adverse event were assessed by two clinicians at various time points: 15 minutes, 1 hour, 2 hours, 3 hours, and 4 hours."( A Single Site, Open Label Clinical Trial, Evaluating the Duration, Efficacy, and Safety of a Novel Lip Plumper.
Alhaddad, M; Boen, M; Goldman, MP; Guiha, I; Wu, DP, 2018
)
0.48
"In this work, a novel quick, easy, cheap, effective, rugged, and safe technique with hydrophobic natural deep eutectic solvent as both extractant and analyte protectant was developed and combined with gas chromatography-tandem mass spectrometry to analyze pyrethroid residues in tomatoes."( A modified quick, easy, cheap, effective, rugged, and safe method with hydrophobic natural deep eutectic solvent as extractant and analyte protectant for analyzing pyrethroid residues in tomatoes.
Cao, X; Dong, D; Fang, M; Hu, Y; Lin, X; Mo, W; Wu, C; Xu, J; Ye, B; Ye, X, 2020
)
0.56
" The incidence of adverse events was comparable between the groups (P = 0."( Antiperistaltic effect and safety of l-menthol oral solution on gastric mucosa for upper gastrointestinal endoscopy in Chinese patients: Phase III, multicenter, randomized, double-blind, placebo-controlled study.
Chen, W; Chen, Y; He, S; Li, W; Li, Z; Meng, F; Wu, Y; Xing, X; Xue, Z; Yao, C; Zhang, S; Zhi, F, 2021
)
0.89
"A new green miniaturized quick, easy, cheap, effective, rugged, and safe approach was developed and used for the extraction of multiclass 16 pesticides in milk before gas chromatography analysis."( Development of a green miniaturized quick, easy, cheap, effective, rugged, and safe approach in tandem with temperature-assisted solidification of floating menthol droplet for analysis of multiclass pesticide residues in milk.
AliAbadi, MHS; Jazani, SS; Nouri, N; Sereshti, H, 2022
)
0.92
" A separate study analyzing voluntary safety surveillance data evaluated the frequency and severity of reported adverse events (AEs)."( A novel duodenal-release formulation of caraway oil and L-menthol is a safe, effective and well tolerated therapy for functional dyspepsia.
Cash, BD; Chey, WD; Corsino, P; Epstein, MS; Lacy, BE; Shah, SM; Zeitzoff, LR, 2022
)
0.97
" Few adverse events (AEs) were reported (0."( A novel duodenal-release formulation of caraway oil and L-menthol is a safe, effective and well tolerated therapy for functional dyspepsia.
Cash, BD; Chey, WD; Corsino, P; Epstein, MS; Lacy, BE; Shah, SM; Zeitzoff, LR, 2022
)
0.97
" Effective and safe therapeutic treatments have yet to be developed for IBS."( Efficacy and safety of a food supplement with standardized menthol, limonene, and gingerol content in patients with irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial.
Beniashvili, AG; Erlykin, AG; Ivashkin, VT; Kovaleva, AL; Krasnov, GS; Kudryavtseva, AV; Mamieva, ZA; Morozova, MA; Poluektov, YM; Poluektova, EA; Shifrin, OS; Trush, EA; Ulyanin, AI, 2022
)
0.96
" Hemodynamic changes, adverse events, and discomfort levels of patients were similar between the two groups."( Antiperistaltic effect and safety of L-menthol for esophagogastroduodenoscopy in the elderly with contraindication to hyoscine-N-butylbromide.
Chen, LK; Chen, PH; Hou, MC; Huang, YH; Lin, MH; Peng, LN; Yang, TC, 2022
)
0.99
" Both substances were lethal in the fumigation bioassay, in addition, the essential oil was about 6-fold more toxic than menthol after 24 and 48 h of exposure."( Toxicity of Essential Oil of Mentha piperita (Lamiaceae) and its Monoterpenoid Menthol Against Tetranychus urticae Kogan 1836 (Acari: Tetranychidae).
Pinheiro, PF; Souza, LP; Stinguel, P; Zago, HB; Zuim, V, 2022
)
1.16
"Only T-2 mycotoxin is emitted as an aerosol and is the most toxic fungal secondary metabolite among mycotoxins."( Convalescent action of menthol against T-2 mycotoxin-induced toxicity: An in vitro study with HaCaT cells.
Alahmadi, TA; Brindhadevi, K; Chinnathambi, A; Karuppusamy, I; Krupashree, K; Pal, A; Rachitha, P; Raghavendra, VB; Shanmuganathan, R, 2023
)
1.22

Pharmacokinetics

Menthol smoking status in the Cmax and area under the plasma concentration versus time curve (AUC) of bupropion and its metabolites in the smoking or nonsmoking phases were not found. The terminal half-life and oral clearance were not affected by menthol.

ExcerptReferenceRelevance
" (AUC)(0-24), (AUC)(0- infinity ), terminal half-life and oral clearance were not affected by menthol."( Influence of menthol on caffeine disposition and pharmacodynamics in healthy female volunteers.
Artok, L; Balkan, D; Benowitz, NL; Gelal, A; Guven, H, 2003
)
0.91
" The purpose of this article is to describe the study design and discuss strategies used to recruit and retain African-American smokers in a pharmacokinetic study."( Design, recruitment, and retention of African-American smokers in a pharmacokinetic study.
Ahluwalia, JS; Bronars, CA; Cox, LS; Faseru, B; Mayo, MS; Okuyemi, KS; Opole, I; Reed, GA, 2010
)
0.36
" Of the 81 who attended the first visit, 48 individuals were enrolled in the pharmacokinetic study, and a total of 40 individuals completed the study (83% retention rate)."( Design, recruitment, and retention of African-American smokers in a pharmacokinetic study.
Ahluwalia, JS; Bronars, CA; Cox, LS; Faseru, B; Mayo, MS; Okuyemi, KS; Opole, I; Reed, GA, 2010
)
0.36
"Although recruitment of African-American smokers into a non-treatment, pharmacokinetic study poses challenges, retention is feasible."( Design, recruitment, and retention of African-American smokers in a pharmacokinetic study.
Ahluwalia, JS; Bronars, CA; Cox, LS; Faseru, B; Mayo, MS; Okuyemi, KS; Opole, I; Reed, GA, 2010
)
0.36
" The pharmacokinetic data indicated that when NPO-11 is sprayed directly onto the gastric mucosa, it is rapidly metabolized to glucuronic acid conjugates that are excreted in urine."( A phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy of L-menthol in upper gastrointestinal endoscopy.
Hasunuma, T; Hiki, N; Kaminishi, M; Nakamura, M; Nomura, S; Suzuki, H; Tajiri, H; Yahagi, N, 2011
)
0.59
" This study examined the effects of menthol on the pharmacokinetic (PK) profiles of bupropion and its principal metabolites, hydroxybupropion, threohydrobupropion, and erythrohydrobupropion among Black smokers."( Effects of menthol on the pharmacokinetics of bupropion among Black smokers.
Ahluwalia, JS; Benowitz, NL; Bronars, CA; Cox, LS; Faseru, B; Mayo, MS; Okuyemi, KS; Opole, I; Reed, GA; Whembolua, GL, 2012
)
1.04
" No differences were found by menthol smoking status in the Cmax and area under the plasma concentration versus time curve (AUC) of bupropion and its metabolites in the smoking or nonsmoking phases."( Effects of menthol on the pharmacokinetics of bupropion among Black smokers.
Ahluwalia, JS; Benowitz, NL; Bronars, CA; Cox, LS; Faseru, B; Mayo, MS; Okuyemi, KS; Opole, I; Reed, GA; Whembolua, GL, 2012
)
1.06
"6 software was used to calculate pharmacokinetic parameters, and the accumulative absorption percentage of menthol was calculated by Loo-Riegelman method."( [Study on pharmacokinetics and in vitro/in vivo correlation of menthol in Zhike Chuanbei Pipa dropping pills in rats].
Du, C; Liu, D; Liu, JJ; Wang, JL; Wang, LF; Wang, Y; Yang, B, 2013
)
0.84
" The present study investigated changes in the pharmacokinetic behavior of intravenously administered midazolam (MDZ), a probe for CYP3A, when rats were treated with menthol."( Change in pharmacokinetic behavior of intravenously administered midazolam due to increased CYP3A2 expression in rats treated with menthol.
Konishi, H; Nagai, K; Suzuki, S; Yamamura, A, 2015
)
0.82

Compound-Compound Interactions

Daily use of a detergent containing dihydroavenanthramide D 5% combined with a moisturizer containing 1% of menthol improves chronic pruritus associated with xerosis in elderly adults with KS. Menthol in combination with itraconazole or nystatin exhibited the synergistic effects against all species of Candida tested.

ExcerptReferenceRelevance
" After removal of excess derivatization reagent and urine matrix components, the monoterpene derivatives were separated by high-performance liquid chromatography (HPLC) in combination with fluorescence (FLD) detection and simultaneous mass spectrometric (MS) identification."( Sensitive determination of monoterpene alcohols in urine by HPLC-FLD combined with ESI-MS detection after online-solid phase extraction of the monoterpene-coumarincarbamate derivates.
Duisken, M; Hollender, J; Jähnigen, H; Meesters, RJ, 2008
)
0.35
" Menthol in combination with itraconazole or nystatin exhibited the synergistic effects against all species of Candida tested."( Synergistic anticandidal activity of menthol in combination with itraconazole and nystatin against clinical Candida glabrata and Candida krusei isolates.
Khosravi, AR; Sharifzadeh, A; Shokri, H; Tari, PS, 2017
)
1.64
" The aim of our study was to evaluate the efficacy of a detergent containing dihydroavenanthramide D 5% combined with a moisturizer containing 1% of menthol for the treatment of chronic pruritus associated with xerosis in elderly KS patients."( Efficacy of a detergent combined with a moisturizer for the treatment of pruritus associated with xerosis in an elderly population affected by Kaposi's sarcoma.
Brambilla, L; Consonni, D; Genovese, G; Tourlaki, A, 2020
)
0.76
"Daily use of a detergent containing dihydroavenanthramide D 5% combined with a moisturizer containing 1% of menthol improves chronic pruritus associated with xerosis in elderly adults with KS."( Efficacy of a detergent combined with a moisturizer for the treatment of pruritus associated with xerosis in an elderly population affected by Kaposi's sarcoma.
Brambilla, L; Consonni, D; Genovese, G; Tourlaki, A, 2020
)
0.77
"This study aimed to investigate the effects of nanoparticles PLGA-NPs and mesoporous silicon nanoparticles(MSNs) of different stiffness before and after combination with menthol or curcumol on the mechanical properties of bEnd."( [Effect of nanoparticles of different stiffness combined with menthol/curcumol on mechanical properties of bEnd.3 cells].
Chen, WL; DU, SY; Guo, ZS; Li, PY; Wang, DL; Wang, XJ; Yang, KL; Zhang, Y; Zhong, LY, 2023
)
1.34
" Besides, we used VER-RM-LNC combined with an envoy drug, menthol, to improve its BBB permeability and neuroprotective activity."( Enhancing the stability, BBB permeability and neuroprotective activity of verbascoside in vitro using lipid nanocapsules in combination with menthol.
Chen, Q; Huang, W; Lu, B; Peng, K; Wang, Y; Wu, L, 2023
)
1.36

Bioavailability

Menthol and poloxamer 188 have a similar systemic bioavailability. The liquid suppository system with P 188 and menthol will be expected to enhance the rectal bioavailability of ibuprofen.

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The relative bioavailability of the model substance 1,8-cineole obtained by using an applicator was 320% as compared with that obtained by using an occlusive dressing."( [Skin absorption of volatile oils. Pharmacokinetics].
Brodbeck, R; Weyers, W, 1989
)
0.28
"61 suggesting it should be poorly absorbed from the lumen of the gastrointestinal tract."( Menthol-beta-D-glucuronide: a potential prodrug for treatment of the irritable bowel syndrome.
Friend, DR; Nolen, HW, 1994
)
1.73
" The results showed that 1,8-cineol is well absorbed from breathing air, with a peak plasma concentration after approximately 18 min."( Pharmacokinetic studies of the fragrance compound 1,8-cineol in humans during inhalation.
Binder, R; Buchbauer, G; Jäger, W; Nasel, B; Nasel, C; Stimpfl, T; Vycudilik, W, 1996
)
0.29
"We conclude that pure menthol and menthol in food or beverages have a similar systemic bioavailability and that menthol has a small cardioaccelerating effect."( Disposition kinetics and effects of menthol.
Benowitz, NL; Gelal, A; Jacob, P; Yu, L, 1999
)
0.89
" FP (1%) gel containing ethanol (25%) and l-menthol (3%) as penetration enhancers was applied to rabbit dorsal skin and the in vivo absorption rate of FP was compared with the in vitro penetration rate through excised skin."( Effect of l-menthol-ethanol-water system on the systemic absorption of flurbiprofen after repeated topical applications in rabbits.
Hayashi, T; Kawabata, S; Morimoto, Y; Seki, T; Sugibayashi, K, 2000
)
0.95
" The bioavailability with respect to the AUC was comparable after administration of test and reference preparation, the 90% confidence interval was 97 to 105%."( Pharmacokinetics of menthol and carvone after administration of an enteric coated formulation containing peppermint oil and caraway oil.
Kikuta, C; Mascher, H; Schiel, H, 2001
)
0.63
" In tracheostomized dogs, both formulations showed comparable pharmacokinetic parameters including Cmax, Tmax, AUC0-12 and bioavailability (F%), indicating that the taste-masking excipients do not have an effect on lung absorption of leuprolide acetate."( Pulmonary peptide delivery: effect of taste-masking excipients on leuprolide suspension metered-dose inhalers.
Adjei, AL; Barber, TE; Fulu, MY; Lee, DY; Zheng, JY, 2001
)
0.31
" In vivo studies in healthy human volunteers indicated that the TTS of nicardipine hydrochloride, designed in the present study, provided steady-state plasma concentration of the drug with minimal fluctuations for 26h with improved bioavailability in comparison with the immediate release capsule dosage form."( Influence of menthol and pressure-sensitive adhesives on the in vivo performance of membrane-moderated transdermal therapeutic system of nicardipine hydrochloride in human volunteers.
Bhaskar, P; Krishnaiah, YS; Satyanarayana, V, 2003
)
0.69
"To improve the bioavailability of poorly water-soluble ibuprofen in the rectum with poloxamer and menthol, the effects of menthol and poloxamer 188 on the aqueous solubility of ibuprofen were investigated."( Enhanced rectal bioavailability of ibuprofen in rats by poloxamer 188 and menthol.
Choi, HG; Choi, JS; Kim, CK; Kim, DC; Kim, DD; Lee, BJ; Rhee, JD; Yang, CH; Yong, CS, 2004
)
0.77
" Although unable to determine the absolute dermal bioavailability of these compounds, there appears to be relatively low systemic exposure to these potentially toxic compounds, even when an unrealistically large number of patches are applied for an unusually long time."( Dermal absorption of camphor, menthol, and methyl salicylate in humans.
Boren, J; Martin, D; Mayersohn, M; Valdez, J, 2004
)
0.61
" Thus, the liquid suppository system with P 188 and menthol, a more convenient and effective rectal dosage form for ibuprofen will be expected to enhance the rectal bioavailability of ibuprofen."( Preparation of ibuprofen-loaded liquid suppository using eutectic mixture system with menthol.
Choi, HG; Jung, SH; Kim, CK; Kim, HD; Oh, YK; Rhee, JD; Yong, CS, 2004
)
0.8
"To improve the oral bioavailability of poorly water-soluble ibuprofen with poloxamer and menthol, the effects of menthol and poloxamer 188 on the aqueous solubility of ibuprofen were investigated."( Enhanced oral bioavailability of ibuprofen in rats by poloxamer gel using poloxamer 188 and menthol.
Choi, HG; Han, SS; Kim, CK; Kim, JA; Kim, JH; Kim, JO; Kong, KH; Lee, MK; Lyoo, WS; Park, YJ; Rhee, JD; Xuan, JJ; Yang, CH; Yong, CS, 2005
)
0.77
" The results showed that the menthol-based TTS patch of nimodipine provided steady plasma concentration of the drug with minimal fluctuations with improved bioavailability in comparison with the immediate release tablet dosage form."( Studies on the transdermal delivery of nimodipine from a menthol-based TTS in human volunteers.
Bhaskar, P; Krishnaiah, YS, 2004
)
0.86
" The bioavailability after percutaneous exposure was equivalent to 15."( Formulation and evaluation of ethylene-vinyl acetate copolymer matrix patches containing formoterol fumarate.
Kakubari, I; Kawakami, J; Shinkai, N; Takayama, K; Takayama, S; Takayasu, T; Uruno, A; Yamauchi, H, 2006
)
0.33
"A randomized, two-way, crossover, bioequivalence study in 6 beagle dogs was conducted to compare the bioavailability of two peppermint oil formulations, soft capsule and hard capsule."( Bioequivalence evaluation of menthol after oral administration of peppermint oil soft capsules in dogs.
Li, KX; Wu, JF; Xiang, BR, 2010
)
0.65
" AMG2850 is potent in vitro at rat TRPM8 (IC90 against icilin activation of 204 ± 28 nM), highly selective (>100-fold IC90 over TRPV1 and TRPA1 channels), and orally bioavailable (F po > 40 %)."( AMG2850, a potent and selective TRPM8 antagonist, is not effective in rat models of inflammatory mechanical hypersensitivity and neuropathic tactile allodynia.
Davis, C; Gavva, NR; Kerstein, PC; Lehto, SG; Stucky, CL; Wang, J; Wang, W; Weyer, AD; Wild, KD; Youngblood, BD; Zhang, M, 2015
)
0.42
" MWC application increases SBFR and subcutaneous drug absorption rate in healthy humans."( A survey of subcutaneous blood flow in patients with SMID and subcutaneous ceftazidime administration using mentholated warm compresses in healthy subjects.
Ebihara, T; Iwasaki, H; Kitazumi, E; Kobayashi, D; Negishi, A; Ohara, K; Ohshima, S; Okita, M; Oshima, S; Yasuda, Y; Yoneyama, A, 2016
)
0.65
"In the clinical setting, raloxifene, a second-generation selective estrogen receptor modulator, is administered orally; however, the bioavailability (BA) is only 2% because of its poor solubility in aqueous fluids and its extensive first-pass metabolism."( Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment.
Kawasaki, N; Nagai, N; Nakazawa, Y; Ogata, F; Otake, H, 2018
)
0.48
"The variations in average particle size, zeta potential, free fatty acids (FFA) release rate, and the bioavailability of menthol under in vitro simulated digestion conditions of peppermint oil nanoemulsion were investigated."( In vitro Simulated Digestion and Microstructure of Peppermint Oil Nanoemulsion.
Jiang, L; Li, Y; Liu, J; Qi, B; Tian, T; Wang, Z; Zhang, X; Zhou, Y; Zhu, Y, 2019
)
0.72
" To improve lipophilicity and therefore the bioavailability of menthol, a novel prodrug called menthol-pentanol was developed by masking the functional polar group of menthol by linking n-pentanol by a carbonate bond."( Anti-echinococcal activity of menthol and a novel prodrug, menthol-pentanol, against Echinococcus multilocularis.
Clemente, CM; Elissondo, MC; Elissondo, N; Fabbri, J; Gambino, G; Hergert, LY; Palma, SD; Ravetti, S, 2020
)
1.09
" To evaluate THEDES anti-CRC therapeutic potential, their physico-chemical properties, bioavailability and bioactivity, were explored."( Selective terpene based therapeutic deep eutectic systems against colorectal cancer.
Duarte, ARC; Miguel Castro, M; Oliveira, F; Paiva, A; Pereira, J; Rita Jesus, A; Santos, F, 2022
)
0.72
"Lopinavir is effective in treatment of HIV infection but experiences low oral bioavailability due to poor solubility, pre-systemic metabolism, and P-gp intestinal efflux."( Menthol augmented niosomes for enhanced intestinal absorption of lopinavir.
El Maghraby, GM; Essa, EA; Fayed, ND, 2022
)
2.16

Dosage Studied

Menthol can be delivered in many dosage forms including the smoke of a mentholated cigarette. The results showed that only (+)-menthol was active, stimulating in a dose-response manner the binding of an allosteric GABA(A) receptor ligand.

ExcerptRelevanceReference
" The activity of each of the three compounds increased in a dose-response manner."( Lytic activity of l-menthol derivatives against the snow blight disease fungus, Micronectriella nivalis.
Hyakumachi, M; Kawazoe, H; Miyazawa, M; Sumi, Y, 2003
)
0.32
"001) in the menthol-treated group 10 min after dosing whereas the placebo group showed no change."( The effects of oral administration of (-)-menthol on nasal resistance to airflow and nasal sensation of airflow in subjects suffering from nasal congestion associated with the common cold.
Eccles, R; Jawad, MS; Morris, S, 1990
)
0.92
" This has practical effects on the dosage and on the frequency of application."( [Skin absorption of volatile oils. Pharmacokinetics].
Brodbeck, R; Weyers, W, 1989
)
0.28
" The results have been evaluated from the methodological aspect to work out an appropriate dosage regime in liver diseases."( Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
Beró, T; Fábián, C; Horváth, T; Jávor, T; Kádas, I; Pár, A, 1983
)
0.27
" This dosage also induces the first and the second phases of reactions."( Human tolerance of flumecinol (Zixoryn, RGH-3332), its regime and dosage in healthy volunteers.
Ferenci, J; Horvath, T; Jávor, T; Nagy, L; Past, T; Radnai, B; Vezekenyi, Z, 1983
)
0.27
"Pulegone was given orally by gavage to groups of 28 SPF Wistar rats at dosage levels of 0 or 160 mg/kg body weight per day for 28 days."( Lack of histological cerebellar changes in Wistar rats given pulegone for 28 days. Comparison of immersion and perfusion tissue fixation.
Mølck, AM; Olsen, P; Poulsen, M; Tindgard Lauridsen, S, 1998
)
0.3
" The following metabolites were isolated and identified from the urine of rats dosed with I: 3-methyl-5-(1-methylethylidene)-cyclopent-2-enone (Ie), Z-4-methyl-2-(1-hydroxymethylethylidene)-cyclopentanone (Ib), E-4-methyl-2-(1-hydroxymethylethylidene)-cyclopentanone (Ia), 3-hydroxy-4-methyl-2-(1-methylethylidene)-cyclopentanone (If), 4-hydroxy-4-methyl-2-(1-methylethylidene)-cyclopentanone (Ic), and E-4-methyl-2-(1-carboxyethylidene)-cyclopentanone (Id)."( Effect of ring size in R-(+)-pulegone-mediated hepatotoxicity: studies on the metabolism of R-(+)-4-methyl-2-(1-methylethylidene)-cyclopentanone and DL-camphorone in rats.
Bhat, VB; Madyastha, MK; Thulasiram, HV, 2001
)
0.31
" However, this fact should not be relevant, in particular since the dosage of the enteric coated capsule lies at the upper limit of the model text and positive clinical studies, also on the therapeutic equivalence of the two formulations, are available."( Pharmacokinetics of menthol and carvone after administration of an enteric coated formulation containing peppermint oil and caraway oil.
Kikuta, C; Mascher, H; Schiel, H, 2001
)
0.63
" Repeated intradermal dosing with Peppermint Oil produced moderate and severe reactions in rabbits, although Peppermint Oil did not appear to be phototoxic."( Final report on the safety assessment of Mentha Piperita (Peppermint) Oil, Mentha Piperita (Peppermint) Leaf Extract, Mentha Piperita (Peppermint) Leaf, and Mentha Piperita (Peppermint) Leaf Water.
Nair, B, 2001
)
0.31
" The activity of each of the three compounds increased in a dose-response manner."( Lytic activity of l-menthol derivatives against the snow blight disease fungus, Micronectriella nivalis.
Hyakumachi, M; Kawazoe, H; Miyazawa, M; Sumi, Y, 2003
)
0.64
" In vivo studies in healthy human volunteers indicated that the TTS of nicardipine hydrochloride, designed in the present study, provided steady-state plasma concentration of the drug with minimal fluctuations for 26h with improved bioavailability in comparison with the immediate release capsule dosage form."( Influence of menthol and pressure-sensitive adhesives on the in vivo performance of membrane-moderated transdermal therapeutic system of nicardipine hydrochloride in human volunteers.
Bhaskar, P; Krishnaiah, YS; Satyanarayana, V, 2003
)
0.69
" Menthol can be delivered in many dosage forms including the smoke of a mentholated cigarette."( Continual smoking of mentholated cigarettes may mask the early warning symptoms of respiratory disease.
Falkner, RV; Garten, S, 2003
)
1.55
" Thus, the poloxamer gel with poloxamer 188 and menthol was a more effective rectal dosage form for ibuprofen."( Enhanced rectal bioavailability of ibuprofen in rats by poloxamer 188 and menthol.
Choi, HG; Choi, JS; Kim, CK; Kim, DC; Kim, DD; Lee, BJ; Rhee, JD; Yang, CH; Yong, CS, 2004
)
0.81
" Thus, the liquid suppository system with P 188 and menthol, a more convenient and effective rectal dosage form for ibuprofen will be expected to enhance the rectal bioavailability of ibuprofen."( Preparation of ibuprofen-loaded liquid suppository using eutectic mixture system with menthol.
Choi, HG; Jung, SH; Kim, CK; Kim, HD; Oh, YK; Rhee, JD; Yong, CS, 2004
)
0.8
" Thus, the ibuprofen-loaded preparation with poloxamer 188 and menthol was a more effective oral dosage form for poorly water-soluble ibuprofen."( Enhanced oral bioavailability of ibuprofen in rats by poloxamer gel using poloxamer 188 and menthol.
Choi, HG; Han, SS; Kim, CK; Kim, JA; Kim, JH; Kim, JO; Kong, KH; Lee, MK; Lyoo, WS; Park, YJ; Rhee, JD; Xuan, JJ; Yang, CH; Yong, CS, 2005
)
0.79
" The results showed that the menthol-based TTS patch of nimodipine provided steady plasma concentration of the drug with minimal fluctuations with improved bioavailability in comparison with the immediate release tablet dosage form."( Studies on the transdermal delivery of nimodipine from a menthol-based TTS in human volunteers.
Bhaskar, P; Krishnaiah, YS, 2004
)
0.86
"7 mg of product/cm2, the latter dosage being the industrial standard for deet based repellents."( Efficacy of repellent products against caged and free flying Anopheles stephensi mosquitoes.
Curtis, CF; Rongsriyam, Y; Trongtokit, Y, 2005
)
0.33
" Both 8-Br-cAMP (100 microM) and forskolin (10 microM) right-shifted the dose-response curves for the TRPM8-mediated effect of icilin and menthol on intracellular Ca(2+)."( Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids.
De Petrocellis, L; Di Marzo, V; Moriello, AS; Orlando, P; Starowicz, K; Vivese, M, 2007
)
0.54
" To test this hypothesis, male and female rats were dosed orally with 14C-labeled pulegone (80 mg/kg, 120 microCi/kg) or menthofuran (60 mg/kg, 120 microCi/kg) or menthones (80 mg/kg, 120 microCi/kg) in corn oil, and the kidney cytosol was prepared 24 h after dosing."( 14C-labeled pulegone and metabolites binding to alpha2u-globulin in kidneys of male F-344 rats.
Borghoff, SJ; Burka, LT; Ferguson, LJ; Lebetkin, EH; Lih, FB; Parkinson, HD; Tomer, KB, 2007
)
0.34
"The purpose of the present study was to develop the meloxicam transdermal dosage form."( The effect of mixed-solvent and terpenes on percutaneous absorption of meloxicam gel.
Chang, JS; Huang, YB; Tsai, YH; Wu, PC, 2007
)
0.34
" The results showed that only (+)-menthol, among the five stereoisomers analyzed, was active, stimulating in a dose-response manner the binding of an allosteric GABA(A) receptor ligand."( Stereo-selective activity of menthol on GABA(A) receptor.
Corvalán, NA; García, DA; Zygadlo, JA, 2009
)
0.92
"Tiaprofenic acid is a potent analgesic and nonsteroidal anti-inflammatory drug (NSAID) and like any other nonsteroidal anti-inflammatory drug, oral administration of the conventional dosage forms of tiaprofenic acid invariably causes gastrointestinal side effects."( The effect of terpenes on percutaneous absorption of tiaprofenic acid gel.
Kaptan, E; Nuriyev, M; Okyar, A; Ozturk, N; Pala-Kara, Z; Yildiz, A, 2010
)
0.36
" These results suggested that the pharmacokinetics behavior was similar between ZCPDP and menthol herbs with the same dosage in rats, with good in vitro/in vivo correlation."( [Study on pharmacokinetics and in vitro/in vivo correlation of menthol in Zhike Chuanbei Pipa dropping pills in rats].
Du, C; Liu, D; Liu, JJ; Wang, JL; Wang, LF; Wang, Y; Yang, B, 2013
)
0.85
" The thermal threshold of activation of these mutants was shifted 2 °C to higher temperatures, and the menthol dose-response curve was displaced to lower concentrations."( Bidirectional modulation of thermal and chemical sensitivity of TRPM8 channels by the initial region of the N-terminal domain.
González, A; Hardy, P; Madrid, R; Pertusa, M; Viana, F, 2014
)
0.62
" Implications for tobacco treatment include the impact on pharmacotherapy dosing and counselling interventions."( Relighting behaviour among cigarette smokers seeking treatment: implications for tobacco treatment and policy.
Delnevo, CD; Manderski, MT; Richardson, DL; Steinberg, MB; Zimmermann, MH, 2014
)
0.4
" The first group was dosed with borneol (0."( Combined use of borneol or menthol with labrasol promotes penetration of baicalin through rabbit cornea in vitro.
Bai, J; Cui, H; Huang, L; Liu, J; Yang, H, 2015
)
0.71
" Study I: A dose-response relationship (N = 20) between 0, 2, and 4 mg nicotine gum."( Psychophysical and Vasomotor Responses of the Oral Tissues: A Nicotine Dose-Response and Menthol Interaction Study.
Arendt Nielsen, T; Arendt-Nielsen, L; Boudreau, SA; Nielsen, BP; Wang, K, 2016
)
0.66
"A dose-response elevation in heart rate was attenuated when nicotine was combined with menthol."( Psychophysical and Vasomotor Responses of the Oral Tissues: A Nicotine Dose-Response and Menthol Interaction Study.
Arendt Nielsen, T; Arendt-Nielsen, L; Boudreau, SA; Nielsen, BP; Wang, K, 2016
)
0.88
"4%, 1%, 2%, 4%, 7%, 8%) were applied to the skin to model the dose-response curve."( Topical menthol increases cutaneous blood flow.
Alexander, LM; Craighead, DH, 2016
)
0.87
" The present study demonstrated an effective method for the preparation of suitable dosage form of MLX with improved solubility and onset of action."( Design, Optimization and Evaluation of Orally Disintegrating Tablet of Meloxicam Using Its Menthol Based Solid Dispersions.
Dehghani, H; Homayouni, A; Taheri, A, 2017
)
0.68
"015 mg/kg/infusion nicotine, menthol dose-response function was determined."( Enhancing effect of menthol on nicotine self-administration in rats.
Avusula, R; Biswas, L; Gong, Y; Harrison, E; Lage, J; Lee, J; Liu, X; Rousselle, T; Zhang, M, 2016
)
1.05
"An inverted U-shaped nicotine dose-response curve was observed."( Enhancing effect of menthol on nicotine self-administration in rats.
Avusula, R; Biswas, L; Gong, Y; Harrison, E; Lage, J; Lee, J; Liu, X; Rousselle, T; Zhang, M, 2016
)
0.76
"38 mg/kg dosage of menthol."( Menthol enhances nicotine-induced locomotor sensitization and in vivo functional connectivity in adolescence.
Colon-Perez, L; Dávila-García, MI; DiFranza, JR; Dubuke, ML; Febo, M; Huang, W; King, JA; Poirier, GL; Robidoux, M; Shaffer, SA; Tam, K; Thompson, MF, 2018
)
2.25
" Our electrophysiological results show a dose-response relationship between the EAG amplitudes and the increasing concentrations of the olfactory compound."( Association between olfactory sensitivity and behavioral responses of Drosophila suzukii to naturally occurring volatile compounds.
Corda, G; Crnjar, R; Delogu, G; Dettori, MA; Fabbri, D; Solari, P; Sollai, G, 2020
)
0.56
"5% provides a cooling sensation for athletes with a dose-response when ingested during exercise."( Development of a "Cooling" Menthol Energy Gel for Endurance Athletes: Effect of Menthol Concentration on Acceptability and Preferences.
Ross, MLR; Stevens, CJ; Vogel, RM, 2021
)
0.92
"A patient reported outcomes (PRO) questionnaire was designed and distributed online to assess real-world satisfaction and dosing frequency of open-label COLM-SST in patients with FD."( A novel duodenal-release formulation of caraway oil and L-menthol is a safe, effective and well tolerated therapy for functional dyspepsia.
Cash, BD; Chey, WD; Corsino, P; Epstein, MS; Lacy, BE; Shah, SM; Zeitzoff, LR, 2022
)
0.97
" These findings, demonstrated in the FDREST trial, were further supported by a large prospective PRO study evaluating self-regulated dosing frequency, symptom improvement, and QOL."( A novel duodenal-release formulation of caraway oil and L-menthol is a safe, effective and well tolerated therapy for functional dyspepsia.
Cash, BD; Chey, WD; Corsino, P; Epstein, MS; Lacy, BE; Shah, SM; Zeitzoff, LR, 2022
)
0.97
" On the other hand, oral menthol dosing did not assist with recovery from MCAO in our study."( Activation of peripheral TRPM8 mitigates ischemic stroke by topically applied menthol.
Chen, YH; Chien, SY; Chu, YT; Chung, HY; Huang, SS; Lee, HH; Luo, ST; MacDonald, IJ; Su, HH; Wang, YH, 2022
)
1.25
" This work has studied the extraction of phenolic compounds from a type of OMWW, olive vegetation water, which presents these compounds in a more diluted dosage than in other studied to date, to revalue this waste stream."( Sustainable recovery of phenolic antioxidants from real olive vegetation water with natural hydrophobic eutectic solvents and terpenoids.
Álvarez-Torrellas, S; García, J; Larriba, M; Martín-Gutiérrez, D; Navarro, P; Rodríguez-Llorente, D; Suárez-Rodríguez, P, 2023
)
0.91
" ORs for developing hypertensive ICH according to overtime working hours showed a dose-response relationship; an overtime of 100 hours/month was associated with a significantly higher OR (1."( Long working hours and risk of hypertensive intracerebral haemorrhage among Japanese workers claiming compensation for overwork-related intracerebral haemorrhage: an unmatched case-control study.
Morita, Y; Takahashi, M; Yoshikawa, T, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (183 Product(s))

Product Categories

Product CategoryProducts
Other34
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Fruits et produits dérivés, Produits déshydratés, Aliments à base de plantes séchées, Fruits secs, Bananes séchées1
Snacks, Snacks sucrés, Cacao et dérivés, Aliments festifs, Chocolats, Moulages en chocolat, Aliments de Pâques, Lapins en chocolat1
en:extra-virgin-olive-oils1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Fruits et produits dérivés, Produits déshydratés, Aliments à base de plantes séchées, Fruits secs, Papaye séchée1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Céréales et pommes de terre, Céréales et dérivés, Pâtes alimentaires, Pâtes alimentaires de céréales, Pâtes de blé dur1
Meats and their products, Meats1
Refeições,Refeições com peixe1
Viandes et dérivés,Charcuteries,Jambons,Jambons blancs1
Viandes et dérivés, Viandes, Charcuteries, Jambons, Jambons blancs1
Snacks, Sweet snacks, Biscuits and cakes, Biscuits, Wafers1
en:energy-drinks1
Meats and their products, Meats, Prepared meats, Sausages, Beef sausages1
Lanches comida, Lanches doces, Biscoitos e Bolos, Biscoitos, Biscoitos de chocolate1
Meats and their products,Prepared meats,Sausages,Sausage meat1
Plant-based foods and beverages, Plant-based foods, Cereals and potatoes, Cereals and their products, Pastas, Spaghetti1
Desserts, Frozen foods, Frozen desserts, Ice creams and sorbets, Ice creams1
Pflanzliche Lebensmittel und Getränke, Pflanzliche Lebensmittel, Teigwaren, Spaghettis1
Snacks, Snacks sucrés, Biscuits et gâteaux, Biscuits, Biscuits sablés1
Snacks, Snacks sucrés, Biscuits et gâteaux, Biscuits, Spéculoos1
Aliments et boissons à base de végétaux, Boissons, Boissons à base de végétaux, Boissons au thé, Thés glacés, Thés glacés saveur pêche, Boissons avec sucre ajouté1
Aides culinaires, Aides à la pâtisserie, Pâtes à sucre1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Légumineuses et dérivés, Légumineuses, Fruits à coques et dérivés, Fruits à coques, Fruits à coque grillés, Cacahuètes, Cacahuètes grillées1
en:peanut-butters1
Vitamins & Supplements13
Beauty & Personal Care108
Herbs, Botanicals & Homeopathy4
Food & Beverages1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
BolognaComplimentsMeats and their products, MeatsSodium nitrite2024-02-12
Classic spaghetti, enriched macaroni productHannafordPlant-based foods and beverages, Plant-based foods, Cereals and potatoes, Cereals and their products, Pastas, Spaghettiriboflavin,ferrous sulfate,niacin2024-02-09
Ice CreamHannafordDesserts, Frozen foods, Frozen desserts, Ice creams and sorbets, Ice creamsniacin,riboflavin2024-02-09
Afrin Nasal Spray 12 Hour Relief Severe Congestion -- 0.5 fl ozAfrinVitamins & Supplementsbenzyl alcohol, camphor, eucalyptol, menthol, propylene glycol2024-11-29 10:47:42
All Terrain Recovery Rub Soothing Massage Cream -- 3 fl ozAll TerrainBeauty & Personal Caregluconolactone, cetearyl alcohol, glycerin, menthol, sodium benzoate2024-11-29 10:47:42
Auromere Ayurvedic Herbal Toothpaste Cinnamon -- 3.57 ozAuromereBeauty & Personal Careanethol, catechu, glycerin, menthol, p thymol2024-11-29 10:47:42
Auromere Ayurvedic Herbal Toothpaste Classic -- 4.16 ozAuromereBeauty & Personal Careanethol, catechu, glycerin, menthol, pthymol, thymol2024-11-29 10:47:42
Auromere Ayurvedic Herbal Toothpaste Fresh Mint -- 4 ozAuromereBeauty & Personal Careanethol, catechu, glycerine, menthol, p Thymol, thymol2024-11-29 10:47:42
Auromere Ayurvedic Herbal Toothpaste in a Jar Fresh Mint -- 4.16 ozAuromereBeauty & Personal Careanethol, catechu, cellulose, glycerine, menthol, p thymol, thymol2024-11-29 10:47:42
Auromere Ayurvedic Mouthwash with Neem & Peelu -- 16 fl ozAuromereBeauty & Personal Caregeranium, catechu, glycerine, menthol, xylitol2024-11-29 10:47:42
Auromere Ayurvedic Neem Picks -- 100 ToothpicksAuromereBeauty & Personal Carementhol2024-11-29 10:47:42
Avalon Organics Scalp Normalizing Shampoo Tea Tree Mint -- 14 fl ozAvalon OrganicsBeauty & Personal CareGlyceryl Oleate, Citric Acid, Terpineol, Benzyl Alcohol, Bisabolol, Camphor, Citric Acid, Citronellol, Decyl Glucoside, Geranyl Acetate, Limonene, Linalyl Acetate, Menthol, Sodium Benzoate, Sodium Sulfate, Sorbitol2024-11-29 10:47:42
Avalon Organics Therapy Medicated Anti-Dandruff Conditioner -- 14 ozAvalon OrganicsBeauty & Personal Careorange, benzyl alcohol, cetyl alcohol, menthol, sodium benzoate, stearic acid, stearyl alcohol2024-11-29 10:47:42
Avalon Organics Therapy Medicated Anti-Dandruff Shampoo -- 14 fl ozAvalon OrganicsBeauty & Personal Careorange, benzyl alcohol, bisabolol, glycerin, limonene, menthol, potassium hydroxide, sodium benzoate2024-11-29 10:47:42
Badger Organic Aromatherapy Travel Kit 5 Pack -- 0.15 ozBadgerBeauty & Personal CareCalendula, Tocopherol, Tocopherol, Menthol2024-11-29 10:47:42
Cantu For Men 2-in-1 Hair & Body Wash -- 13.5 fl ozCantuBeauty & Personal Cared-limonene, citric acid, laureth-4, benzyl benzoate, caffeine, citric acid, cocamidopropyl betaine, laureth-4, ethylhexylglycerin, glyceryl stearate, glycerin, hemp, linalool, menthol, phenoxyethanol, sodium hydroxide, sodium sulfate2024-11-29 10:47:42
Clean Age Toothpaste Tabs Mint -- 62 TabsClean AgeBeauty & Personal Carekaolin, calcium carbonate, limonene, menthol, sodium lauroyl sarcosinate, sodium bicarbonate, Sorbitol, stevioside2024-11-29 10:47:42
Daeng Gi Meo Ri Shampoo For Damaged Hair -- 16.9 fl ozDaeng Gi Meo RiBeauty & Personal Caremethylchloroisothiazolinone, allantoin, carbomer, cocamidopropyl betaine, panthenol, lauramine oxide, disodium EDTA, glycerin, dimethicone, menthol, methylparaben, sodium cocoyl glutamate, triethanolamine2024-11-29 10:47:42
Daeng Gi Meo Ri Shampoo For Oily Scalp -- 16.9 fl ozDaeng Gi Meo RiBeauty & Personal Carecarbomer, cocamidopropyl betaine, panthenol, lauramine oxide, disodium EDTA, dimethicone, limonene, linalool, menthol, phenoxyethanol, propylene glycol, sodium benzoate, triethanolamine2024-11-29 10:47:42
Davids Premium Toothpaste Herbal Citrus Mint -- 5.25 ozDavidsBeauty & Personal Careorange, Calcium carbonate, menthol, stevia, sodium bicarbonate, sodium cocoyl glutamate, xylitol2024-11-29 10:47:42
Dead Sea Naturals Foot Cream -- 3.4 fl ozDead Sea NaturalsBeauty & Personal Careallantoin, benzoic acid, cetearyl alcohol, tocopherol, dehydroacetic acid, ethylhexylglycerin, tocopherol, vitamin E, dimethicone, limonene, linalool, menthol, phenoxyethanol, potassium phosphate, salicylic acid, sodium benzoate2024-11-29 10:47:42
Derma E Alba Ramos Clean Curls Curl Repair Deep Treatment -- 10 ozDerma EBeauty & Personal Careallantoin, biotin, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin, menthol2024-11-29 10:47:42
Derma E Keratin Thickening Spray -- 3.35 fl ozDerma EBeauty & Personal Carebiotin, caffeine, fructose, panthenol, provitamin B5, ethylhexylglycerin, glycerin, hydroxyethylcellulose, menthol, menthone2024-11-29 10:47:42
Derma E Purifying Daily Detox Scrub -- 4 ozDerma EBeauty & Personal Careglyceryl oleate, cetyl alcohol, glycerin, menthol, phenoxyethanol2024-11-29 10:47:42
Derma E Scalp Relief Conditioner -- 8 fl ozDerma EBeauty & Personal Carecetearyl alcohol, panthenol, provitamin B5, glycerin, menthol, phenoxyethanol, propanediol, salicylic acid2024-11-29 10:47:42
Derma E Scalp Relief Rinse -- 4 fl ozDerma EBeauty & Personal Caredecyl glucoside, panthenol, ethylhexylglycerin, glycerin, glycolic acid, lactic acid, menthol, propanediol, salicylic acid, sodium hydroxide2024-11-29 10:47:42
Derma E Scalp Relief Shampoo -- 8 fl ozDerma EBeauty & Personal Carevitamin E, panthenol, provitamin B5, vitamin E, glycerin, menthol, phenoxyethanol, retinyl palmitate, vitamin A, salicylic acid2024-11-29 10:47:42
Derma E Scalp Relief Treatment -- 1 fl ozDerma EBeauty & Personal Carecaffeine, ethylhexylglycerin, glycerin, menthol, niacinamide2024-11-29 10:47:42
Derma E Thickening Conditioner -- 10 fl ozDerma EBeauty & Personal Careallantoin, biotin, cetyl alcohol, panthenol, ethylhexylglycerin, glycerin, menthol, phenoxyethanol2024-11-29 10:47:42
Derma E Thickening Shampoo -- 10 fl ozDerma EBeauty & Personal Carebakuchiol, cocamidopropyl betaine, panthenol, glycerin, menthol, glyceryl laurate, phenoxyethanol2024-11-29 10:47:42
Desert Essence Natural Neem Toothpaste Cinnamint -- 6.25 ozDesert EssenceBeauty & Personal Carechamomile, calcium ascorbate, goldenseal, glycerin, Calcium carbonate, menthol, phytic acid, sodium lauroyl sarcosinate, sodium bicarbonate2024-11-29 10:47:42
Desert Essence Replenishing Shampoo Tea Tree -- 12.9 fl ozDesert EssenceBeauty & Personal Careglyceryl oleate, citric acid, citric acid, glycerin, menthol, glyceryl caprylate2024-11-29 10:47:42
Desert Essence Tea Tree Replenishing Conditioner -- 12.7 fl ozDesert EssenceBeauty & Personal Caregluconolactone, cetearyl alcohol, tocopherol, behenyl alcohol, tocopherol, vitamin e, glycerin, menthol, glyceryl caprylate2024-11-29 10:47:42
Desert Essence Ultra Care Tea Tree Oil Mouthwash Mega Mint -- 16 fl ozDesert EssenceBeauty & Personal Carechamomile, ascorbic acid, calcium ascorbate, goldenseal, glycerin, menthol, phytic acid2024-11-29 10:47:42
Desert Essence Ultra Care Toothpaste Tea Tree Oil Mega Mint -- 6.25 ozDesert EssenceBeauty & Personal Carechamomile, vitamin C, calcium ascorbate, goldenseal, glycerin, Calcium carbonate, menthol, phytic acid, sodium bicarbonate2024-11-29 10:47:42
Eco-dent DailyCare Toothpowder Anise -- 2 ozEco-dentBeauty & Personal Caredicalcium phosphate dihydrate, calcium carbonate, magnesium carbonate, menthol, Sodium bicarbonate, tartaric acid2024-11-29 10:47:42
Eco-dent DailyCare Toothpowder Cinnamon -- 2 ozEco-dentBeauty & Personal CareDicalcium Phosphate Dihydrate, Calcium Carbonate, Magnesium Carbonate, Menthol, Sodium Bicarbonate, Tartaric Acid2024-11-29 10:47:42
Eco-dent DailyCare Toothpowder Original Mint -- 2 ozEco-dentBeauty & Personal CareAnethole, Dicalcium Phosphate Dihydrate, Calcium Carbonate, Magnesium Carbonate, Menthol, Sodium Bicarbonate, Tartaric Acid2024-11-29 10:47:42
Eco-dent GentleFloss Premium Dental Floss Mint -- 100 YardsEco-dentBeauty & Personal Careorange, geranium, anethole, basil, menthol2024-11-29 10:47:42
Eco-dent Ultimate Daily Rinse Spicy Cool Cinnamon -- 8 fl ozEco-dentBeauty & Personal Careorange, geranium, anethole, CoQ10, golden seal, basil, menthol, stevia, baking soda, ubiquinone2024-11-29 10:47:42
Eco-dent Ultimate Essential MouthCare -- 8 fl ozEco-dentBeauty & Personal Careorange, geranium, anethole, CoQ10, golden seal, basil, glycerin, menthol, stevia, ubiquinone2024-11-29 10:47:42
Euthymol Original Mouthwash -- 16.9 fl ozEuthymolBeauty & Personal Carecitric acid, citric acid, red 33, glyceryl stearate, glycerin, menthol, methyl salicylate, poloxamer 407, sodium benzoate, sodium citrate, tristearin2024-11-29 10:47:42
Every Man Jack 2-In-1 Shampoo + Conditioner - Tea Tree -- 13.5 fl ozEvery Man JackBeauty & Personal Carecitric acid, benzyl alcohol, betaine, citric acid, cocamidopropyl betaine, decyl glucoside, panthenol, glycerin, hexylene glycol, menthol, phenoxyethanol, glycol stearate2024-11-29 10:47:42
Every Man Jack Daily Energizing Face Wash - Skin Revive -- 5 ozEvery Man JackBeauty & Personal Carecitric acid, allantoin, caffeine, citric acid, cocamidopropyl betaine, panthenol, ethylhexylglycerin, glycerin, menthol, phenoxyethanol, sodium benzoate2024-11-29 10:47:42
Every Man Jack Post Shave Balm -- 3.2 fl ozEvery Man JackBeauty & Personal Caredecyl glucoside, sodium gluconate, glycerin, menthol, phenoxyethanol, squalane2024-11-29 10:47:42
Giovanni Deep Cleanse Shampoo Golden Wheat -- 8.5 fl ozGiovanniBeauty & Personal Carecocamidopropyl betaine, vitamin E, decyl glucoside, panthenol, vitamin E, glycerin, menthol, sodium cocoyl glutamate2024-11-29 10:47:42
Giovanni Shampoo Tea Tree Triple Treat -- 2 fl ozGiovanniBeauty & Personal Carecitric acid, citric acid, cocamidopropyl betaine, decyl glucoside, panthenol, menthol, phenoxyethanol, sodium cocoyl glutamate2024-11-29 10:47:42
Giovanni Tea Tree Triple Treat Invigorating Conditioner -- 8.5 fl ozGiovanniBeauty & Personal Carecitric acid, cetearyl alcohol, cetyl alcohol, citric acid, panthenol, ethylhexylglycerin, glycerin, menthol, phenoxyethanol, stearyl alcohol2024-11-29 10:47:42
Giovanni Wellness System Step 1 Shampoo with Chinese Botanicals -- 8.5 fl ozGiovanniBeauty & Personal Carecitric acid, citric acid, cocamidopropyl betaine, decyl glucoside, panthenol, pro-vitamin B-5, ginsenosides, glycerin, menthol, phenoxyethanol, sodium lauroyl sarcosinate2024-11-29 10:47:42
Godefroy Double Lash & Brown Eyelash & Eyebrow Growth Serum -- 0.1 fl ozGodefroyBeauty & Personal Carecaprylyl glycol, vitamin E, ethylhexylglycerin, tocopherol, vitamin E, menthol, retinol palmitate2024-11-29 10:47:42
Green Beaver Natural Toothpaste Frosty Mint -- 2.5 fl ozGreen BeaverBeauty & Personal Carecalcium ascorbate, glycerin, menthol, sorbitol, xylitol2024-11-29 10:47:42
Green Beaver Natural Toothpaste Zesty Orange -- 2.5 fl ozGreen BeaverBeauty & Personal Carecalcium ascorbate, glycerin, menthol, sorbitol, xylitol2024-11-29 10:47:42
Hempz Scalp Care Herbal Conditioner Tea Tree & Chamomile -- 17 fl ozHempzBeauty & Personal Careaminomethyl propanol, iodopropynyl butylcarbamate, citric acid, acetic acid, cetearyl alcohol, cetyl alcohol, chlorphenesin, citric acid, tocopherol, panthenol, disodium EDTA, etidronic acid, tocopherol, glycerin, PEG-4, dimethicone, hydroxyethylcellulose, menthol, octyldodecanol, phenoxyethanol, laureth-9, sodium acetate, stearyl alcohol2024-11-29 10:47:42
Hempz Scalp Care Herbal Shampoo Tea Tree & Chamomile -- 17 fl ozHempzBeauty & Personal Careaminomethyl propanol, citric acid, benzoic acid, citric acid, tocopherol, disodium EDTA, ethylhexylglycerin, tocopherol, glycerin, menthol, phenoxyethanol, propanediol, sodium benzoate, sodium hydroxide2024-11-29 10:47:42
Herbion All Natural Cough Drops Honey Lemon -- 18 DropsHerbionVitamins & SupplementsMenthol2024-11-29 10:47:42
Herbion All Natural Cough Drops Orange -- 18 DropsHerbionVitamins & SupplementsMenthol2024-11-29 10:47:42
Herbion Naturals - All Natural Cough Drops Cherry -- 18 DropsHerbionVitamins & Supplementscitric acid, Vitamin C, citric acid, menthol, Cane sugar2024-11-29 10:47:42
Herbion Naturals - All Natural Cough Drops Honey Lemon -- 25 DropsHerbionVitamins & Supplementscitric acid, Vitamin C, citric acid, menthol, Cane sugar2024-11-29 10:47:42
Herbion Naturals - All Natural Cough Drops Mint -- 18 DropsHerbionVitamins & Supplementscitric acid, Vitamin C, citric acid, menthol, Cane sugar2024-11-29 10:47:42
Herbion Naturals - Respiratory Care Lemon -- 10 SachetsHerbionVitamins & Supplementsmenthol, Cane sugar2024-11-29 10:47:42
Herbion Naturals Cough Drops Cherry -- 25 DropsHerbionVitamins & Supplementscitric acid, Vitamin C, citric acid, menthol, Cane sugar2024-11-29 10:47:42
Herbs Etc. ChlorOxygen Chlorophyll Herbal Supplement Mint -- 2 fl ozHerbs Etc.Herbs, Botanicals & Homeopathymenthol2024-11-29 10:47:42
Heritage Store Hydrogen Peroxide Mouthwash HPM plus White -- 16 fl ozHeritage StoreBeauty & Personal Carementhol, xylitol2024-11-29 10:47:42
Himalayan Chandra Eco Neti Pot Complete Sinus Cleansing System -- 1 KitHimalayan ChandraVitamins & Supplementsmenthol2024-11-29 10:47:42
Himalayan Chandra Neti Pot Complete Sinus Cleansing System -- 1 KitHimalayan ChandraVitamins & Supplementsmenthol2024-11-29 10:47:42
Himalayan Chandra Neti Wash Plus® Daily Neti Pot Boost -- 2 fl ozHimalayan ChandraVitamins & Supplementsmenthol2024-11-29 10:47:42
Jason Anti-Dandruff Scalp Care Shampoo -- 12 fl ozJasonBeauty & Personal Carebenzyl alcohol, camphor, cetyl alcohol, triethyl citrate, glycerin, linalool, maltodextrin, menthol, methyl salicylate, palmitic acid, palmitic acid, potassium hydroxide, stearic acid2024-11-29 10:47:42
Jason Extra Volumizing Biotin Conditioner -- 8 fl ozJasonBeauty & Personal Careisopropyl alcohol, citric acid, ascorbyl palmitate, linolenic acid, benzyl alcohol, biotin, cetearyl alcohol, cetyl alcohol, citric acid, panthenol, triethyl citrate, glycerin, linoleic acid, maltodextrin, menthol, phenoxyethanol, phenethyl alcohol, stearyl alcohol2024-11-29 10:47:42
Jason Healthy Mouth Anticavity Fluoride Toothpaste Cinnamon -- 4.2 ozJasonBeauty & Personal Careglycerin, menthol, sodium cocoyl glutamate2024-11-29 10:47:42
Jason Healthy Mouth Tartar Control Toothpaste Fluoride Free Cinnamon -- 4.2 ozJasonBeauty & Personal Careglycerin, menthol, sodium cocoyl glutamate2024-11-29 10:47:42
Jason Powersmile Anticavity Fluoride Toothpaste Peppermint -- 4.2 ozJasonBeauty & Personal Carecitric acid, citric acid, menthol, sodium bicarbonate, titanium dioxide2024-11-29 10:47:42
Jason PowerSmile Whitening Toothpaste Fluoride Free Peppermint -- 4.2 ozJasonBeauty & Personal Carecitric acid, citric acid, menthol, sodium bicarbonate2024-11-29 10:47:42
Jason Sea Fresh Anticavity Fluoride Toothpaste Spearmint -- 4.2 ozJasonBeauty & Personal Carecitric acid, citric acid, menthol, sodium benzoate, sodium bicarbonate, titanium dioxide, triacetin2024-11-29 10:47:42
Jason Soothing 98% Aloe Vera Moisturizing Gel -- 4 ozJasonBeauty & Personal Careamyl cinnamal, allantoin, arginine, benzyl benzoate, benzyl salicylate, gluconolactone, carbomer, panthenol, glycerin, hexyl cinnamal, limonene, linalool, menthol, phenoxyethanol, potassium hydroxide, sodium benzoate2024-11-29 10:47:42
Jason Thicken & Restore Biotin + Hyaluronic Acid Shampoo -- 16 fl ozJasonBeauty & Personal Carecitric acid, ascorbyl palmitate, benzyl alcohol, biotin, citric acid, panthenol, triethyl citrate, glycerin, linoleic acid, menthol, phenoxyethanol, phenethyl alcohol2024-11-29 10:47:42
Kiss My Face Sensitive Toothpaste Fluoride Free Whitening Gel Citrus Mint -- 4.5 ozKiss My FaceBeauty & Personal Careglycerin, menthol, sodium lauroyl sarcosinate, xylitol2024-11-29 10:47:42
Kiss My Face Super White Toothpaste Cool Mint Gel -- 4.5 ozKiss My FaceBeauty & Personal Careglycerin, menthol, sodium lauroyl sarcosinate2024-11-29 10:47:42
Kiss My Face Triple Action Toothpaste Herbal Mint Gel -- 4.5 ozKiss My FaceBeauty & Personal CareCo-Q10, glycerin, menthol, stevia, sodium lauroyl sarcosinate, ubiquinone, xylitol2024-11-29 10:47:42
Life-Flo Cooling Mist - Sage & Mint -- 3.4 fl ozLife-FloHerbs, Botanicals & Homeopathyorange, bisabolol, decyl glucoside, basil, menthol, propanediol2024-11-29 10:47:42
Life-Flo Magnesium Cooling Gel - Sage & Mint -- 3.4 fl ozLife-FloHerbs, Botanicals & Homeopathyorange, bisabolol, dimethyl sulfone, basil, glycerin, maltodextrin, menthol, propanediol2024-11-29 10:47:42
Life-Flo Magnesium Oil Sport Spray -- 8 fl ozLife-FloVitamins & Supplementsmenthol2024-11-29 10:47:42
Mikanaturals Arnica Montana & Yucca Gel Plus with Menthol and Peppermint -- 8 fl ozMikanaturalsHerbs, Botanicals & Homeopathytocopherol acetate, chamomile, camphor, carbomer, Vitamin E, Vitamin E, menthol, retinyl palmitate, Vitamin A2024-11-29 10:47:42
Miracle Anti-Aging™ Shampoo -- 6 fl ozMiracleBeauty & Personal Carephytantriol, citric acid, methylchloroisothiazolinone, ascorbyl palmitate, vitamin E acetate, citric acid, cocamidopropyl betaine, panthenol, pro-vitamin B5, glycerin, linoleic acid, menthol, retinyl palmitate2024-11-29 10:47:42
NutriBiotic Mouth Fresh Mouthwash Peppermint -- 16 fl ozNutriBioticBeauty & Personal Careglycerin, menthol2024-11-29 10:47:42
Ola Botanicals Dental Floss 100% Vegan-Waxed Peppermint -- 100 YardsOla BotanicalsBeauty & Personal Careorange, anethole, basil, menthol2024-11-29 10:47:42
Olbas Instant WellnessTea -- 7 ozOlbasFood & Beverages chamomile, Grape sugar, menthol, sugar2024-11-29 10:47:42
Pacha Soap Co Salt Block - Breathe -- 5 ozPacha Soap CoBeauty & Personal Carecitric acid, ferric ammonium ferrocyanide, camphor, citric acid, clay, indigo, kaolin, magnesium sulfate, menthol, sodium bicarbonate2024-11-29 10:47:42
Pacifica Rosemary Purify Invigorating Conditioner -- 8 fl ozPacificaBeauty & Personal Carecetearyl alcohol, cetyl alcohol, vitamin E, panthenol, ethylhexylglycerin, vitamin E, glycerin, menthol, vitamin B5, sodium benzoate, sorbitol, stearyl alcohol, tocopherols2024-11-29 10:47:42
Pacifica Rosemary Purify Invigorating Shampoo -- 12 fl ozPacificaBeauty & Personal Carecocamidopropyl betaine, panthenol, ethylhexylglycerin, glycerin, menthol, sodium benzoate2024-11-29 10:47:42
Perioe Himalaya Pink Salt Toothpaste Ice Mint -- 3.4 ozPerioeBeauty & Personal Careglycerin, microcrystalline cellulose, mannitol, menthol, sodium lauryl sulfate, tetrasodium pyrophosphate, sorbitol, titanium dioxide2024-11-29 10:47:42
Perioe Himilaya Pink Salt Toothpaste Charcoal -- 3.4 ozPerioeBeauty & Personal Carecellulose, glycerin, mannitol, menthol, methylcellulose, sodium benzoate, sodium lauryl sulfate, tetrasodium pyrophosphate, sorbitol, titanium dioxide2024-11-29 10:47:42
Petal Fresh Hair ResQ Thickening Follicle Stimulator Serum with Biotin -- 2 fl ozPetal FreshBeauty & Personal Carebenzyl salicylate, vitamin B7, caffeine, citronellol, coumarin, coumarin, tocopherol, panthenol, tocopherol, geraniol, vitamin E, glycerin, hexyl cinnamal, limonene, menthol, niacin, vitamin B5, vitamin B6, vitamin B62024-11-29 10:47:42
Petal Fresh Hair ResQ Thickening Shampoo with Biotin -- 12 fl ozPetal FreshBeauty & Personal Carecitric acid, chamomile, betaine, vitamin B7, caffeine, citric acid, dehydroacetic acid, panthenol, ethylhexylglycerin, hexyl cinnamal, menthol, niacin, vitamin B5, cane sugar2024-11-29 10:47:42
Sea-Band Anti-Nausea Ginger Gum -- 24 PiecesSea-BandVitamins & Supplementsmenthol, sugar, titanium dioxide2024-11-29 10:47:42
SheaMoisture Men Tea Tree Oil & Shea Butter Bald Head Moisturizer -- 5.5 fl ozSheaMoistureBeauty & Personal Careallantoin, benzoic acid, cetyl alcohol, triethyl citrate, glyceryl stearate, hydroxyethylcellulose, menthol, glyceryl caprylate, sodium hydroxide, stearyl alcohol2024-11-29 10:47:42
Shikai CBD Balm Mentholated Double Strength -- 425 mg CBD - 1.65 ozShikaiBeauty & Personal Carevitamin E acetate, cannabidiol, menthol2024-11-29 10:47:42
Shikai CBD Cream with Borage Oil Dry Skin Formula -- 375 mg CBD - 3 ozShikaiBeauty & Personal Carevitamin E acetate, batyl alcohol, cetyl alcohol, glycerin, menthol, phenoxyethanol2024-11-29 10:47:42
Shikai CBD Cream with Menthol Cooling Formul -- 375 mg CBD - 3 ozShikaiBeauty & Personal Carevitamin E acetate, batyl alcohol, cannabidiol, cetyl alcohol, glycerin, menthol, phenoxyethanol2024-11-29 10:47:42
Shikai CBD Cream with Menthol Cooling Formula -- 125 mg CBD - 1 ozShikaiBeauty & Personal Carevitamin E acetate, batyl alcohol, cannabidiol, cetyl alcohol, glycerin, menthol, phenoxyethanol2024-11-29 10:47:42
Shikai Tea Tree Conditioner -- 1 GallonShikaiBeauty & Personal Carepanthenol, ethylhexyl glycerin, glycerin, menthol, phenoxyethanol2024-11-29 10:47:42
Shikai Tea Tree Conditioner -- 12 fl ozShikaiBeauty & Personal Carepanthenol, ethylhexyl glycerin, glycerin, menthol, phenoxyethanol2024-11-29 10:47:42
Shikai Tea Tree Conditioner -- 24 fl ozShikaiBeauty & Personal Carepanthenol, ethylhexyl glycerin, glycerin, menthol, phenoxyethanol2024-11-29 10:47:42
Shikai Tea Tree Shampoo -- 1 GallonShikaiBeauty & Personal Caregluconolactone, panthenol, glycerin, menthol2024-11-29 10:47:42
Shikai Tea Tree Shampoo -- 12 fl ozShikaiBeauty & Personal Caregluconolactone, panthenol, glycerin, menthol2024-11-29 10:47:42
Soothing Touch Herbal Freeze Topical Pain Relief Gel -- 2 fl ozSoothing TouchBeauty & Personal Careglycerin, menthol, triethanolamine2024-11-29 10:47:42
Sukin Deep Cleanse Shampoo - Hair Care -- 16.9 fl ozSukinBeauty & Personal Carecitric acid, benzyl alcohol, citric acid, cocamidopropyl betaine, tocopherol, tocopherol, vitamin E, glycerin, lactic acid, menthol, phenoxyethanol, sodium benzoate, sorbitol2024-11-29 10:47:42
Tecnu Rash Relief Spray -- 6 fl ozTecnuBeauty & Personal Carebenzethonium chloride, disodium EDTA, glycerin, menthol2024-11-29 10:47:42
The Honey Pot 100% Organic Cotton Cover Everyday Herbal Pantiliners -- 20 LinersThe Honey PotBeauty & Personal Caremethyl lactate, l-menthol, methyl lactate2024-11-29 10:47:42
The Honey Pot 100% Organic Cotton Cover Everyday Liners -- 30 LinersThe Honey PotBeauty & Personal Caremethyl lactate, l-menthol, methyl lactate2024-11-29 10:47:42
The Honey Pot 100% Organic Cotton Cover Incontinence Daytime Pads with Wings -- 16 PadsThe Honey PotBeauty & Personal Caremethyl lactate, l-menthol, methyl lactate2024-11-29 10:47:42
The Honey Pot 100% Organic Cotton Cover Incontinence Overnight Pads with Wings -- 16 PadsThe Honey PotBeauty & Personal Caremethyl lactate, l-menthol, methyl lactate2024-11-29 10:47:42
The Honey Pot 100% Organic Cotton Cover Overnight Pads with Wings -- 12 PadsThe Honey PotBeauty & Personal Caremethyl lactate, l-menthol, methyl lactate2024-11-29 10:47:42
The Honey Pot 100% Organic Cotton Cover Regular Pads with Wings -- 20 PadsThe Honey PotBeauty & Personal Caremethyl lactate, l-menthol, methyl lactate2024-11-29 10:47:42
The Honey Pot Company Organic Top Sheet Postpartum Herbal Pads -- 12 PadsThe Honey PotBeauty & Personal Caremethyl lactate, l-menthol, methyl lactate2024-11-29 10:47:42
The Honey Pot Organic Cotton Cover Super Pads with Wings -- 16 PadsThe Honey PotBeauty & Personal Caremethyl lactate, l-menthol, methyl lactate2024-11-29 10:47:42
The Humble Co Dental Toothpaste Tablets Fluoride-Free -- 60 TabletsThe Humble CoBeauty & Personal Carekaolin, calcium carbonate, maltodextrin, menthol, sodium bicarbonate, stevioside2024-11-29 10:47:42
The Natural Dentist Heathy White Pre-Brush Rinse Clean Mint -- 16 fl ozThe Natural DentistBeauty & Personal Carecitric acid, citric acid, menthol, xylitol2024-11-29 10:47:42
TheraNeem Naturals - Neem Tooth & Gum Oil -- 0.5 fl ozTheraNeemBeauty & Personal Carecamphora, eugenia caryophyllata, co-q10, menthol, ashwagandha, withania somnifera2024-11-29 10:47:42
Tree to Tub Biotin & Caffeine Volumizing Conditioner for Sensitive Scalp -- 8.5 fl ozTree to TubBeauty & Personal Carecaprylyl glycol, butylene glycol, citric acid, ascorbyl palmitate, vitamin c, vitamin B7, cetearyl alcohol, palm, citric acid, vitamin e, vitamin e, glycerin, lactic acid, menthol, glyceryl caprylate, pantothenic acid, propanediol, retinyl palmitate, vitamin A, sorbic acid, sugar2024-11-29 10:47:42
Tree to Tub Biotin & Caffeine Volumizing Shampoo for Sensitive Scalp -- 8 fl ozTree to TubBeauty & Personal Carecaprylyl glycol, orange, vitamin B7, caffeine, cocamidopropyl betaine, decyl glucoside, menthol, vitamin B3, Nicotinamide, vitamins A, sodium lauroyl sarcosinate2024-11-29 10:47:42
Tree to Tub Dry Scalp Spray Instant Calm -- 3.4 fl ozTree to TubBeauty & Personal Carebutylene glycol, 4-terpineol, allantoin, lactic acid, menthol, piroctone olamine, propylene glycol, sugar2024-11-29 10:47:42
Tree to Tub Strengthening & Volumizing Caffeine and Biotin Shampoo and Conditioner Set -- 1 SetTree to TubBeauty & Personal Carecaprylyl glycol, butylene glycol, citric acid, ascorbyl palmitate, vitamin c, vitamin b7, cetearyl alcohol, palm, citric acid, cocamidopropyl betaine, vitamin e, decyl glucoside, vitamin e, glycerin, lactic acid, menthol, glyceryl caprylate, vitamin b3, niacinamide, pantothenic acid, propanediol, retinyl palmitate, vitamin a, sodium lauroyl sarcosinate, sodium benzoate, sorbic acid, sugar2024-11-29 10:47:42
Unpaste Fluoride Toothpaste Tabs Mint -- 1.4 ozUnpasteBeauty & Personal Carementhol, stevia, sodium bicarbonate, stevioside2024-11-29 10:47:42
Unpaste Fluoride-Free Toothpaste Tabs Mint -- 1.4 ozUnpasteBeauty & Personal Carementhol, stevia, sodium bicarbonate, stevioside2024-11-29 10:47:42
Vitabath Men Gentle Face Wash Lime & Cedarleaf -- 8 fl ozVitabathBeauty & Personal Carecaprylyl glycol, ascorbic acid, chlorphenesin, cocamidopropyl betaine, panthenol, disodium EDTA, glycerin, menthol, niacinamide, phenoxyethanol, retinyl palmitate, sodium hydroxide2024-11-29 10:47:42
Zimba Teeth Whitening Pen -- 2 mLZimbaBeauty & Personal Carecarbomer, glycerol, menthol, PVP, propylene glycol2024-11-29 10:47:42
Zion Health Claybrite Activated Charcoal Toothpaste Natural Mint -- 4 ozZion HealthBeauty & Personal Careglycerin, menthol, sodium bicarbonate, sorbitol, calcium phosphate, xylitol2024-11-29 10:47:42
Zion Health ClayBrite White Natural Toothpaste with Xylitol Green Tea Extract Natural Mint -- 4 ozZion HealthBeauty & Personal Careglycerin, menthol, sodium bicarbonate, sorbitol, calcium phosphate, xylitol2024-11-29 10:47:42
Zion Health Mineral Toothpaste Fluoride Free ClayBrite Extra Natural Mint -- 3.2 ozZion HealthBeauty & Personal Careglycerin, menthol, sodium bicarbonate, sorbitol, calcium phosphate, xylitol2024-11-29 10:47:42

Roles (4)

RoleDescription
antipruritic drugA drug, usually applied topically, that relieves pruritus (itching).
antitussiveAn agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
antispasmodic drugA drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder.
volatile oil componentAny plant metabolite that is found naturally as a component of a volatile oil.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
p-menthan-3-olAny secondary alcohol that is one of the eight possible diastereoisomers of 5-methyl-2-(propan-2-yl)cyclohexan-1-ol.
p-menthane monoterpenoid
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Olfactory Signaling Pathway8028
menthol biosynthesis821
Sensory Perception21568

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.05010.003245.467312,589.2998AID2517
acetylcholinesteraseHomo sapiens (human)Potency71.96540.002541.796015,848.9004AID1347398
GLI family zinc finger 3Homo sapiens (human)Potency31.88090.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency12.33320.000221.22318,912.5098AID743042; AID743054
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency69.49740.013326.981070.7614AID1346978
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.13140.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency63.55540.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency27.91690.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency43.80580.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency31.04330.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.36410.000229.305416,493.5996AID743069
caspase-3Homo sapiens (human)Potency69.49740.013326.981070.7614AID1346978
aryl hydrocarbon receptorHomo sapiens (human)Potency61.93960.000723.06741,258.9301AID743122
activating transcription factor 6Homo sapiens (human)Potency54.94100.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency40.14540.057821.109761.2679AID1159526
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency6.18770.000323.4451159.6830AID743065
farnesoid X nuclear receptorHomo sapiens (human)Potency0.00220.375827.485161.6524AID588527
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency54.94770.001019.414170.9645AID743094
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency39.81070.354828.065989.1251AID504847
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency68.58960.000323.4451159.6830AID743065
Cellular tumor antigen p53Homo sapiens (human)Potency27.05630.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Secreted chorismate mutaseMycobacterium tuberculosis H37RvIC50 (µMol)26.38000.99001.27251.9600AID1803444
Transient receptor potential cation channel subfamily M member 8Homo sapiens (human)IC50 (µMol)210.33330.02001.27553.9000AID506722; AID506723; AID506724
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)96.00000.00033.166210.0000AID1488875
Transient receptor potential cation channel subfamily M member 8Homo sapiens (human)EC50 (µMol)10.10000.06001.12003.0000AID1488874
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)30.00760.00033.166210.0000AID1549771; AID482142
Transient receptor potential cation channel subfamily M member 8Homo sapiens (human)EC50 (µMol)122.36670.06001.12003.0000AID506713; AID506714; AID506715; AID506716; AID506717; AID506718; AID506719; AID506720; AID780253
Transient receptor potential cation channel subfamily A member 1Mus musculus (house mouse)EC50 (µMol)69.00000.40002.771410.0000AID1549784; AID482139
Transient receptor potential cation channel subfamily M member 8Rattus norvegicus (Norway rat)EC50 (µMol)75.00000.11000.46671.1000AID1289984
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily M member 8Homo sapiens (human)Activity10.00000.09905.049510.0000AID500218
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (142)

Processvia Protein(s)Taxonomy
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
positive regulation of cold-induced thermogenesisTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
positive regulation of cold-induced thermogenesisTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (39)

Processvia Protein(s)Taxonomy
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
protein bindingTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
ligand-gated calcium channel activityTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
protein bindingTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
ligand-gated calcium channel activityTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
endoplasmic reticulum membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
external side of plasma membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
membrane raftTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulum membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
external side of plasma membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
membrane raftTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (106)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID776516Agonist activity at TRPM8 in differentiated rat/mouse F11 cells assessed as increase in intracellular Ca2+ level at 1 to 300 uM measured after 1 to 15 seconds by Fura-2-AM based fluorescence assay2013European journal of medicinal chemistry, Nov, Volume: 69Isoxazole derivatives as potent transient receptor potential melastatin type 8 (TRPM8) agonists.
AID403629Inhibition of COX2 at 0.1 ug/mL2005Journal of natural products, Jul, Volume: 68, Issue:7
Expanding the ChemGPS chemical space with natural products.
AID1488879Agonist activity at full length recombinant human TRPM8 Y745H mutant expressed in HEK293 cells 30 and 200 uM by Fluo4-AM dye-based fluorescence assay2017ACS medicinal chemistry letters, Jul-13, Volume: 8, Issue:7
Identification of a Novel TRPM8 Agonist from Nutmeg: A Promising Cooling Compound.
AID776517Agonist activity at TRPM8 in differentiated rat/mouse F11 cells assessed as increase in intracellular Ca2+ level measured after 20 seconds by Fura-2-AM based fluorescence assay2013European journal of medicinal chemistry, Nov, Volume: 69Isoxazole derivatives as potent transient receptor potential melastatin type 8 (TRPM8) agonists.
AID776502Potentiation of acetone-induced cold allodynic response in Swiss CD-1 mouse chronic constriction injury model applied topically 20 mins prior to acetone-challenge measured for 7 to 9 mins post acetone-challenge2013European journal of medicinal chemistry, Nov, Volume: 69Isoxazole derivatives as potent transient receptor potential melastatin type 8 (TRPM8) agonists.
AID1102313Lytic activity against Monographella nivalis var. nivalis MAFF 305031 assessed as hyphal lysis at 0.2 mg/ml after 48 hr by cotton blue staining2003Journal of agricultural and food chemistry, Mar-26, Volume: 51, Issue:7
Lytic activity of l-menthol derivatives against the snow blight disease fungus, Micronectriella nivalis.
AID776501Potentiation of acetone-induced cold allodynic response in Swiss CD-1 mouse chronic constriction injury model applied topically 20 mins prior to acetone-challenge measured for 14 to 16 mins post acetone-challenge2013European journal of medicinal chemistry, Nov, Volume: 69Isoxazole derivatives as potent transient receptor potential melastatin type 8 (TRPM8) agonists.
AID776514Agonist activity at TRPM8 in differentiated rat/mouse F11 cells at 100 uM treated in Ca2+-free solution by Fura-2-AM based fluorescence assay2013European journal of medicinal chemistry, Nov, Volume: 69Isoxazole derivatives as potent transient receptor potential melastatin type 8 (TRPM8) agonists.
AID1488875Agonist activity at recombinant human TRPA1 expressed in HEK293 cells assessed as increase in intracellular Ca2+ level pre-incubated for 5 mins by Fluo4-AM dye-based fluorescence assay2017ACS medicinal chemistry letters, Jul-13, Volume: 8, Issue:7
Identification of a Novel TRPM8 Agonist from Nutmeg: A Promising Cooling Compound.
AID776515Agonist activity at TRPM8 in differentiated rat/mouse F11 cells assessed as effect on intracellular Ca2+ level at 100 uM by Fura-2-AM based fluorescence assay in presence of TRPM8 antagonist BCTC2013European journal of medicinal chemistry, Nov, Volume: 69Isoxazole derivatives as potent transient receptor potential melastatin type 8 (TRPM8) agonists.
AID1488874Agonist activity at full length recombinant human TRPM8 expressed in HEK293 cells assessed as increase in intracellular Ca2+ level pre-incubated for 5 mins by Fluo4-AM dye-based fluorescence assay2017ACS medicinal chemistry letters, Jul-13, Volume: 8, Issue:7
Identification of a Novel TRPM8 Agonist from Nutmeg: A Promising Cooling Compound.
AID624614Specific activity of expressed human recombinant UGT2A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID776503Potentiation of acetone-induced cold allodynic response in Swiss CD-1 mouse chronic constriction injury model applied topically 20 mins prior to acetone-challenge measured up to 2 mins post acetone-challenge2013European journal of medicinal chemistry, Nov, Volume: 69Isoxazole derivatives as potent transient receptor potential melastatin type 8 (TRPM8) agonists.
AID1488882Induction of cooling effect in human at 0.02% measured immediately after washing by simple mouth washing method2017ACS medicinal chemistry letters, Jul-13, Volume: 8, Issue:7
Identification of a Novel TRPM8 Agonist from Nutmeg: A Promising Cooling Compound.
AID336478Inhibition of COX2 at 100 uM by scintillation proximity assay2002Journal of natural products, Nov, Volume: 65, Issue:11
Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346556Human TRPA1 (Transient Receptor Potential channels)2008The Journal of neuroscience : the official journal of the Society for Neuroscience, Sep-24, Volume: 28, Issue:39
Identification of transmembrane domain 5 as a critical molecular determinant of menthol sensitivity in mammalian TRPA1 channels.
AID1346556Human TRPA1 (Transient Receptor Potential channels)2007The Journal of neuroscience : the official journal of the Society for Neuroscience, Sep-12, Volume: 27, Issue:37
Bimodal action of menthol on the transient receptor potential channel TRPA1.
AID1346567Mouse TRPA1 (Transient Receptor Potential channels)2006Molecular and cellular neurosciences, Aug, Volume: 32, Issue:4
More than cool: promiscuous relationships of menthol and other sensory compounds.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID506718Activity at human TRPM8 R862A mutant expressed in HEK293 cells assessed as compound concentration causing leftward shift of voltage for half maximal activation2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID1289976Agonist activity at mouse TRPM8 expressed in HEK293 cells assessed as increase in calcium flux at 0.5 uM after 60 mins by Fluo-4 NW dye based fluorometric assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Tryptamine-Based Derivatives as Transient Receptor Potential Melastatin Type 8 (TRPM8) Channel Modulators.
AID506726Displacement of [3H]menthol from human TRPM8 Y745H mutant expressed in HEK293 cell membranes at 100 uM by scintillation counting2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID1111944Insecticidal activity against fenpropathrin-resistant female Tetranychus urticae FRT-53 (two-spotted spider mite) in kidney bean assessed as mortality in 3 cm disks measured after 24 hr exposure by vapour-phase mortality bioassay2011Pest management science, Dec, Volume: 67, Issue:12
Fumigant toxicity of lemon eucalyptus oil constituents to acaricide-susceptible and acaricide-resistant Tetranychus urticae.
AID1399359Antioxidant activity assessed as trolox equivalent of tert-butyl peroxyl radical scavenging activity by CYPMPO spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID1549806Agonist activity at human TRPA1 Cys261Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 100 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID331812Mosquito repellent activity in white mouse assessed as ratio of number of biting mosquito in treated to untreated control at 1.5 hrs2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
QSAR study of mosquito repellents from terpenoid with a six-member-ring.
AID338298Acaricidal activity against Psoroptes cuniculi at 0.25% dilution in physiological saline after 48 hrs by direct contact assay1995Journal of natural products, Aug, Volume: 58, Issue:8
Structure/activity relationship of some natural monoterpenes as acaricides against Psoroptes cuniculi.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID338303Acaricidal activity against Psoroptes cuniculi at 36 uL after 24 hrs by inhalation assay1995Journal of natural products, Aug, Volume: 58, Issue:8
Structure/activity relationship of some natural monoterpenes as acaricides against Psoroptes cuniculi.
AID555346Effect on growth in Staphylococcus aureus MN8 at 6.40 mM after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID506719Activity at human TRPM8 R842K mutant expressed in HEK293 cells assessed as compound concentration causing leftward shift of voltage for half maximal activation2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID1102450Fungitoxicity against Colletotrichum gloeosporioides assessed as mycelial growth inhibition by poisoned food technique2003Journal of agricultural and food chemistry, Aug-27, Volume: 51, Issue:18
Quantitative structure-fungitoxicity relationships of some monohydric alcohols.
AID338297Acaricidal activity against Psoroptes cuniculi at 1% dilution in physiological saline after 48 hrs by direct contact assay1995Journal of natural products, Aug, Volume: 58, Issue:8
Structure/activity relationship of some natural monoterpenes as acaricides against Psoroptes cuniculi.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID506717Activity at human TRPM8 K856A mutant expressed in HEK293 cells assessed as compound concentration causing leftward shift of voltage for half maximal activation2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID1399361Antioxidant activity assessed as trolox equivalent of singlet oxygen scavenging activity by TMPD spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID338300Acaricidal activity against Psoroptes cuniculi at 6 uL after 24 hrs by inhalation assay1995Journal of natural products, Aug, Volume: 58, Issue:8
Structure/activity relationship of some natural monoterpenes as acaricides against Psoroptes cuniculi.
AID506722Displacement of [3H]menthol from human TRPM8 expressed in HEK293 cell membranes by scintillation counting2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1399360Antioxidant activity assessed as trolox equivalent of superoxide radical scavenging activity by CYPMPO spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID500218Agonist activity at TRPM82005Nature chemical biology, Jul, Volume: 1, Issue:2
Sensing with TRP channels.
AID506729Binding affinity to human TRPM8 expressed in HEK293 cell membranes2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID506713Activity at human TRPM8 expressed in HEK293 cells assessed as compound concentration causing leftward shift of voltage for half maximal activation2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1112517Toxicity to Musca domestica (house fly) applied to pronotum assessed as compound level per fly causing insect mortality measured after 24 hr2012Pest management science, Aug, Volume: 68, Issue:8
Quantitative structure-activity relationships of monoterpenoid binding activities to the housefly GABA receptor.
AID1111942Insecticidal activity against abamectin-resistant female Tetranychus urticae ART-53 (two-spotted spider mite) in kidney bean assessed as mortality in 3 cm disks measured after 24 hr exposure by vapour-phase mortality bioassay2011Pest management science, Dec, Volume: 67, Issue:12
Fumigant toxicity of lemon eucalyptus oil constituents to acaricide-susceptible and acaricide-resistant Tetranychus urticae.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID332912Antimicrobial activity Propionibacterium acnes ATCC 11827 after 2 days by broth dilution method1994Journal of natural products, Jan, Volume: 57, Issue:1
Naturally occurring antiacne agents.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1399358Antioxidant activity assessed as trolox equivalent of alkoxyl radical scavenging activity by DMPO spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID506730Binding affinity to human TRPM8 S4b_M mutant expressed in HEK293 cell membranes2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID1111946Insecticidal activity against acaricide-susceptible female Tetranychus urticae KST (two-spotted spider mite) in kidney bean assessed as mortality in 3 cm disks measured after 24 hr exposure by vapour-phase mortality bioassay2011Pest management science, Dec, Volume: 67, Issue:12
Fumigant toxicity of lemon eucalyptus oil constituents to acaricide-susceptible and acaricide-resistant Tetranychus urticae.
AID780253Inhibition of human TRPM8 (unknown origin) expressed in HEK293 cells assessed as inhibition of WS12-induced Ca2+ elevation by FLIPR assay2013Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22
Serendipity in drug-discovery: a new series of 2-(benzyloxy)benzamides as TRPM8 antagonists.
AID506714Activity at human TRPM8 R842A mutant expressed in HEK293 cells assessed as compound concentration causing leftward shift of voltage for half maximal activation2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID506716Activity at human TRPM8 R851Q mutant expressed in HEK293 cells assessed as compound concentration causing leftward shift of voltage for half maximal activation2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID506727Displacement of [3H]menthol from human TRPM8 S4b_M5 mutant expressed in HEK293 cell membranes at 100 uM by scintillation counting2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID1289984Agonist activity at rat TRPM8 expressed in HEK293 cells assessed as increase in current amplitude at +80 mV holding potential by whole cell patch-clamp assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Tryptamine-Based Derivatives as Transient Receptor Potential Melastatin Type 8 (TRPM8) Channel Modulators.
AID1549811Agonist activity at human TRPA1 Phe909Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 100 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID506721Binding affinity to human TRPM8 expressed in HEK293 cell membranes using [3H]labeled compound by scintillation counting2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID1399357Antioxidant activity assessed as trolox equivalent of hydroxyl radical scavenging activity by DMPO spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID338299Acaricidal activity against Psoroptes cuniculi at 0.125% dilution in physiological saline after 48 hrs by direct contact assay1995Journal of natural products, Aug, Volume: 58, Issue:8
Structure/activity relationship of some natural monoterpenes as acaricides against Psoroptes cuniculi.
AID482139Antagonist activity at mouse TRPA1 channel expressed in CHO cells assessed as blockade of agonist-induced whole cell conductance by electrophysiology2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID506724Displacement of [3H]menthol from human TRPM8 R842A mutant expressed in HEK293 cell membranes by scintillation counting2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID1111945Insecticidal activity against chlorfenapyr-resistant female Tetranychus urticae CRT-53 (two-spotted spider mite) in kidney bean assessed as mortality in 3 cm disks measured after 24 hr exposure by vapour-phase mortality bioassay2011Pest management science, Dec, Volume: 67, Issue:12
Fumigant toxicity of lemon eucalyptus oil constituents to acaricide-susceptible and acaricide-resistant Tetranychus urticae.
AID555378Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 6.40 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID506725Displacement of [3H]menthol from human TRPM8 L1009R mutant expressed in HEK293 cell membranes at 100 uM by scintillation counting2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID506715Activity at human TRPM8 H845A mutant expressed in HEK293 cells assessed as compound concentration causing leftward shift of voltage for half maximal activation2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID1289973Agonist activity at rat TRPM8 expressed in HEK293 cells assessed as current density at +80 mV holding potential by whole cell patch-clamp assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Tryptamine-Based Derivatives as Transient Receptor Potential Melastatin Type 8 (TRPM8) Channel Modulators.
AID482142Activation of TRPA1 channel2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID1549784Agonist activity at mouse TRPA1 expressed in CHO cells assessed as increase in calcium influx by patch clamp electrophysiology method2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID506728Activity at human TRPM8 S4b_M mutant expressed in HEK293 cells assessed as compound concentration causing leftward shift of voltage for half maximal activation2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID338304Acaricidal activity against Psoroptes cuniculi at 18 uL after 24 hrs by inhalation assay1995Journal of natural products, Aug, Volume: 58, Issue:8
Structure/activity relationship of some natural monoterpenes as acaricides against Psoroptes cuniculi.
AID1080459Antifeedant activity against apterous adult stage of Lipaphis erysimi (mustard aphids) in compound pre-treated cabbage leaves assessed as antifeedant ratio measured after 48 hr2008Journal of agricultural and food chemistry, Dec-10, Volume: 56, Issue:23
Quantitative structure-activity relationship of terpenoid aphid antifeedants.
AID555347Effect on growth in Staphylococcus aureus MN8 at 3.20 mM after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID506723Displacement of [3H]menthol from human TRPM8 K856A mutant expressed in HEK293 cell membranes by scintillation counting2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID1549818Agonist activity at human TRPA1 Phe944Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 100 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID1112518Displacement of [3H]TBOB binding to GABA receptor in Musca domestica (house fly) heads homogenates assessed as [3H]TBOB binding at 500 uM incubated for 90 min by scintillation counting method2012Pest management science, Aug, Volume: 68, Issue:8
Quantitative structure-activity relationships of monoterpenoid binding activities to the housefly GABA receptor.
AID1289985Effect on current amplitude in non-transfected HEK293 cells at +80 mV holding potential by whole cell patch-clamp assay2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Tryptamine-Based Derivatives as Transient Receptor Potential Melastatin Type 8 (TRPM8) Channel Modulators.
AID1399362Antioxidant activity assessed as trolox equivalent of methyl radical scavenging activity by DMPO spin trap-based ESR spectrometric method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
Monoterpene's multiple free radical scavenging capacity as compared with the radioprotective agent cysteamine and amifostine.
AID1549771Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID506720Activity at human TRPM8 K856R mutant expressed in HEK293 cells assessed as compound concentration causing leftward shift of voltage for half maximal activation2007Nature chemical biology, Mar, Volume: 3, Issue:3
TRPM8 voltage sensor mutants reveal a mechanism for integrating thermal and chemical stimuli.
AID555379Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 3.20 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID1581192Agonist activity at mouse TRPM8 expressed in HEK293 cells assessed as increase in calcium influx at 1 uM incubated for 1 min by Fluo-4-AM dye based FLIPR assay2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID1111943Insecticidal activity against pyridaben-resistant female Tetranychus urticae PRT-53 (two-spotted spider mite) in kidney bean assessed as mortality in 3 cm disks measured after 24 hr exposure by vapour-phase mortality bioassay2011Pest management science, Dec, Volume: 67, Issue:12
Fumigant toxicity of lemon eucalyptus oil constituents to acaricide-susceptible and acaricide-resistant Tetranychus urticae.
AID1803444CM Assay from Article 10.3109/14756366.2013.823958: \\Identification and structure-activity relationship study of carvacrol derivatives as Mycobacterium tuberculosis chorismate mutase inhibitors.\\2014Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 29, Issue:4
Identification and structure-activity relationship study of carvacrol derivatives as Mycobacterium tuberculosis chorismate mutase inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,365)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990308 (13.02)18.7374
1990's219 (9.26)18.2507
2000's459 (19.41)29.6817
2010's865 (36.58)24.3611
2020's514 (21.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 92.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index92.95 (24.57)
Research Supply Index7.89 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index175.67 (26.88)
Search Engine Supply Index2.05 (0.95)

This Compound (92.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials210 (8.52%)5.53%
Reviews1 (5.88%)6.00%
Reviews126 (5.11%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies63 (2.55%)4.05%
Observational0 (0.00%)0.25%
Observational5 (0.20%)0.25%
Other16 (94.12%)84.16%
Other2,062 (83.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (107)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II, Randomized, Double-blind, Active Comparator, Parallel Group Study to Evaluate the Efficacy and Safety of K-285 Compared With Menthol Gel for the Treatment of Delayed Onset Muscle Soreness (DOMS) in the Lower Extremity [NCT04484428]Phase 2126 participants (Actual)Interventional2020-08-15Terminated(stopped due to Internal business decision)
Comparative Efficacy of the Suppository Composed by Guaiacol, Eucalyptol, Menthol and Camphor Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin [NCT01119534]Phase 3270 participants (Anticipated)Interventional2011-05-31Not yet recruiting
Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes [NCT04038515]Phase 260 participants (Anticipated)Interventional2022-10-27Enrolling by invitation
Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% as a New Surrogate Model of Itch [NCT03943407]0 participants (Actual)Interventional2019-11-30Withdrawn(stopped due to The Imiquimod 3.75% was ineffective)
The Cognitive Benefits of Interactive Mental and Physical Exercise for Older Adults at Risk for or With Mild Cognitive Impairment (MCI) [NCT02237560]111 participants (Actual)Interventional2014-09-30Completed
A Single-Center, Randomized, Open-Label, Crossover Study to Assess Elements of Abuse Liability for Three Menthol Electronic Cigarettes [NCT02664012]71 participants (Actual)Interventional2016-01-31Completed
"Prospective, Multicenter, Open, Randomized, Parallel, Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray [Menthol], 0,5 mg + 2 mg / 1 ml (Sandoz d.d., Slovenia), and ANTI-ANGIN® FORMULA, Topical Metered Spray, 0,12 [NCT03095508]Phase 3229 participants (Actual)Interventional2017-02-22Completed
Menthol Flavored E-cigarette Use During a Simulated Ban of Menthol Cigarettes [NCT03164668]38 participants (Actual)Interventional2017-05-03Completed
The Use of the Menthol Popsicle to Manage the Elderly Patient's Thirst in the Immediate Postoperative Period: a Randomized Clinical Trial [NCT03621800]40 participants (Actual)Interventional2018-06-07Completed
Manipulating Tobacco Constituents in Female Menthol Smokers [NCT02048852]381 participants (Actual)Interventional2014-07-31Completed
"A Prospective, Multi-center, Open, Randomized Clinical Study in Parallel Groups, for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol], 1 mg + 5 mg (Sandoz d.d., Slovenia), and ANTI-ANGIN® FORMULA, Lozenges, 0,2 mg + 2 mg + 5 [NCT03095521]Phase 3228 participants (Actual)Interventional2017-02-22Completed
Attitude of Unscreened Women Face to Different Strategies to Participate in Cervical Cancer Screening by Vaginal Self-sampling : Home-mailed or Invitation to Remove to Their General Practitioner [NCT02255084]3,612 participants (Actual)Interventional2015-02-28Completed
Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 1 [NCT02179034]Phase 159 participants (Actual)Interventional2014-10-23Completed
A Single-Center Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes [NCT02185898]71 participants (Actual)Interventional2014-05-31Completed
Effects of Menthol on Dyspnoea Induced by Exercise in COPD Patients [NCT03626519]63 participants (Actual)Interventional2019-09-23Completed
Topical Menthol Application in Chemotherapy-Related Peripheral Neuropathy in Patients With Breast Cancer [NCT05429814]60 participants (Actual)Interventional2022-07-01Completed
Assessing Tobacco Product Choice When the Cost of Menthol Cigarettes Increases [NCT03612349]60 participants (Anticipated)Interventional2018-07-09Recruiting
Open-label, Randomized, Four-treatment, Four-sequence, Four-period, Crossover, Single-application Study Evaluating and Comparing Product Adhesion in Healthy Adult Subjects Using ZTlido 1.8% Versus Salonpas(Lidocaine Patch 4%), Aspercreme(Lidocaine Patch 4 [NCT05106400]Phase 124 participants (Actual)Interventional2021-07-01Completed
The Impact of Menthol and Mint E-liquid Bans on Menthol Cigarette Smokers [NCT04879225]66 participants (Actual)Interventional2021-06-21Completed
A Pharmacokinetics Study Comparing Systemic Exposure of Topical Diclofenac/Menthol Gels Versus Voltaren Gel and Oral Diclofenac Sodium in Healthy Volunteers at Steady State [NCT02201238]Phase 118 participants (Actual)Interventional2014-10-01Completed
Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Mentholated Cigarettes With Characterization of Nicotine Exposure Profiles in Adult Smokers [NCT03559725]Phase 155 participants (Actual)Interventional2018-05-01Completed
L-Menthol Injection as a Novel Technique During Colonoscopy: The MINT-C Study [NCT02588248]Phase 382 participants (Actual)Interventional2017-04-27Terminated(stopped due to Sponsor/Investigator has decided to close out the study)
The Effects of Nasal Airflow on Upper Airway Dilator Muscles During Sleep [NCT03506178]30 participants (Anticipated)Interventional2017-09-12Recruiting
A Cumulative Skin Irritation Study Investigating the Skin Irritancy Potential of MFC51123 Diclofenac-Menthol Gel [NCT02169154]Phase 136 participants (Actual)Interventional2014-06-01Completed
Temporal Profile of the Nociceptive Desensitization Induced by 8% Topical Capsaicin and the Functional Independence of Transient Receptor Potential Ankyrin 1 (TPRA1)- and Vanilloid 1 (TRPV1)-Expressing Nociceptive Afferents [NCT03132142]22 participants (Anticipated)Interventional2017-04-30Recruiting
A Randomized, Controlled Study to Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers After a 5-Day In-Clinic Confinement Switch to an Electronic Cigarette or Nicotine Gum [NCT02323438]153 participants (Actual)Interventional2014-12-31Completed
Experimentally Testing Legally Feasible Regulatory Options for Reducing the Impact of the Point-of-sale Retail Environment on Adolescent Tobacco Use [NCT04259749]267 participants (Actual)Interventional2020-01-16Completed
Effects of Flavors on Nicotine Reinforcement in Smokers [NCT03243630]Early Phase 126 participants (Actual)Interventional2018-04-23Completed
A Randomized, Double-Blind, Placebo Control Trial Comparing Effects and Safety of DANSHU Capsule(Menthol) and Placebo on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patients [NCT01408446]Phase 2/Phase 336 participants (Actual)Interventional2012-08-01Completed
Manipulating Tobacco Constituents in Male Menthol Smokers [NCT02592772]118 participants (Actual)Interventional2016-02-04Completed
Activation of Peripheral TRPM8 Mitigates Acute Ischemic Stroke by Topically Applied Menthol [NCT05877079]Phase 460 participants (Anticipated)Interventional2023-05-20Not yet recruiting
Methodology of Application and Immediate Effect of the Essential Oils and 0.2% Chlorhexidine on Oral Biofilm: Immersion Versus Mouthwash. [NCT02267239]Phase 415 participants (Anticipated)Interventional2014-10-31Recruiting
Prospective Analgesic Compound Efficacy (PACE) Study [NCT02403687]300 participants (Actual)Observational [Patient Registry]2015-06-30Completed
Evaluating The Effects Of E-cigarettes Versus Oral Nicotine Pouches and Product Constituents (Menthol Flavor, Nicotine Concentration) On Adult Cigarette Smoking and Addiction [NCT06077240]256 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Examine the Effects of Novel E-cigarette Constituents and Determining Appropriate Concentrations Among Adults [NCT05932693]30 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Evaluating the Potential Impact of a Menthol Ban in Cigarettes and E-cigarettes Among Current Menthol Smokers [NCT05259566]150 participants (Anticipated)Interventional2022-12-01Recruiting
A Randomised, Cross-Over, Nicotine Pharmacokinetic and Pharmacodynamic Study of Heated Tobacco Products Compared to Combustible Cigarettes [NCT05459857]24 participants (Actual)Interventional2021-10-01Completed
Vascular Effects of a Single Bout of Electronic Cigarette Use [NCT03209661]Phase 116 participants (Actual)Interventional2017-04-28Completed
Safety Study to Investigate the Skin Sensitization Potential of MFC51123 [NCT02192203]Phase 1227 participants (Actual)Interventional2014-04-01Completed
Effect of L-menthol on Breathlessness and Exercise Capacity in Chronic Obstructive Pulmonary Disease: a Randomized [NCT05888597]Phase 220 participants (Anticipated)Interventional2023-05-24Recruiting
The Effect of Menthol on ENDS Users' Dependence, Respiratory, and Toxicants Emission Outcomes. [NCT05338801]250 participants (Anticipated)Interventional2022-06-22Recruiting
Phase II Study of NPO-13 in Patients Undergoing Colonoscopy [NCT04097574]Phase 2158 participants (Actual)Interventional2019-08-26Completed
High-concentration L-menthol as a Counter-irritant to TRPA1-induced Neurogenic Inflammation, Thermal and Mechanical Hyperalgesia Caused by Trans-cinnamaldehyde [NCT02653703]14 participants (Actual)Interventional2014-10-31Completed
A Randomized, Open-Label, Cross-Over Study to Characterize Puffing Topography With Use of JUUL Electronic Nicotine Delivery Systems (ENDS) in Adult, Closed-System ENDS Consumers [NCT04088175]56 participants (Actual)Interventional2019-10-28Completed
Open Clinical Trial to Assess Safety and Efficacy of the Sore Throat Lozenges in Patients With Acute Sore Throats [NCT04139681]Phase 474 participants (Actual)Interventional2019-03-12Completed
A Randomized, Open Label, Parallel Group Study in Adult Smokers to Evaluate Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to Using JUUL Electronic Nicotine Delivery Systems With Two Different Nicotine Conce [NCT04107779]279 participants (Actual)Interventional2019-09-17Completed
Phase III Placebo-controlled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy (Randomized, Double-blind, Parallel-assignment, Placebo-controlled Study) [NCT01411176]Phase 385 participants (Actual)Interventional2011-09-30Completed
Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy [NCT01411189]Phase 333 participants (Actual)Interventional2011-09-30Completed
Effect of a Medicated Topical Therapy, Petrolatum, and No Treatment on Nocturnal Cough and Congestion for Children With Upper Respiratory Infections [NCT00743990]143 participants (Actual)Interventional2008-10-31Completed
Effectiveness and Mechanisms of Menthol Inhalation for the Relief of Dyspnea in Health and COPD [NCT05785026]120 participants (Anticipated)Interventional2023-01-01Recruiting
Addiction and Behavior Related to Menthol Cigarette Substitutes [NCT04844762]120 participants (Actual)Interventional2019-12-16Completed
A Randomized, Open-Label, Multi-Center, Cross-Over Study of Adult Electronic Nicotine Delivery Systems (ENDS) Consumers to Assess Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With RELX Infinity ENDS [NCT04620616]29 participants (Actual)Interventional2020-09-11Completed
Effect of Banning Menthol Flavorant on Cigarette and E-Cigarette Use [NCT03402243]47 participants (Actual)Interventional2018-02-26Completed
Antiperistaltic Effect and Safety of L-menthol and Placebo for Upper GI Endoscopy in the Elderly With Contraindication to Buscopan: a Prospective, Randomized, Double-blind Study [NCT04593836]Phase 360 participants (Anticipated)Interventional2012-03-31Recruiting
Characterization of Nicotine Exposure and Urge-to-Smoke Following a Single Controlled Administration and Short-Term Ad Lib Use of Electronic Cigarettes and Conventional Cigarettes in Adult Smokers [NCT02210754]24 participants (Actual)Interventional2014-03-31Completed
A PHASE 1, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF SELF-AMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALS [NCT05227001]Phase 1442 participants (Actual)Interventional2022-04-28Completed
The Impact of Menthol Regulation for Cigarettes and E-cigarettes on Tobacco Use Patterns for Current Menthol Smokers [NCT05896033]240 participants (Anticipated)Interventional2023-10-23Recruiting
Acute Oral Effects of Heated Tobacco Products Compared to Traditional Cigarettes [NCT05538702]10 participants (Actual)Interventional2021-10-01Completed
Randomized Controlled Trial Comparing the Efficacy and Safety of Calmoseptine Ointment and Desitin Maximum Strength 40% Zinc Oxide Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants [NCT02716415]Phase 4319 participants (Actual)Interventional2015-03-31Completed
Comparison of Prescription Lidocaine Patch to Over the Counter Lidocaine Patch and Placebo for Back Pain and Arthritis [NCT02749123]100 participants (Anticipated)Interventional2016-04-30Recruiting
A Double Blind, Randomized Crossover Study of Efficacy and Safety of Topical Menthol, With and Without Mannitol, in the Treatment of Painful Diabetic Peripheral Neuropathy [NCT02728687]Phase 1/Phase 272 participants (Actual)Interventional2017-03-15Completed
A Study to Assess Nicotine Pharmacokinetic Parameters of Digital Vapor Cigarettes in Adopters and Compare Them to Nicotine Pharmacokinetic Parameters of Cigarettes in Smokers [NCT02730676]44 participants (Actual)Observational2016-04-30Completed
Impact of Combined Non-surgical and Surgical Periodontal Treatment in Patients With Type 2 Diabetes Mellitus [NCT02874963]160 participants (Anticipated)Interventional2015-11-30Recruiting
Iron Metabolism in Dragon Boat Athletes - An Analysis of Changes in Blood Count Parameters Under Sport-specific Stress [NCT01431118]40 participants (Anticipated)Interventional2011-04-30Completed
A Multi-site, Open-Label, Parallel-Group Study To Evaluate Changes In Tobacco-Related Biomarkers of Exposure and Biomarkers of Potential Harm With Use of Heated Tobacco Products Compared to Combustible Cigarettes in Adult Smokers [NCT06179290]300 participants (Anticipated)Interventional2023-10-02Recruiting
Menthol-based Topical Analgesic Induces Similar Upper and Lower Body Increases in Pain Pressure Threshold: A Randomized Trial [NCT04677985]16 participants (Actual)Interventional2019-05-01Completed
[NCT01849835]120 participants (Anticipated)Interventional2013-01-31Recruiting
A Randomized, Open-Label, Single-Center, Cross-Over Study of Adult Smokers to Assess Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With RELX Infinity Electronic Nicotine Delivery Systems (ENDS) [NCT04640285]41 participants (Actual)Interventional2020-11-03Completed
Effect of a Menthol Gel (Biofreeze) on the Symptoms Associated With Knee Osteoarthritis: a Double-blind Randomized Control Trial. [NCT04351594]Phase 2/Phase 3100 participants (Anticipated)Interventional2020-11-01Recruiting
The Effect on Thirst, Nausea-Vomiting, Hemodynamic Parameters, and Comfort Levels of Menthol Lozenge Applied After Extubation to Patients to Undergoing Cardiovascular Surgery [NCT04994262]118 participants (Actual)Interventional2020-05-01Completed
A Randomized, Controlled, Open-label, 4-arm Parallel Group Study to Demonstrate Reductions in Exposure to Selected Harmful and Potentially Harmful Constituents (HPHC) in Healthy Smokers Switching to 2 Variants of P4M3 Gen 2.0, an Electronic Nicotine Deliv [NCT05487456]68 participants (Actual)Interventional2022-07-15Completed
Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor [NCT04711044]20 participants (Actual)Interventional2021-02-01Completed
Effects of Electronic Cigarettes on Nicotine Concentrations Before and 5, 10, 15, 20 and 30 Minutes After Use [NCT01775787]27 participants (Actual)Interventional2012-10-31Completed
A Randomised, Controlled, Double-Blind Study to Examine Nicotine Pharmacokinetics and Smoking Behaviour in Healthy Smokers When Smoking Cigarettes Containing Different Commonly Used Ingredients [NCT03272295]40 participants (Actual)Interventional2017-09-12Completed
The Use of the Menthol Popsicle to Manage the Patient's Seat in the Preoperative Period: a Randomized Clinical Trial [NCT03236623]40 participants (Anticipated)Interventional2017-05-10Recruiting
Determining the Right Acupuncture for Good Recovery Over Neuropsychiatric Trauma (DRAGON) [NCT05516862]75 participants (Anticipated)Interventional2022-10-01Recruiting
An Open Clinical Cross-Over Trial to Compare the Kinetics of Etheric Oils Applied Onto the Skin or Via Smart Textiles [NCT00299559]Phase 16 participants (Actual)Interventional2006-03-31Completed
The Effect of Cigarette Holders, Plastic Menthol Cigarettes, and Cognitive Behavioral Therapy for Smoking Reduction Among Schizophrenia Inpatients: A Comparative Study [NCT00302432]37 participants (Actual)Interventional2006-03-31Completed
Effectiveness of Menthol Chewing Gum in the Management of Preoperative Thirst: Randomized Clinical Trial [NCT03200197]102 participants (Actual)Interventional2016-11-30Completed
Acute Effect of Topical Menthol on Pain Symptoms in Slaughterhouse Workers With Symptoms of Carpal Tunnel Syndrome: Randomized Controlled Trial [NCT01716767]10 participants (Actual)Interventional2012-12-31Completed
The Impact of Menthol Flavoring on Switching in Adult Menthol Smokers [NCT05555069]800 participants (Anticipated)Interventional2022-11-08Recruiting
Smoking Topography and Harm Exposure in Menthol Cigarettes [NCT01329263]87 participants (Actual)Interventional2010-09-30Completed
[NCT02342327]122 participants (Actual)Interventional2014-10-28Completed
A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy [NCT02984072]Phase 410 participants (Actual)Interventional2018-10-23Completed
A Study to Evaluate the Efficacy and Tolerability of STOPAIN in the Treatment of a Single Migraine Attack [NCT01687101]32 participants (Actual)Interventional2012-05-31Completed
Characterization of Selected Aerosol Constituents Levels in the Exhaled Breath of Adult e-Vapor Users During Use of Four e-Vapor Products [NCT04881942]35 participants (Actual)Interventional2017-03-27Completed
Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, and Gingerol Content in Patients With Irritable Bowel Syndrome: a Double-blind, Randomized, Placebo-controlled Trial [NCT04484467]56 participants (Actual)Interventional2018-02-09Completed
Topical Menthol for Chemotherapy Induced Peripheral Neuropathy (CIPN): A Randomized, Placebo Controlled Phase II Trial [NCT01855607]Phase 211 participants (Actual)Interventional2013-08-31Terminated(stopped due to Lack of feasibility)
Switching to Reduced Nicotine Content Cigarettes or Reduced Reactive Oxygen/Reactive Nitrogen Species Cigarettes in Smokers [NCT02415270]37 participants (Actual)Interventional2016-01-31Completed
Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study [NCT04900129]Phase 143 participants (Actual)Interventional2020-12-01Completed
Menthol's Effects on Nicotine Reinforcement in Smokers [NCT02102100]57 participants (Actual)Interventional2014-03-26Completed
Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain [NCT04497870]Phase 10 participants (Actual)Interventional2020-07-09Withdrawn(stopped due to This study was superseded by NCT03295747)
The Additional Role of Supplemental Oxygen Therapy in Accelerated Corneal Collagen Cross-linking in Progressive Keratoconus. A Randomized Clinical Trial [NCT04343326]Phase 2/Phase 330 participants (Anticipated)Interventional2020-01-01Recruiting
A Randomized, Controlled, Open-label, 3-arm Parallel Group, Multi-center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Apparently Healthy Smokers Switching to the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) or Obse [NCT01989156]160 participants (Actual)Interventional2013-12-31Completed
A Randomised, Double Blind, Cross Over Clinical Study in Healthy Human Volunteers to Assess the Efficacy and Safety of Three Different Topical Analgesics (DCF100, TIB200 And SPR300) Versus in a Model of UV-Induced Inflammatory Pain [NCT02666846]Phase 160 participants (Actual)Interventional2015-03-31Completed
A Randomized, Multi-Center, Open-Label, Parallel-Cohort Study to Characterize Product Use in Smokers Switching From Combustible Cigarettes to a RELX Electronic Nicotine Delivery System (ENDS) [NCT04708106]194 participants (Actual)Interventional2020-10-15Completed
A Longitudinal Ambulatory Study to Assess Changes in Cigarette Consumption and Biomarkers of Exposure During a 6-week Switch to Very Low Nicotine Cigarettes [NCT03571724]142 participants (Actual)Interventional2018-06-28Completed
Effect of Oral Menthol on the Swallow Response of Patients With Oropharyngeal Dysphagia Associated With Neurological Diseases and Aging [NCT03050957]Phase 238 participants (Actual)Interventional2013-05-31Completed
A Clinical Study to Assess the Efficacy and Onset of Pain Relief of Topical MFC51123 Diclofenac-Menthol Gel Versus Controls in Ankle Sprain [NCT02100670]Phase 3385 participants (Actual)Interventional2013-11-01Completed
Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 2 [NCT03168191]Phase 156 participants (Actual)Interventional2017-05-02Completed
Quantitative Analysis of Different Acupuncture Needle Manipulation to Treat Chronic Shoulder Pain [NCT03197207]60 participants (Actual)Interventional2016-06-03Completed
An Open-Label, Multi-Center Study to Evaluate Selected Constituents in the Exhaled Breath Samples From the Use of JUUL Nicotine Salt Pod System Product (5% and 3% Virginia Tobacco, Mint, Mango, Menthol) Users and Conventional Cigarettes (Non-Menthol and M [NCT04143256]135 participants (Actual)Interventional2019-10-03Completed
The Influence of Interactive Media on Child Development in Children From 24 to 36 Months of Age: Protocol of a Randomized Controlled Clinical Trial [NCT04831229]64 participants (Anticipated)Interventional2021-08-21Not yet recruiting
A Randomized, Controlled, Multi-center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Smokers Switching to THS 2.2 Menthol or Smoking Abstinence Compared to Smoking Menthol Conventional Cigarettes, for 90 Days [NCT01970995]160 participants (Actual)Interventional2013-08-31Completed
Menthol Mouth Rinsing and Performance Responses of Elite Football Referees in the Heat: a Randomized Crossover Trial [NCT05632692]10 participants (Anticipated)Interventional2023-04-10Not yet recruiting
The Influence of Topical Menthol Gel on Thermoregulatory and Perceptual Outcomes During Exercise Within the Heat [NCT05302804]Phase 412 participants (Actual)Interventional2022-05-01Completed
A Randomized, Single-Blind, Two-Arm, Cross-Over Study to Compare Use of Two Tobacco and Two Menthol Flavor e-Liquids in Electronic Nicotine Delivery System Users [NCT05134415]40 participants (Actual)Interventional2021-10-12Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01329263 (4) [back to overview]Nicotine Levels
NCT01329263 (4) [back to overview]Smoking Topography- Carbon Monoxide Boost
NCT01329263 (4) [back to overview]Smoking Topography- Puff Volume
NCT01329263 (4) [back to overview]Subjective Rating of Cigarettes
NCT01687101 (1) [back to overview]Efficacy of STOPAIN in the Acute Treatment of Migraine
NCT01775787 (1) [back to overview]Effects E-cig Use on Venous Nicotine Concentrations Before and 5 Minutes After Use
NCT01970995 (5) [back to overview]Concentration of Total 4-(Methylnitrosamino)-1-(3- Pyridyl)-1-butanol) (Total NNAL)
NCT01970995 (5) [back to overview]Concentration of S-phenylmercapturic Acid (S-PMA)
NCT01970995 (5) [back to overview]Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA)
NCT01970995 (5) [back to overview]Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)
NCT01970995 (5) [back to overview]Levels of Carboxyhemoglobin (COHb)
NCT01989156 (5) [back to overview]Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)
NCT01989156 (5) [back to overview]Concentration of Monohydroxybutenylmercapturic Acid (MHBMA)
NCT01989156 (5) [back to overview]Concentration of S-phenylmercapturic Acid (S-PMA)
NCT01989156 (5) [back to overview]Levels of Carboxyhemoglobin (COHb)
NCT01989156 (5) [back to overview]Levels of Total 4-(Methylnitrosamino)-1-(3- Pyridyl)-1-butanol (Total NNAL)
NCT02100670 (14) [back to overview]Skin Temperature
NCT02100670 (14) [back to overview]Pain Intensity Difference (PID) on Movement
NCT02100670 (14) [back to overview]Patient's Global Assessment in Response to Treatment (PGART)
NCT02100670 (14) [back to overview]PID at Rest
NCT02100670 (14) [back to overview]Total Pain Relief (TOTPAR)
NCT02100670 (14) [back to overview]Sum of Pain Intensity Difference (SPID)
NCT02100670 (14) [back to overview]Pain Relief Score (PRS)
NCT02100670 (14) [back to overview]Ankle Swelling
NCT02100670 (14) [back to overview]Time to Complete Recovery
NCT02100670 (14) [back to overview]Time of Onset of Pain Relief (TOPR)
NCT02100670 (14) [back to overview]Time of Onset of Meaningful Pain Relief (TOMR)
NCT02100670 (14) [back to overview]Time of Onset of Cooling Sensation (TOCS)
NCT02100670 (14) [back to overview]AUC1-3 Days of PI on Movement for Diclofenac Sodium + Methanol, Diclofenac, Methanol and Placebo
NCT02100670 (14) [back to overview]Area Under the Curve From Day 1 to Day 3 (AUC1-3 Days) of Pain Intensity(PI) on Movement for Diclofenac/Methanol Gel and Placebo Gel
NCT02102100 (1) [back to overview]Drug Effects Questionnaire (DEQ)- 'Good Drug Effects'
NCT02342327 (2) [back to overview]Time to Relapse
NCT02342327 (2) [back to overview]Time to Lapse
NCT02588248 (2) [back to overview]Advanced Adenoma Detection Rates
NCT02588248 (2) [back to overview]Procedure Time
NCT02666846 (8) [back to overview]Adverse Events (AEs)
NCT02666846 (8) [back to overview]Area Under the Plasma Concentration Versus Time Curve
NCT02666846 (8) [back to overview]Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade -
NCT02666846 (8) [back to overview]Intensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units])
NCT02666846 (8) [back to overview]Number of Recorded Abnormal Clinical Assessments
NCT02666846 (8) [back to overview]Peak Plasma Concentration (Cmax)
NCT02666846 (8) [back to overview]Physical Exams to Ensure Safety and Well Being of the Subjects
NCT02666846 (8) [back to overview]To Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects
NCT03095508 (6) [back to overview]Change From Baseline in TSS Total Score
NCT03095508 (6) [back to overview]Number of Participants Who Fully Recovered
NCT03095508 (6) [back to overview]Percentage of Participants With a ≥50% TSS Total Score Reduction
NCT03095508 (6) [back to overview]Period of Time Required for Disappearance of the Disease Symptoms
NCT03095508 (6) [back to overview]Change in the Sore Throat Intensity by 100 mm VAS
NCT03095508 (6) [back to overview]Percentage of Patients Without Sore Throat According to the Tonsillopharyngitis Severity Score (TSS)
NCT03095521 (6) [back to overview]50% Reduction Tss SCORE
NCT03095521 (6) [back to overview]Days to Recovery, Defined by the Patient's Diary (Subjective Evaluation by the Patient)
NCT03095521 (6) [back to overview]Percentage of Participants Without Sore Throat According to TSS Score
NCT03095521 (6) [back to overview]Change From Baseline in TSS Total Score
NCT03095521 (6) [back to overview]Change From Baseline in Sore Throat Intensity by 100 mm in Visual Analogue Scale Filled in by the Patient (VAS) .
NCT03095521 (6) [back to overview]Number of Participants Who Fully Recovered up to Day 5
NCT03243630 (1) [back to overview]The Reinforcing Drug Effects Will be Measured With the Drug Effects Questionnaire (DEQ).
NCT03402243 (3) [back to overview]Amount of Tobacco Product Used
NCT03402243 (3) [back to overview]"How Much of Each Product is Obtained From the Experimental Marketplace"
NCT03402243 (3) [back to overview]Motivation to Quit Smoking Cigarettes
NCT03571724 (25) [back to overview]Biomarkers of Exposure -Cotinine
NCT03571724 (25) [back to overview]Cigarettes Per Day
NCT03571724 (25) [back to overview]Nicotine Pharmacokinetics - Area Under Nicotine Concentration Curve (AUC)
NCT03571724 (25) [back to overview]Nicotine Pharmacokinetics - Area Under Nicotine Concentration Curve (AUC)
NCT03571724 (25) [back to overview]Nicotine Pharmacokinetics - Maximum Nicotine Concentration (C-Max)
NCT03571724 (25) [back to overview]Nicotine Pharmacokinetics - Maximum Nicotine Concentration (C-Max)
NCT03571724 (25) [back to overview]Nicotine Pharmacokinetics - Peak Nicotine Time (T-Max)
NCT03571724 (25) [back to overview]Nicotine Pharmacokinetics - Peak Nicotine Time (T-Max)
NCT03571724 (25) [back to overview]Smoking Topography - Average Flow Rate
NCT03571724 (25) [back to overview]Smoking Topography - Inter-puff Interval
NCT03571724 (25) [back to overview]Smoking Topography - Peak Puff Flow Rate
NCT03571724 (25) [back to overview]Smoking Topography - Puff Duration
NCT03571724 (25) [back to overview]Smoking Topography - Puff Volume
NCT03571724 (25) [back to overview]Biomarkers of Exposure - 1-hydroxy Pyrene(1-OHP)
NCT03571724 (25) [back to overview]Subjective Effects - Perceived Health Risks
NCT03571724 (25) [back to overview]Subjective Effects -Brief Questionnaire of Smoking Urges (QSU-Brief)
NCT03571724 (25) [back to overview]Subjective Effects -Fagerstrom Test for Cigarette Dependance (FTCD)
NCT03571724 (25) [back to overview]Biomarkers of Exposure - 3-hydroxypropylmercapturic Acid (3-HPMA)
NCT03571724 (25) [back to overview]Biomarkers of Exposure - Carboxyhemoglobin (COHb)
NCT03571724 (25) [back to overview]Biomarkers of Exposure - S-phenylmercapturic Acid (S-PMA)
NCT03571724 (25) [back to overview]Subjective Effects - Minnesota Nicotine Withdrawal Scale - Revised (MNWS-R)
NCT03571724 (25) [back to overview]Biomarkers of Exposure - Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1 Butanol (NNAL)
NCT03571724 (25) [back to overview]Biomarkers of Exposure - Total N-Nitrosonornicotine (NNN)
NCT03571724 (25) [back to overview]Biomarkers of Exposure - Total Nicotine Equivalents
NCT03571724 (25) [back to overview]Biomarkers of Exposure -Cotinine
NCT04259749 (11) [back to overview]Proportion of Participants Susceptible to Using Little Cigar/Cigarillos (LCC) After Shopping in the StoreLab (Non-flavored)
NCT04259749 (11) [back to overview]Proportion of Participants Susceptible to Using Little Cigar/Cigarillos (LCC) After Shopping in the StoreLab (Menthol-flavored)
NCT04259749 (11) [back to overview]Proportion of Participants Susceptible to Using Electronic Nicotine Delivery Device (ENDS) After Shopping in the StoreLab (Sweet-flavored)
NCT04259749 (11) [back to overview]Proportion of Participants Susceptible to Using Electronic Nicotine Delivery Device (ENDS) After Shopping in the StoreLab (Non-flavored)
NCT04259749 (11) [back to overview]Proportion of Participants Susceptible to Using Little Cigar/Cigarillos (LCC) After Shopping in the StoreLab (Sweet-flavored)
NCT04259749 (11) [back to overview]Proportion of Participants Susceptible to Smoking Cigarettes After Shopping in the StoreLab (Non-flavored)
NCT04259749 (11) [back to overview]Proportion of Participants Susceptible to Smoking Cigarettes After Shopping in the StoreLab (Menthol)
NCT04259749 (11) [back to overview]Proportion of Participants Susceptible to Using Smokeless Tobacco After Shopping in the StoreLab (Menthol-flavored)
NCT04259749 (11) [back to overview]Proportion of Participants Susceptible to Using Smokeless Tobacco After Shopping in the StoreLab (Sweet-flavored)
NCT04259749 (11) [back to overview]Proportion of Participants Susceptible to Using Smokeless Tobacco After Shopping in the StoreLab (Non-flavored)
NCT04259749 (11) [back to overview]Proportion of Participants Susceptible to Using Electronic Nicotine Delivery Device (ENDS) After Shopping in the StoreLab (Menthol-flavored)

Nicotine Levels

Urine nicotine levels will be measured to examine the effect of cigarette menthol on harm exposure measures. Participants provided samples on the final day of each period. NNK and 1-hop were not analyzed, total nicotine metabolites were assayed. (NCT01329263)
Timeframe: 35 days

,
Interventionmicrograms/mL (Mean)
Period 1 Baseline Own cigarettePeriod 2 Own cigarette or CCrush non-mentholPeriod 3 Own cigarette or CCrush non-menthol
Control2.23.42.8
Experimental1.72.72.49

[back to top]

Smoking Topography- Carbon Monoxide Boost

Carbon monoxide content in exhaled breath samples is measured before and after each cigarette smoked during study sessions. CO boost is the amount in parts per million that the subject's CO increases. (NCT01329263)
Timeframe: Measured before and after each cigarette smoked at study sessions

,
Interventionparts per million (Mean)
Period 1 Baseline Own cigarettePeriod 2 Own cigarette or CCrush mentholPeriod 3 Own cigarette or CCrush non-menthol
Control5.35.75.5
Experimental5.93.73.9

[back to top]

Smoking Topography- Puff Volume

The total puff volume for a single subject is the sum of puff volumes for a subject's cigarette smoked during the study session. The mean puff volume for the subjects will be used to examine the effect of cigarette menthol on smoking topography. The values provided are the average of subjects at study Day 5 (completion of baseline smoking own cigarettes), Day 20 and Day 35. (NCT01329263)
Timeframe: over 35 day study period

,
InterventionmL (Mean)
Period 1 Own cigarettePeriod 2 Own cigarette or CCrush mentholPeriod 3 Own cigarette or CCrush non-menthol
Control661620645
Experimental518650678

[back to top]

Subjective Rating of Cigarettes

Subjects completed a visual analog scale rating each cigarette smoked at each session. Subjects rated characteristics of the cigarette on a scale represented as a continuous horizontal line 10 cm long. Subjects drew an intersecting line to represent their rating. The rating reported is for the taste of the cigarette at the end of the period averaged across subjects in the group. A rating of 0 corresponds to Very Bad and a rating of 100 to Very Good for taste. There is no better or worse outcome for higher or lower ratings for taste. (NCT01329263)
Timeframe: Immediately after a cigarette smoked at the study session

,
Interventionunits on a scale (Mean)
Period 1 Own cigarettePeriod 2 Own cigarette or CCrush mentholPeriod 3 Own cigarette or CCrush non-menthol
Control807271
Experimental615239

[back to top]

Efficacy of STOPAIN in the Acute Treatment of Migraine

"To evaluate the efficacy of STOPAIN in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level equal to no pain) at 2 hours post dose using a four point numeric rating scale (0=no pain, 1= mild pain, 2=moderate pain, 3=severe pain)." (NCT01687101)
Timeframe: 2 hours after the time of gel application

Interventionunits on a scale (Mean)
STOPAIN Topical Gel1.92

[back to top]

Effects E-cig Use on Venous Nicotine Concentrations Before and 5 Minutes After Use

To determine the effects of acute E-cig use on venous nicotine concentrations 5 minutes before and 5 minutes after 7-10 days of e-cigarette use. (NCT01775787)
Timeframe: 7-10 days

,
Interventionng/ml (Mean)
Before Ecig used5 minutes after ecig use
Tobacco & Menthol Flavor4.118.77
Tobacco Flavor4.308.66

[back to top]

Concentration of Total 4-(Methylnitrosamino)-1-(3- Pyridyl)-1-butanol) (Total NNAL)

"Concentrations measured at Day 90 in urine, adjusted for creatinine.~Geometric Least Squares (LS) means are provided as descriptive statistics." (NCT01970995)
Timeframe: 90 days

Interventionpg/mg creat (Least Squares Mean)
THS 2.2 Menthol (mTHS 2.2)22.48
Menthol Conventional Cigarette (mCC)96.65
Smoking Abstinence (SA)14.90

[back to top]

Concentration of S-phenylmercapturic Acid (S-PMA)

"Concentrations measured at Day 5 in urine, adjusted for creatinine.~Geometric Least Squares (LS) means are provided as descriptive statistics." (NCT01970995)
Timeframe: 5 days

Interventionpg/mg creat (Least Squares Mean)
THS 2.2 Menthol (mTHS 2.2)119.18
Menthol Conventional Cigarette (mCC)1086.89
Smoking Abstinence (SA)104.83

[back to top]

Concentration of Monohydroxybutenyl Mercapturic Acid (MHBMA)

"Concentrations measured at Day 5 in urine, adjusted for creatinine.~Geometric Least Squares (LS) means are provided as descriptive statistics." (NCT01970995)
Timeframe: 5 days

Interventionpg/mg creat (Least Squares Mean)
THS 2.2 Menthol (mTHS 2.2)83.21
Menthol Conventional Cigarette (mCC)617.04
Smoking Abstinence (SA)83.57

[back to top]

Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)

"Concentrations measured at Day 5 in urine, adjusted for creatinine.~Geometric Least Squares (LS) means are provided as descriptive statistics." (NCT01970995)
Timeframe: 5 days

Interventionng/mg creat (Least Squares Mean)
THS 2.2 Menthol (mTHS 2.2)304.56
Menthol Conventional Cigarette (mCC)601.11
Smoking Abstinence (SA)183.61

[back to top]

Levels of Carboxyhemoglobin (COHb)

"% COHb blood measurements performed in the evening of Day 5, expressed as % of saturation of hemoglobin.~Geometric Least Squares means are provided as descriptive statistics." (NCT01970995)
Timeframe: 5 days

Intervention% of saturation of hemoglobin (Least Squares Mean)
THS 2.2 Menthol (mTHS 2.2)2.47
Menthol Conventional Cigarette (mCC)5.49
Smoking Abstinence (SA)2.49

[back to top]

Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)

Concentrations measured in urine, adjusted for creatinine, at Day 5 for the smokers of all arms (mTHS, mCC and SA). Geometric Least Squares means are provided as descriptive statistics. (NCT01989156)
Timeframe: 5 days

Interventionng/mg creat (Geometric Mean)
THS 2.2 Menthol (mTHS 2.2)278.13
Menthol Conventional Cigarette (mCC)607.68
Smoking Abstinence (SA)152.05

[back to top]

Concentration of Monohydroxybutenylmercapturic Acid (MHBMA)

Concentrations measured in urine, adjusted for creatinine, at Day 5 for the smokers of all arms (mTHS, mCC and SA). Geometric Least Squares means are provided as descriptive statistics. (NCT01989156)
Timeframe: 5 days

Interventionpg/mg creat (Geometric Mean)
THS 2.2 Menthol (mTHS 2.2)110.96
Menthol Conventional Cigarette (mCC)882.25
Smoking Abstinence (SA)94.97

[back to top]

Concentration of S-phenylmercapturic Acid (S-PMA)

Concentrations measured in urine, adjusted for creatinine, at Day 5 for the smokers of all arms (mTHS, mCC and SA). Geometric Least Squares means are provided as descriptive statistics. (NCT01989156)
Timeframe: 5 days

Interventionpg/mg creat (Geometric Mean)
THS 2.2 Menthol (mTHS 2.2)134.11
Menthol Conventional Cigarette (mCC)1065.91
Smoking Abstinence (SA)131.05

[back to top]

Levels of Carboxyhemoglobin (COHb)

Carboxyhemoglobin (COHb) is assayed from whole blood. Expressed as % of saturation of hemoglobin. Blood measurements performed in the evening of Day 5, for the smokers of all arms (mTHS, mCC and SA). Geometric Least Squares means are provided as descriptive statistics. (NCT01989156)
Timeframe: 5 days

Intervention% of saturation of hemoglobin (Geometric Mean)
THS 2.2 Menthol (mTHS 2.2)2.33
Menthol Conventional Cigarette (mCC)6.11
Smoking Abstinence (SA)2.39

[back to top]

Levels of Total 4-(Methylnitrosamino)-1-(3- Pyridyl)-1-butanol (Total NNAL)

Concentrations measured in urine, adjusted for creatinine, at Day 90 for the smokers of all arms (mTHS, mCC and SA). Geometric Least Squares means are provided as descriptive statistics. (NCT01989156)
Timeframe: 90 days

Interventionpg/mg creat (Geometric Mean)
THS 2.2 Menthol (mTHS 2.2)41.05
Menthol Conventional Cigarette (mCC)155.45
Smoking Abstinence (SA)54.03

[back to top]

Skin Temperature

Skin temperature was measured by thermal imaging. (NCT02100670)
Timeframe: At 10, 30, 60 minutes, 4 and 6 hours

,,,
Interventiondegree celsius (°C) (Mean)
At 10 min.At 30 min.At 60 min.At 240 min.At 360 min.
1% Diclofenac Sodium29.3129.8130.7431.2631.53
1% Diclofenac Sodium+3% Menthol27.6928.2628.6430.5231.02
3% Menthol29.9230.5030.2231.1531.27
Placebo30.9331.4731.7831.5732.07

[back to top]

Pain Intensity Difference (PID) on Movement

"PID on movement, calculated as PI at a given time 't' (after walking 5 steps on a flat surface) subtracted by the PI at baseline.~Participants assessed the severity of ankle pain (PI) using the NRS scale from 0 (no pain) to 10 (extreme pain). PI was measured at baseline (prior to treatment) and at 10, 30 minutes (min.) and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing." (NCT02100670)
Timeframe: Baseline to 10 days

,,,
Interventionscore on scale (Mean)
PI at Baseline (n=117, 112, 77, 75)PID at 10 min. (n=117, 112, 77, 75)PID at 30 min. (n=117, 112, 77, 75)PID at 1 hour (n=117, 112, 77, 75)PID at 4 hour (n=117, 112, 77, 75)PID at 6 hour (n=117, 112, 77, 75)PID at 12 hour (n= 117, 112, 77, 75)PID at 18 hour (n=117, 112, 77, 75)PID at 24 hour (n=117, 112, 77, 75)PID at 36 hour (n=117, 112, 77, 75)PID at 48 hour (n=117, 112, 77, 75)PID at 60 hour (n=117, 112, 77, 75)PID at 72 hour (n=117, 112, 77, 75)PID at 84 hour (n=113, 107, 75, 75)PID at 96 hour (n=112, 107, 75, 74)PID at 108 hour (n=112, 107, 75, 74)PID at 120 hour (n=111, 107, 74, 74)PID at 132 hour (n=110, 107, 74, 74)PID at 144 hour (n=110, 107, 74, 74)PID at 156 hour (n=109, 107, 74, 74)PID at 168 hour (n=105, 104, 73, 74)PID at 180 hour (n=105, 104, 73, 72)PID at 192 hour (n=101, 102, 71, 72)PID at 204 hour (n=101, 100, 71, 72)PID at 216 hour (n=95, 100, 69, 72)PID at 228 hour (n=95, 100, 69, 72)PID at 240 hour (n=32, 43, 22, 42)
1% Diclofenac Sodium7.40.190.360.500.480.670.991.321.581.652.012.262.422.682.783.013.173.533.784.054.114.454.594.945.215.625.44
1% Diclofenac Sodium+3% Menthol7.80.230.440.560.710.790.841.191.621.591.912.412.552.843.103.343.383.703.764.174.264.584.555.175.285.715.56
3% Menthol7.80.290.490.640.790.911.171.441.751.552.042.562.553.083.033.483.353.723.683.953.904.374.214.874.875.285.41
Placebo7.70.320.550.640.690.870.951.161.531.321.922.052.282.682.783.183.143.473.593.883.954.084.224.564.785.015.60

[back to top]

Patient's Global Assessment in Response to Treatment (PGART)

PGART was measured at the end of study in a scale from 0-4 (Where: 0- Poor; 1- Fair; 2- Good; 3- Very Good; 4- Excellent) (NCT02100670)
Timeframe: up to Day 10

,,,
InterventionParticipants (Number)
Poor=0Fair=1Good=2Very Good=3Excellent=4
1% Diclofenac Sodium132046266
1% Diclofenac Sodium+3% Menthol32444359
3% Menthol61226265
Placebo91427214

[back to top]

PID at Rest

"PID at rest was calculated as PI at a given time point't' (at rest) subtracted by the PI at baseline. Participants assessed the severity of ankle pain (PI) using the NRS scale from 0 (no pain) to 10 (extreme pain).~PI was measured at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing." (NCT02100670)
Timeframe: Baseline to 10 days

,,,
Interventionscore on a scale (Mean)
PI at Baseline (n=117, 112, 77, 75)PID at 10 min. (n=117, 112, 77, 75)PID at 30 min. (n=117, 112, 77, 75)PID at 1 hour (n=117, 112, 77, 75)PID at 4 hour (n=117, 112, 77, 75)PID at 6 hour (n= 117, 112, 77, 75)PID at 12 hour (n= 117, 112, 77, 75)PID at 18 hour (n= 117, 112, 77, 75)PID at 24 hour (n= 117, 112, 77, 75)PID at 36 hour (n= 117, 112, 77, 75)PID at 48 hour (n=117, 112, 77, 75)PID at 60 hour (n= 117, 112, 77, 75)PID at 72 hour (n= 117, 112, 77, 75)PID at 84 hour (n= 113, 107, 75, 75)PID at 96 hour (n= 112, 107, 75, 74)PID at 108 hour (n=112, 107, 75, 74)PID at 120 hour (n= 111, 107, 74, 74)PID at 132 hour (n= 110, 107, 74, 74)PID at 144 hour (n= 110, 107, 74, 74)PID at 156 hour (n= 109, 107, 74, 74)PID at 168 hour (n= 105, 104, 73, 74)PID at 180 hour (n= 105, 104, 73, 72)PID at 192 hour (n= 101, 102, 71, 72)PID at 204 hour (n= 101, 100, 71, 72)PID at 216 hour (n= 95, 100, 69, 72)PID at 228 hour (n= 95, 100, 69, 72)PID at 240 hour (n= 32, 43, 22, 42)
1% Diclofenac Sodium7.40.430.450.620.530.620.861.141.391.321.531.831.912.192.172.432.482.782.773.113.153.383.303.613.874.024.23
1% Diclofenac Sodium+3% Menthol7.80.340.560.640.620.680.761.031.321.201.431.911.912.112.262.462.592.762.773.063.083.373.383.673.774.093.94
3% Menthol7.80.170.320.480.660.750.901.101.471.221.511.881.862.192.232.482.302.682.592.772.752.952.903.373.223.643.36
Placebo7.70.250.440.410.430.530.680.851.131.091.451.641.762.032.002.272.092.492.492.652.642.883.003.213.263.533.67

[back to top]

Total Pain Relief (TOTPAR)

TOTPAR was calculated as sum of the products of PRS with time interval from one time point to the other. PRS was measured at each time point on a scale: 0= No pain relief, 1= A little or perceptible pain relief, 2= Meaningful pain relief, 3= A lot of relief, 4= Complete relief. The possible range of TOTPAR for 0-6 hours was from 0 to 24, for 0-12 hours was from 0 to 48, for 0-24 hours was from 0 to 96, for 0-72 hours was from 0 to 288, for 24-72 hours was from 0 to 192 and for 0-168 hours was from 0 to 672. (NCT02100670)
Timeframe: Baseline to 168 hours

,,,
InterventionPRS Score (0 - 4 scale) (Mean)
0-6 hours0-12 hours0- 24 hours0-72 hours24-72 hours0-168 hours
1% Diclofenac Sodium2.646.8116.1461.2445.11170.73
1% Diclofenac Sodium+3% Menthol2.816.8616.0460.1444.10172.97
3% Menthol3.278.0218.8566.6947.84184.17
Placebo2.756.3515.7158.7543.04174.00

[back to top]

Sum of Pain Intensity Difference (SPID)

SPID was calculated as the time weighted sum of pain intensity differences (PID) from 0 to 7 Days. PID was calculated as PI at a given time point 't' subtracted by the PI at baseline. PI was measured on NRS scale from 0 (no pain) to 10 (extreme pain). The possible range of SPID for 0-6 hours was from -60 to 60, for 0-12 hours was from -120 to 120, for 0-1 day was from -240 to 240, for 0-3 days was from -720 to 720, for 0-7 days was from -1680 to 1680. A higher value of SPID indicates greater pain relief. (NCT02100670)
Timeframe: Baseline to Day 7

,,,
Interventionscore on a scale (Mean)
At 0-6 hoursAt 0-12 hoursAt 0-1 daysAt 1 to 3 daysAt 0 to 7 days
1% Diclofenac Sodium3.199.1326.54100.07452.44
1% Diclofenac Sodium+3% Menthol4.169.1926.01101.54451.12
3% Menthol4.7211.7430.91104.26464.96
Placebo4.3710.0526.2190.88438.45

[back to top]

Pain Relief Score (PRS)

Pain relief was measured at each time point using a 5-point Pain Relief Scale ranging from 0-4 while at rest (Where: 0- No pain relief; 1- A little or perceptible pain relief; 2- Meaningful pain relief; 3- A lot of relief; 4- Complete relief). Participants assessed the degree of ankle pain relief using the PRS scores at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after the first day of treatment. (NCT02100670)
Timeframe: Day 1 to Day 7

,,,
Interventionscore on a scale (Mean)
At 10 min. (n= 117, 111, 77, 74)At 30 min. (n=117, 111, 77, 75)At 1 hour (n=116, 112, 77, 75)At 4 hour (n= 115, 110, 74, 71)At 6 hour (n= 109, 105, 70, 69)At 12 hour (n= 77, 89, 53, 58)At 18 hour (n= 76, 78, 53, 57)At 24 hour (n= 111, 105, 72, 72)At 36 hour (n= 116, 112, 77, 74)At 48 hour (n= 116, 112, 77, 75)At 60 hour (n=115, 111, 77, 75)At 72 hour (n= 114, 109, 75, 74)At 84 hour (n= 113, 106, 75, 75)At 96 hour (n= 112, 106, 75, 74)At 108 hour (n= 111, 105, 75, 74)At 120 hour (n= 111, 107, 74, 72)At 132 hour (n= 110, 107, 73, 74)At 144 hour (n= 110, 107, 74, 73)At 156 hour (n= 109, 106, 74, 74)At 168 hour (n= 105, 103, 73, 73)
1% Diclofenac Sodium0.290.360.460.450.540.720.730.740.840.841.001.061.001.031.131.141.241.211.301.31
1% Diclofenac Sodium+3% Menthol0.330.440.480.470.500.600.710.790.840.901.070.931.071.091.181.111.341.211.411.41
3% Menthol0.320.490.570.510.630.740.830.900.880.991.161.161.251.011.281.241.341.301.471.34
Placebo0.360.440.400.490.450.620.700.810.780.990.960.971.111.091.151.101.301.271.321.40

[back to top]

Ankle Swelling

"Ankle swelling measured by figure of eight method of injured ankle." (NCT02100670)
Timeframe: Day 1 (baseline), 3, and 7

,,,
InterventionMillimeters (Mean)
At Day 1At Day 3At Day 7
1% Diclofenac Sodium573.6566.9558.8
1% Diclofenac Sodium+3% Menthol573.9566.2558.3
3% Menthol577.1567.0558.4
Placebo576.1565.4557.0

[back to top]

Time to Complete Recovery

Time to complete recovery measured as the day with complete relief of ankle pain (Participant-rated NRS scores were 0 for pain intensity at rest and pain) and swelling (Participants did not have any apparent swelling nor experience any pain or limitation of movement of the injured ankle as determined by the Principal Investigator or designee during the course of an ankle exam). (NCT02100670)
Timeframe: up to 240 hours

InterventionHours (Median)
1% Diclofenac Sodium+3% Menthol240.00
1% Diclofenac Sodium240.00
3% Menthol240.00
Placebo240.00

[back to top]

Time of Onset of Pain Relief (TOPR)

"TOPR was measured by time when participants reported PRS ≥ 1, i.e. a little or perceptible pain relief'." (NCT02100670)
Timeframe: Baseline to 10 days (end of study)

InterventionHours (Median)
1% Diclofenac Sodium+3% Menthol1.03
1% Diclofenac Sodium4.00
3% Menthol1.00
Placebo4.00

[back to top]

Time of Onset of Meaningful Pain Relief (TOMR)

"TOMR was measured by time when participants reported PRS ≥ 2, i.e. some or meaningful pain relief" (NCT02100670)
Timeframe: up to 10 days (end of study)

InterventionHours (Median)
1% Diclofenac Sodium+3% Menthol92.50
1% Diclofenac Sodium76.83
3% Menthol72.00
Placebo93.50

[back to top]

Time of Onset of Cooling Sensation (TOCS)

"Time of onset of cooling sensation measured by time when subjects reported to have a 'cooling effect as an enhancement of pain relief'. To assess this endpoint, participants were asked at 10, 30 minutes and at 1, 4, 6 hours post first dose Do you feel a cooling sensation at the injured ankle from the study gel?" (NCT02100670)
Timeframe: up to 6 hours

InterventionHours (Median)
1% Diclofenac Sodium+3% Menthol0.17
1% Diclofenac Sodium0.17
3% Menthol0.17
Placebo0.17

[back to top]

AUC1-3 Days of PI on Movement for Diclofenac Sodium + Methanol, Diclofenac, Methanol and Placebo

AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing. (NCT02100670)
Timeframe: up to 72 hours

InterventionNRS Score (0 - 10 scale) * hrs (Mean)
1% Diclofenac Sodium+3% Menthol276.97
1% Diclofenac Sodium261.11
3% Menthol272.65
Placebo282.88

[back to top]

Area Under the Curve From Day 1 to Day 3 (AUC1-3 Days) of Pain Intensity(PI) on Movement for Diclofenac/Methanol Gel and Placebo Gel

AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing. (NCT02100670)
Timeframe: up to 72 hours

InterventionNRS Score (0 - 10 scale) * hrs (Mean)
1% Diclofenac Sodium Plus (+) 3% Menthol276.97
Placebo282.88

[back to top]

Drug Effects Questionnaire (DEQ)- 'Good Drug Effects'

"The Drug Effects Questionnaire (DEQ) is used in studies of acute subjective response (SR) to a variety of substances. The DEQ consists of 11 questions: cooling effect, dislike the sensation, any sensations, feel a drug effect, high, feel stimulated, feel a head rush, like drug effect, dislike any effects, craving a cigarette, and like more of the drug. To calculate the DEQ- 'Good Drug Effects', peak values from post-infusion time points were calculated for the change in the intensity of positive subjective effects as measured with 2 DEQ questions - DEQ question #6 'like drug effect' and DEQ question #11 'would like more of the drug'. Each question was measured on a scale with a minimum score of 0 and a maximum score of 100.The peak values for like and I want more were averaged to obtain a summary score to represent the feel 'Good Drug Effects' composite factor. DEQ measures were skewed and square root transformations were used. Higher scores indicate more positive effects." (NCT02102100)
Timeframe: up to 55 minutes post-infusion

,
Interventionscores on a scale (Least Squares Mean)
Across Conditions (main effect)High Menthol w High NicotineHigh Menthol w Low NicotineHigh Menthol w SalineLow Menthol w High NicotineLow Menthol w Low NicotineLow Menthol w Saline
Menthol-Preferring Smokers5.19795.62355.2265.06995.89715.54814.4655
Non-Menthol Preferring Smokers6.83847.62857.43517.62857.58086.76566.3960

[back to top]

Time to Relapse

Days from the quit attempt until the first of seven consecutive smoking days (NCT02342327)
Timeframe: 6 months

Interventiondays (Median)
Continue Smoking Menthol Cigarettes7
Switch to Non-menthol Cigarettes42

[back to top]

Time to Lapse

Time from smoking cessation until first lapse (i.e. a cigarette is smoked) (NCT02342327)
Timeframe: 6 months

Interventiondays (Median)
Continue Smoking Menthol Cigarettes1.07
Switch to Non-menthol Cigarettes2.55

[back to top]

Advanced Adenoma Detection Rates

Evaluate for changes in advanced adenoma detection rates with the use of intraluminal peppermint oil application vs placebo during coloscopy. Advanced adenoma will be define as an adenoma with significant villous features (>25%), size of 1.0 cm or more, high-grade dysplasia, or early invasive cancer. (NCT02588248)
Timeframe: 2 weeks

,
Interventionparticipants (Number)
Tubular AdenomaTubulovillous AdenomaVillous AdenomaSerrated AdenomaCancerNo Adenoma
Peppermint Oil19001118
Placebo19004118

[back to top]

Procedure Time

Evaluate for changes in total procedure time, cecal intubation time, and withdrawal time with the use of intraluminal peppermint oil application vs sterile water application during colonoscopy. (NCT02588248)
Timeframe: immediate

,
Interventionminutes (Median)
Cecal Intubation time in minutesWithdraw Time in minutes
Peppermint Oil12.420.5
Placebo12.917.2

[back to top]

Adverse Events (AEs)

Local and systemic Adverse Events (AEs). (NCT02666846)
Timeframe: Estimated study duration for each subject will be approximately 6 weeks

InterventionEvents (Number)
Cohort 1: TIB200 Gel 10%5
Cohort 1: Nurofen Gel 10%5
Cohort 1: Nurofen Tablets1
Cohort 1: TIB200 Placebo Gel1
Cohort 2: DCF100 Gel 2%1
Cohort 2: DCF100 Gel 4%1
Cohort 2: Voltaren Gel 2%0
Cohort 2: Voltarol Oral Tablet2
Cohort 2: DCF100 Placebo Gel0
Cohort 3: SPR300 Gel (15%:7%)3
Cohort 3: SPR300 Placebo Gel1

[back to top]

Area Under the Plasma Concentration Versus Time Curve

Area under the concentration vs. time curve from time zero to 6 hours (AUC0-6h) (up to 6 subjects per cohort only) laser Doppler imaging [flux units], up to 6 subjects per cohort) (NCT02666846)
Timeframe: 15 minutes before and 1, 2, 4 and 6 hours post administration

Interventionh*ng/ml (Mean)
Cohort 1: TIB200 Gel 10%47.7
Cohort 1: Nurofen Gel 10%19.9
Cohort 1: Nurofen Tablets90000
Cohort 2: DCF100 Gel 2%0
Cohort 2: DCF100 Gel 4%0
Cohort 2: Voltaren Gel 2%0
Cohort 2: Voltarol Oral Tablet1030
Cohort 3: SPR300 Gel (15%:7%)0
Cohort 3: SPR300 Placebo Gel0

[back to top]

Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade -

To assess the pharmacodynamic effect by Heat Pain Tolerance Test (HPTT) which measured the point at which the heat became painful (degrees centigrade) of three topical analgesics, DCF100, TIB200, and SPR300 versus topical placebo and active topical reference products in a model of UV-induced inflammatory pain. (NCT02666846)
Timeframe: 15 minutes before to 6 hours post administration

InterventionDegrees Centigrade (Mean)
Cohort 1: TIB200 Gel 10%0.3635
Cohort 1: Nurofen Gel 10%0.7358
Cohort 1: Nurofen Tablets0.0887
Cohort 1: TIB200 Placebo Gel-0.1983
Cohort 2: DCF100 Gel 2%0.6679
Cohort 2: DCF100 Gel 4%0.8722
Cohort 2: Voltaren Gel 2%0.7978
Cohort 2: Voltarol Oral Tablet0.6835
Cohort 2: DCF100 Placebo Gel0.1688
Cohort 3: SPR300 Gel (15%:7%)0.3934
Cohort 3: SPR300 Placebo Gel-0.0123

[back to top]

Intensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units])

Intensity of the Ultra Violet B radiation (UVB)-induced erythema (determined by assessment of skin blood flow by laser Doppler imaging [flux units], up to 8 subjects per cohort) - Change from baseline (NCT02666846)
Timeframe: 15 minutes before to 6 hours post administration

InterventionLaser doppler imaging (Flux Units) (Least Squares Mean)
Cohort 1: TIB200 Gel 10%-313.3879
Cohort 1: Nurofen Gel 10%-171.5589
Cohort 1: Nurofen Tablets-262.0693
Cohort 1: TIB200 Placebo Gel-95.3974
Cohort 2: DCF100 Gel 2%-228.3016
Cohort 2: DCF100 Gel 4%-278.1918
Cohort 2: Voltaren Gel 2%-198.1408
Cohort 2: Voltarol Oral Tablet-198.1408
Cohort 2: DCF100 Placebo Gel-45.376
Cohort 3: SPR300 Gel (15%:7%)12.2265
Cohort 3: SPR300 Placebo Gel67.3931

[back to top]

Number of Recorded Abnormal Clinical Assessments

"Laboratory assessments - standard clinical trial assessments for clinical chemistry and haematology~Listing of individual laboratory measurements by subjects and evaluation of each laboratory parameter" (NCT02666846)
Timeframe: Estimated study duration for each subject will be approximately 6 weeks

InterventionAssessments (Number)
Cohort 1: TIB200 Gel 10%0
Cohort 1: Nurofen Gel 10%0
Cohort 1: Nurofen Tablets0
Cohort 1: TIB200 Placebo Gel0
Cohort 2: DCF100 Gel 2%0
Cohort 2: DCF100 Gel 4%0
Cohort 2: Voltaren Gel 2%0
Cohort 2: Voltarol Oral Tablet0
Cohort 2: DCF100 Placebo Gel0
Cohort 3: SPR300 Gel (15%:7%)0
Cohort 3: SPR300 Placebo Gel0

[back to top]

Peak Plasma Concentration (Cmax)

Maximum observed plasma concentration (Cmax), time corresponding to occurrence of Cmax (tmax) (up to 6 subjects per cohort only) laser Doppler imaging [flux units], up to 6 subjects per cohort) (NCT02666846)
Timeframe: 15 minutes before and 1, 2, 4 and 6 hours post administration

Interventionng/ml (Mean)
Cohort 1: TIB200 Gel 10%11.5
Cohort 1: Nurofen Gel 10%5.15
Cohort 1: Nurofen Tablets29900
Cohort 2: DCF100 Gel 2%0
Cohort 2: DCF100 Gel 4%0
Cohort 2: Voltaren Gel 2%0
Cohort 2: Voltarol Oral Tablet772
Cohort 3: SPR300 Gel (15%:7%)0
Cohort 3: SPR300 Placebo Gel0

[back to top]

Physical Exams to Ensure Safety and Well Being of the Subjects

Physical examinations - including assessments of the application site. examination. (NCT02666846)
Timeframe: Estimated study duration for each subject will be approximately 6 weeks

InterventionAbnormalities (Number)
Cohort 1: TIB200 Gel 10%0
Cohort 1: Nurofen Gel 10%0
Cohort 1: Nurofen Tablets0
Cohort 1: TIB200 Placebo Gel0
Cohort 2: DCF100 Gel 2%0
Cohort 2: DCF100 Gel 4%0
Cohort 2: Voltaren Gel 2%0
Cohort 2: Voltarol Oral Tablet0
Cohort 2: DCF100 Placebo Gel0
Cohort 3: SPR300 Gel (15%:7%)0
Cohort 3: SPR300 Placebo Gel0

[back to top]

To Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects

To determine Vital Signs and Electrocardiograms (ECGs) that were abnormal to ensure safety and well being of the subjects (NCT02666846)
Timeframe: Estimated study duration for each subject will be approximately 6 weeks

InterventionAbnormal readings (Number)
Cohort 1: TIB200 Gel 10%0
Cohort 1: Nurofen Gel 10%0
Cohort 1: Nurofen Tablets0
Cohort 1: TIB200 Placebo Gel0
Cohort 2: DCF100 Gel 2%0
Cohort 2: DCF100 Gel 4%0
Cohort 2: Voltaren Gel 2%0
Cohort 2: Voltarol Oral Tablet0
Cohort 2: DCF100 Placebo Gel0
Cohort 3: SPR300 Gel (15%:7%)0
Cohort 3: SPR300 Placebo Gel0

[back to top]

Change From Baseline in TSS Total Score

"Change from baseline in TSS total score completed by the Investigator as compared to the baseline.~The Tonsillopharyngitis Severity Score (TSS) scale consists of the following symptoms:~throat pain, difficulty in swallowing, salivation, erythema and fever rated on a 4-point scale (0 = no symptom to 3 = significant symptom). Total score range from 0 - 15." (NCT03095508)
Timeframe: 4 days

Interventionunits on a scale (Median)
Angal S (Arm A)-6
ANTI-ANGIN® FORMULA (Arm B)-6

[back to top]

Number of Participants Who Fully Recovered

Number of Participants who Fully Recovered by Day 4 in Group A and by Day 5 in Group B (the outcome of a disease according to the objective evaluation by the Investigator, the total score according to the TSS questionnaire ≤ 2) (NCT03095508)
Timeframe: Group A: 4 days Group B: 5 days

InterventionParticipants (Count of Participants)
Angal S (Arm A)106
ANTI-ANGIN® FORMULA (Arm B)107

[back to top]

Percentage of Participants With a ≥50% TSS Total Score Reduction

"Percentage of participants with a ≥50% TSS Total Score Reduction according to the TSS questionnaire completed by the Investigator as compared to the baseline.~The Tonsillopharyngitis Severity Score (TSS) scale consists of the following symptoms:~throat pain, difficulty in swallowing, salivation, erythema and fever rated on a 4-point scale (0 = no symptom to 3 = significant symptom). Total score range from 0 - 15." (NCT03095508)
Timeframe: 4 days

Interventionpercentage of participants (Number)
Angal S (Arm A)96.49
ANTI-ANGIN® FORMULA (Arm B)98.26

[back to top]

Period of Time Required for Disappearance of the Disease Symptoms

A period of time required for disappearance of the disease symptoms, determined according to the patient's diary (subjective patient's evaluation), but no more than 5 days during the trial-for patients who have achieved the corresponding outcome. (NCT03095508)
Timeframe: 5 Days

InterventionDays (Mean)
Angal S (Arm A)3.75
ANTI-ANGIN® FORMULA (Arm B)3.94

[back to top]

Change in the Sore Throat Intensity by 100 mm VAS

"Change in the sore throat intensity by 100 mm VAS (visual analogue scale filled in by the patient) at the start and after 3 days of therapy. The VAS is a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of no pain at all and worst pain imaginable. The VAS ranges from 0 to 100. A decrease from baseline in the VAS score to reflect pain intensity indicates a decrease in pain intensity." (NCT03095508)
Timeframe: 4 days

,
Interventionmm (Mean)
Baseline (Visit 1)Day 4 (Visit 2)
Angal S (Arm A)64.762.99
ANTI-ANGIN® FORMULA (Arm B)65.845.06

[back to top]

Percentage of Patients Without Sore Throat According to the Tonsillopharyngitis Severity Score (TSS)

"The Tonsillopharyngitis Severity Score (TSS) scale consists of the following symptoms:~throat pain, difficulty in swallowing, salivation, erythema and fever rated on a 4-point scale (0 = no symptom to 3 = significant symptom). Total score range from 0 - 15." (NCT03095508)
Timeframe: 4 Days

,
InterventionPercentage of Participants (Number)
Score 0 (no sore throat)Score 1Score 2Score 3
Angal S (Arm A)89.477.022.630.88
ANTI-ANGIN® FORMULA (Arm B)75.6519.134.350.87

[back to top]

50% Reduction Tss SCORE

Frequency of 50 % or more total score reduction by the TSS questionnaire completed by the Investigator relative to baseline in both Angal and ANTI-ANGIN FORMULA arms at visit 2 (NCT03095521)
Timeframe: day 4

Interventionpercentage of participants (Number)
ANGAL97.35
ANTIANGIN98.13

[back to top]

Days to Recovery, Defined by the Patient's Diary (Subjective Evaluation by the Patient)

only patients for which outcomes were available were included , 111 out of 113 for Angal and 102 out of 107 for Antiangin, per protocol set (NCT03095521)
Timeframe: 5 days

Interventiondays (Mean)
ANGAL3.75
ANTIANGIN3.93

[back to top]

Percentage of Participants Without Sore Throat According to TSS Score

"TSS (Tonsillopharyngitis Severity Score) is a questionnaire for evaluation of the five following symptoms severity: pharyngalgia, difficulty in swallowing, salivation, hyperemia of pharyngeal mucosa, and body temperature increase according to a 4-point scale:~0 : no symptoms~: insignificant symptom~: moderate symptom~: significant symptom fever~0 pts : <37.5 °С;~pts : 37.5 to <38.5 °С;~pts : 38.5 to <39.5 °С;~pts : ≥ 39.5 °С. TSS total ranges are 0-15." (NCT03095521)
Timeframe: 4 days

,
Interventionpercentage of participants (Number)
sore throat TSS score 0sore throat TSS score 1sore throat TSS score 2sore throat TSS score 3
ANGAL84.3513.911.740
ANTIANGIN73.2117.868.930

[back to top]

Change From Baseline in TSS Total Score

"Change from baseline in TSS total score. A negative change from baseline means an improvement.TSS (Tonsillopharyngitis Severity Score) is a questionnaire for evaluation of the five following symptoms severity: pharyngalgia, difficulty in swallowing, salivation, hyperemia of pharyngeal mucosa, and body temperature increase according to a 4-point scale:~0 : no symptoms~: insignificant symptom~: moderate symptom~: significant symptom fever~0 pts : <37.5 °С;~pts : 37.5 to <38.5 °С;~pts : 38.5 to <39.5 °С;~pts : ≥ 39.5 °С. TSS total ranges are 0-15." (NCT03095521)
Timeframe: baseline and day 4

,
Interventionunit on a scale (Mean)
baselineday 4
ANGAL6.880.45
ANTIANGIN7.030.83

[back to top]

Change From Baseline in Sore Throat Intensity by 100 mm in Visual Analogue Scale Filled in by the Patient (VAS) .

"The VAS is a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of no pain at all and worst pain imaginable. The VAS ranges from 0 to 100. A decrease from baseline in the VAS score to reflect pain intensity indicates a decrease in pain intensity." (NCT03095521)
Timeframe: baseline, day 4

,
Interventionmillimeters (Mean)
Baselineday 4
ANGAL66.382.35
ANTIANGIN66.994.67

[back to top]

Number of Participants Who Fully Recovered up to Day 5

Number of participants who fully recovered up to day 5 (the outcome of a disease according to the objective evaluation by the Investigator, the total score according to the TSS questionnaire ≤ 2) (NCT03095521)
Timeframe: 4 days for Angal, 5 days for AntiAngin

Interventionparticipants (Number)
ANGAL102
ANTIANGIN104

[back to top]

The Reinforcing Drug Effects Will be Measured With the Drug Effects Questionnaire (DEQ).

"The (DEQ) Drug Effects Questionnaire has eleven questions with a minimum score of 0 to a maximum score of 100.~Peak values from each time points were calculated for the change in the intensity of positive subjective effects as measured with these peak values for like and want more were averaged to obtain a summary score to represent the feel good drug effects composite factor. Higher scores for each DEQ represent greater endorsement of that subjective effect (e.g., on the like drug scale a response of 90 represents greater liking than a response of 50)." (NCT03243630)
Timeframe: up to 3 hours per test session.

,,
Interventionunits on a scale (Mean)
Higher Nicotine : Max_CoolHigher Nicotine : Max_LikeHigher Nicotine : Max_DislikeHigher Nicotine : Max_CravingLower Nicotine: Max_CoolLower Nicotine: Max_LikeLower Nicotine: Max_DislikeLower Nicotine: Max_CravingSaline: Max_CoolSaline: Max_LikeSaline: Max_DislikeSaline: Max_Craving
Green Apple and Menthol E-liquid25.2050.8020.8049.9025.9042.9014.5049.0024.6032.9014.4055.80
Green Apple E-liquid26.2253.4425.8846.0017.4750.1113.3653.1615.5035.8015.5057.70
Menthol E-liquid43.1856.0024.3641.2733.2746.0913.6348.0031.4533.008.7246.09

[back to top]

Amount of Tobacco Product Used

Total number of cigarettes smoked and puffs of e-cigarettes used (NCT03402243)
Timeframe: 6 weeks

,,
Interventiontobacco products use per day (Mean)
Cigarettes smoked per dayPuffs of e-cigarettes used per day
Menthol Ban for Cigarettes and E-cigarettes18.610.7
Menthol Ban Only for Cigarettes13.156.7
No Menthol Ban15.34.5

[back to top]

"How Much of Each Product is Obtained From the Experimental Marketplace"

"Number of packs of cigarettes obtained and amount of e-liquid obtained from the experimental marketplace" (NCT03402243)
Timeframe: 6 weeks

,,
Interventionunits of tobacco (Mean)
Packs of cigarettesUnits of e-cigarette liquid
Menthol Ban for Cigarettes and E-cigarettes29.31.2
Menthol Ban Only for Cigarettes22.63.13
No Menthol Ban28.81.06

[back to top]

Motivation to Quit Smoking Cigarettes

Based on a question asking how motivated from 1 (not at all) to 10 (extremely) the participant is to quit smoking cigarettes at this time (NCT03402243)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Menthol Ban Only for Cigarettes3.6
Menthol Ban for Cigarettes and E-cigarettes3.1
No Menthol Ban3.2

[back to top]

Biomarkers of Exposure -Cotinine

Blood will be drawn to evaluate cotinine levels before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per pre-switch Arms/Group assignment. (NCT03571724)
Timeframe: Week -1, and at 2 and 6 weeks.

,
Interventionng/mL (Mean)
Week -1Week 2Week 6
UB Mentholated242.0223.9207.2
UB Non-Mentholated221.4195.8187.7

[back to top]

Cigarettes Per Day

Primary objective is to measure a change in cigarette consumption behavior before, during and after switching from usual brand to to VLN cigarettes. Subjects will record their cigarette consumption daily in an electronic diary. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment).All 142 randomized subjects were included in the ITT population based on product use. Out of these, 71 subjects were included in the PP Population and 71 were excluded. All excluded subjects had a ratio of [plasma cotinine/CPD VLN]/[plasma cotinine/CPD baseline] > 0.2. It was pre-specified to exclude participants with a ratio >0.2 as they were considered non-compliant. (NCT03571724)
Timeframe: Assessed daily from Week -1 to Week 6; Week -1, Week 2, and Week 6 reported

,,,,,
InterventionCigarettes Per Day (CPD) (Mean)
Week -1Week 2Week 6
Usual Brand Combined16.5515.8415.29
Usual Brand Mentholated16.2915.4714.69
Usual Brand Non-Mentholated16.8016.1715.89
Very Low Nicotine Combined15.7618.9017.98
Very Low Nicotine Mentholated14.7515.6614.43
Very Low Nicotine Non-Mentholated17.1923.3221.20

[back to top]

Nicotine Pharmacokinetics - Area Under Nicotine Concentration Curve (AUC)

Blood samples will be drawn at -5, 2, 5, 7, 10, 12, 15, 20, 30, 45, 60, 90, 120, 150 and 180 minutes relative to the start of cigarette smoking a single cigarette for determination of AUC at weeks -1, 2 and 6. The baseline data were collected for participants at Week -1, and Week -1 data are reported per pre-switch Arms/Group assignment. (NCT03571724)
Timeframe: Week -1, and at 2 and 6 weeks.

,
Interventionmg*hr/mL (Mean)
Week -1
UB Mentholated13.60
UB Non-Mentholated13.18

[back to top]

Nicotine Pharmacokinetics - Area Under Nicotine Concentration Curve (AUC)

Blood samples will be drawn at -5, 2, 5, 7, 10, 12, 15, 20, 30, 45, 60, 90, 120, 150 and 180 minutes relative to the start of cigarette smoking a single cigarette for determination of AUC at weeks -1, 2 and 6. The baseline data were collected for participants at Week -1, and Week -1 data are reported per pre-switch Arms/Group assignment. (NCT03571724)
Timeframe: Week -1, and at 2 and 6 weeks.

,
Interventionmg*hr/mL (Mean)
Week 2Week 6
VLN Mentholated0.22640.2348
VLN Non-Mentholated0.20060.2620

[back to top]

Nicotine Pharmacokinetics - Maximum Nicotine Concentration (C-Max)

Blood samples will be drawn at -5, 2, 5, 7, 10, 12, 15, 20, 30, 45, 60, 90, 120, 150 and 180 minutes relative to the start of cigarette smoking a single cigarette for determination of C-max at weeks -1, 2 and 6. The baseline data were collected for participants at Week -1, and Week -1 data are reported per pre-switch Arms/Group assignment. (NCT03571724)
Timeframe: Week -1, and at 2 and 6 weeks.

,
Interventionng/mL (Mean)
Week -1
UB Mentholated12.98
UB Non-Mentholated13.28

[back to top]

Nicotine Pharmacokinetics - Maximum Nicotine Concentration (C-Max)

Blood samples will be drawn at -5, 2, 5, 7, 10, 12, 15, 20, 30, 45, 60, 90, 120, 150 and 180 minutes relative to the start of cigarette smoking a single cigarette for determination of C-max at weeks -1, 2 and 6. The baseline data were collected for participants at Week -1, and Week -1 data are reported per pre-switch Arms/Group assignment. (NCT03571724)
Timeframe: Week -1, and at 2 and 6 weeks.

,
Interventionng/mL (Mean)
Week 2Week 6
VLN Mentholated0.35610.3259
VLN Non-Mentholated0.32640.4026

[back to top]

Nicotine Pharmacokinetics - Peak Nicotine Time (T-Max)

Blood samples will be drawn at -5, 2, 5, 7, 10, 12, 15, 20, 30, 45, 60, 90, 120, 150 and 180 minutes relative to the start of cigarette smoking a single cigarette for determination of T-Max at weeks -1, 2 and 6. The baseline data were collected for participants at Week -1, and Week -1 data are reported per pre-switch Arms/Group assignment. (NCT03571724)
Timeframe: Week -1, and at 2 and 6 weeks.

,
Interventionhr (Mean)
Week -1
UB Mentholated13.60
UB Non-Mentholated0.1408

[back to top]

Nicotine Pharmacokinetics - Peak Nicotine Time (T-Max)

Blood samples will be drawn at -5, 2, 5, 7, 10, 12, 15, 20, 30, 45, 60, 90, 120, 150 and 180 minutes relative to the start of cigarette smoking a single cigarette for determination of T-Max at weeks -1, 2 and 6. The baseline data were collected for participants at Week -1, and Week -1 data are reported per pre-switch Arms/Group assignment. (NCT03571724)
Timeframe: Week -1, and at 2 and 6 weeks.

,
Interventionhr (Mean)
Week 2Week 6
VLN Mentholated0.14300.2895
VLN Non-Mentholated0.11540.1446

[back to top]

Smoking Topography - Average Flow Rate

Average Puff Flow Rate will be measured before, during, and after switching to VLN cigarettes. Topography will be measured during an ad libitum smoking session. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2 and 6 weeks.

,,
InterventionmL/sec (Mean)
Week -1Week 2Week 6
VLN Combined28.186624.569825.5016
VLN Mentholated28.542825.453424.1247
VLN Non-Mentholated27.830523.630926.7164

[back to top]

Smoking Topography - Inter-puff Interval

Inter-puff interval will be measured before, during, and after switching to VLN cigarettes. Topography will be measured during an ad libitum smoking session. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2 and 6 weeks.

,,
Interventionsec (Mean)
Week -1Week 2Week 6
VLN Combined29.74625.48823.937
VLN Mentholated29.22226.62427.215
VLN Non-Mentholated30.26924.28021.044

[back to top]

Smoking Topography - Peak Puff Flow Rate

Peak Puff Flow Rate will be measured before, during, and after switching to VLN cigarettes. Topography will be measured during an ad libitum smoking session. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2 and 6 weeks.

,,
InterventionmL/sec (Mean)
Week -1Week 2Week 6
VLN Combined45.142640.597541.8300
VLN Mentholated45.963941.441240.0195
VLN Non-Mentholated44.321339.701043.4274

[back to top]

Smoking Topography - Puff Duration

Puff duration will be measured before, during, and after switching to VLN cigarettes. Topography will be measured during an ad libitum smoking session. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2 and 6 weeks.

,,
Interventionseconds (Mean)
Week -1Week 2Week 6
VLN Combined25.63923.94022.039
VLN Mentholated27.78324.55922.122
VLN Non-Mentholated23.49423.28221.966

[back to top]

Smoking Topography - Puff Volume

Puff volume will be measured before, during, and after switching to VLN cigarettes. Topography will be measured during an ad libitum smoking session. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2 and 6 weeks.

,,
InterventionmL (Mean)
Week -1Week 2Week 6
VLN Combined54.321547.275147.4005
VLN Mentholated57.893449.736846.7513
VLN Non-Mentholated50.749644.659547.9733

[back to top]

Biomarkers of Exposure - 1-hydroxy Pyrene(1-OHP)

Total 24 hour urine will be collected to evaluate changes in 1-OHP before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2 and 6 weeks.

,,,,,
Interventionng/24 hour (Mean)
Week -1Week 2Week 6
UB Combined315.629276.502286.043
UB Mentholated316.566263.305274.171
UB Non-Mentholated314.736289.071299.312
VLN Combined324.962239.722241.652
VLN Mentholated315.203214.010203.396
VLN Non-Mentholated334.920262.756278.998

[back to top]

Subjective Effects - Perceived Health Risks

Subjects will answer a Perceived health risks questionnaire. The subjects indicated their perception of the risk of becoming addicted to the cigarette they were currently using on a scale from 1 to 10. Scale =1 was a very low risk of becoming addicted and Scale =10 was a very high risk of becoming addicted. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2, 4, and 6 weeks.

,,,,,
Interventionunits on a scale (Mean)
Week -1Week 2Week 4Week 6
UB Combined7.16.97.06.7
UB Mentholated7.77.07.46.9
UB Non-Mentholated6.66.86.76.6
VLN Combined7.33.7343.4
VLN Mentholated7.64.03.43.6
VLN Non-Mentholated7.03.43.43.2

[back to top]

Subjective Effects -Brief Questionnaire of Smoking Urges (QSU-Brief)

Subjects will answer a Brief Questionnaire of Smoking Urges (QSU-Brief). QSU is on a scale of 1-7, with 1 being strongly disagree and 7 being strongly agree. The average score of the following is taken to determine the Factor Score 1 and Factor Score 2; Factor 1: Average of Questions 1, 3, 6, 7, and 10; Factor 2: Average of Questions 2, 4, 5, 8, and 9. The score for each factor is calculated by summing the item scores; the total score is calculated by summing all questions together. The higher the score, the greater the urge to smoke. The total score range for this questionnaire is 10-70. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: Week -1, and at 2, 4, and 6 weeks.

,,,,,
Interventionscore on a scale (Mean)
Week -1Week 2Week 4Week 6
UB Combined4.14.03.73.8
UB Mentholated3.83.73.73.5
UB Non-Mentholated4.514.33.84.1
VLN Combined4.34.53.83.9
VLN Mentholated4.35.43.94.4
VLN Non-Mentholated4.23.73.83.4

[back to top]

Subjective Effects -Fagerstrom Test for Cigarette Dependance (FTCD)

Subjects will answer a Fagerstrom Test for Cigarette Dependance (FTCD) questionnaire which contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence.The Fagerstrom Test for Nicotine Dependence, is scored from 0 to 1 for yes/no items and 0 to 3 for multiple-choice items.The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the greater the patient's physical dependence on nicotine. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2, 4, and 6 weeks.

,,,,,
Interventionscore on a scale (Mean)
Week -1Week 2Week 4Week 6
UB Combined5.35.15.35.3
UB Mentholated5.44.95.35.2
UB Non-Mentholated5.25.25.35.4
VLN Combined5.65.75.65.4
VLN Mentholated6.06.36.36.0
VLN Non-Mentholated5.25.04.84.7

[back to top]

Biomarkers of Exposure - 3-hydroxypropylmercapturic Acid (3-HPMA)

Total 24 hour urine will be collected to evaluate changes in 3-HPMA (acrolein biomarker) before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2 and 6 weeks.

,,,,,
Interventionµg/24 hour (Mean)
Week -1Week 2Week 6
UB Combined1720.5511524.9401562.429
UB Mentholated1520.9211329.8441336.103
UB Non-Mentholated1910.6751710.7471815.382
VLN Combined1719.1511469.4961261.069
VLN Mentholated1644.1131204.5301035.064
VLN Non-Mentholated1795.7191706.8621481.693

[back to top]

Biomarkers of Exposure - Carboxyhemoglobin (COHb)

Blood will be drawn to evaluate COHb before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: Week -1, and at 2 and 6 weeks.

,,,,,
Intervention% Saturation (Mean)
Week -1Week 2Week 6
UB Combined5.335.495.07
UB Mentholated5.415.594.61
UB Non-Mentholated5.255.405.56
VLN Combined5.956.365.31
VLN Mentholated5.695.554.63
VLN Non-Mentholated6.207.105.97

[back to top]

Biomarkers of Exposure - S-phenylmercapturic Acid (S-PMA)

Total 24 hour urine will be collected to evaluate changes in S-PMA (benzene biomarker) before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2 and 6 weeks.

,,,,,
Interventionµg/24 hour (Mean)
Week -1Week 2Week 6
UB Combined8.0837.6447.042
UB Mentholated8.2397.7316.845
UB Non-Mentholated7.9357.5617.261
VLN Combined6.8507.4866.446
VLN Mentholated6.5616.7345.589
VLN Non-Mentholated7.1448.1607.282

[back to top]

Subjective Effects - Minnesota Nicotine Withdrawal Scale - Revised (MNWS-R)

Subjects will answer a MNWS-R questionnaire. The MNWS is considered as the briefest scale among the self-report measures of nicotine withdrawal symptoms currently available. The original MNWS was developed by Hughes and Hatsukami in 1986. It consisted of nine nicotine withdrawal symptoms including craving. The scale was modified to reflect changes made in the fourth edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for nicotine withdrawal. The total score of the scale range from 0 to 36 depending on participant's rate for the symptoms as not present (0), slight (1), mild (2), moderate (3), and severe (4). A high total score implies high nicotine addiction. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2, 4, and 6 weeks.

,,,,,
Interventionscore on a scale (Mean)
Week -1Week 2Week 4Week 6
UB Combined9.98.68.17.9
UB Mentholated9.29.07.88.3
UB Non-Mentholated10.68.18.47.5
VLN Combined10.612.310.19.5
VLN Mentholated13.016.013.513.4
VLN Non-Mentholated8.18.46.55.4

[back to top]

Biomarkers of Exposure - Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1 Butanol (NNAL)

Total 24 hour urine will be collected to evaluate changes in NNAL (4-methylnitrosamino)-1-3-pyridyl)-1-butanone biomarker) before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2 and 6 weeks.

,,,,,
Interventionng/24 hour (Mean)
Week -1Week 2Week 6
UB Combined548.658521.037517.997
UB Mentholated479.979458.036431.458
UB Non-Mentholated614.06581.039614.717
VLN Combined502.500266.766309.833
VLN Mentholated423.752214.139240.970
VLN Non-Mentholated582.855313.911377.057

[back to top]

Biomarkers of Exposure - Total N-Nitrosonornicotine (NNN)

Total 24 hour urine will be collected to evaluate changes in NNN before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2 and 6 weeks.

,,,,,
Interventionng/24 hour (Mean)
Week -1Week 2Week 6
UB Combined18.23716.52315.373
UB Mentholated13.64112.0249.359
UB Non-Mentholated22.61420.80922.095
VLN Combined16.18111.79210.643
VLN Mentholated12.3709.0526.382
VLN Non-Mentholated20.07014.24614.803

[back to top]

Biomarkers of Exposure - Total Nicotine Equivalents

Total 24 hour urine will be collected to evaluate changes in total nicotine equivalents before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per post-switch Arms/Group randomization (instead of pre-switch Arms/Group assignment). (NCT03571724)
Timeframe: -1 week, and at 2 and 6 weeks.

,,,,,
Interventionmg/24 hour (Mean)
Week -1Week 2Week 6
UB Combined16.85216.14115.888
UB Mentholated15.92815.27914.418
UB Non-Mentholated17.73216.96217.530
VLN Combined16.6904.5597.989
VLN Mentholated15.8853.6166.800
VLN Non-Mentholated17.5115.4049.150

[back to top]

Biomarkers of Exposure -Cotinine

Blood will be drawn to evaluate cotinine levels before, during, and after switching to VLN cigarettes. The baseline data were collected for participants at Week -1, and Week -1 data are reported per pre-switch Arms/Group assignment. (NCT03571724)
Timeframe: Week -1, and at 2 and 6 weeks.

,
Interventionng/mL (Mean)
Week 2Week 6
VLN Mentholated58.7110.1
VLN Non-Mentholated58.8102.0

[back to top]

Proportion of Participants Susceptible to Using Little Cigar/Cigarillos (LCC) After Shopping in the StoreLab (Non-flavored)

"Self-report items: Do you think you will try an unflavored cigarillos/filtered cigar soon?, Do you think you will use an unflavored cigarillos/filtered cigar anytime in the next year?; and If one of your best friends offered you an unflavored cigarillos/filtered cigar, would you use it?. Responses to each item were made on a 1 (Definitely Not) to 10 (Definitely Yes) scale and the three items were summed. The total scale score was dichotomized: those who scored a '3' were recoded as '0' (not susceptible) and any scores greater than '3' were coded as '1' (susceptible). Outcome is proportion of participants susceptible to using LCCs after shopping in the StoreLab (number susceptible over the total number of participants within condition)." (NCT04259749)
Timeframe: There is one visit in this research: This variable is assessed at that visit, immediately after the experimental manipulation.

Interventionproportion of participants (Number)
Status Quo.09
Flavors Banned.10
Flavors and Menthol Banned.17

[back to top]

Proportion of Participants Susceptible to Using Little Cigar/Cigarillos (LCC) After Shopping in the StoreLab (Menthol-flavored)

"Self-report items: Do you think you will try a cigarillos/filtered cigar flavored with menthol or mint soon?, Do you think you will use a cigarillos/filtered cigar flavored with menthol or mint anytime in the next year?; and If one of your best friends offered you a cigarillos/filtered cigar flavored with menthol or mint would you use it?. Responses to each item were made on a 1 (Definitely Not) to 10 (Definitely Yes) scale and the three items were summed. The total scale score was dichotomized: those who scored a '3' were recoded as '0' (not susceptible) and any scores greater than '3' were coded as '1' (susceptible). Outcome is proportion of participants susceptible to using LCCs after shopping in the StoreLab (number of susceptible over number in condition)." (NCT04259749)
Timeframe: There is one visit in this research: This variable is assessed at that visit, immediately after the experimental manipulation.

Interventionproportion of participants (Number)
Status Quo.10
Flavors Banned.13
Flavors and Menthol Banned.21

[back to top]

Proportion of Participants Susceptible to Using Electronic Nicotine Delivery Device (ENDS) After Shopping in the StoreLab (Sweet-flavored)

"Self-report items: Do you think you will try a vaping product flavored with fruit, candy, alcohol or non-alcohol drink, or some other sweet flavor soon?, Do you think you will use a vaping product flavored with fruit, candy, alcohol or non-alcohol drink, or some other sweet flavor anytime in the next year?; and If one of your best friends offered you a vaping product flavored with fruit, candy, alcohol or non-alcohol drink, or some other sweet flavor, would you use it?. Responses to each item were made on a 1 (Definitely Not) to 10 (Definitely Yes) scale and the three items were summed. The total scaled score was dichotomized: those who scored a '3' were recoded as '0' (not susceptible) and any scores greater than '3' were coded as '1' (susceptible). Proportion of susceptible participants was the outcome (number susceptible over the total number of participants within condition)." (NCT04259749)
Timeframe: There is one visit in this research: This variable is assessed at that visit, immediately after the experimental manipulation.

Interventionproportion of participants (Number)
Status Quo.34
Flavors Banned.35
Flavors and Menthol Banned.42

[back to top]

Proportion of Participants Susceptible to Using Electronic Nicotine Delivery Device (ENDS) After Shopping in the StoreLab (Non-flavored)

"Self-report items: Do you think you will try an unflavored vaping product soon?, Do you think you will use an unflavored vaping product anytime in the next year?; and If one of your best friends offered you an unflavored vaping product would you use it?. Responses to each item were made on a 1 (Definitely Not) to 10 (Definitely Yes) scale and the three items were summed. The total scale score was dichotomized: those who scored a '3' were recoded as '0' (not susceptible) and any scores greater than '3' were coded as '1' (susceptible). Outcome is number of participants susceptible to using ENDS after shopping in the StoreLab (non-flavored). Proportion of susceptible participants was the outcome (number susceptible over the total number of participants within condition)." (NCT04259749)
Timeframe: There is one visit in this research: This variable is assessed at that visit, immediately after the experimental manipulation.

Interventionproportion of participants (Number)
Status Quo.17
Flavors Banned.23
Flavors and Menthol Banned.34

[back to top]

Proportion of Participants Susceptible to Using Little Cigar/Cigarillos (LCC) After Shopping in the StoreLab (Sweet-flavored)

"Self-report items: Do you think you will try a cigarillos/filtered cigar flavored with fruit, candy, alcohol or some other sweet flavor soon?, Do you think you will use a cigarillos/filtered cigar flavored with fruit, candy, alcohol or some other sweet flavor anytime in the next year?; and If one of your best friends offered you a cigarillos/filtered cigar flavored with fruit, candy, alcohol or some other sweet flavor would you use it?. Responses to each item were made on a 1 (Definitely Not) to 10 (Definitely Yes) scale and the three items were summed. The total scale score was dichotomized: those who scored a '3' were recoded as '0' (not susceptible) and any scores greater than '3' were coded as '1' (susceptible). Proportion of susceptible participants was the outcome (number susceptible over the total number of participants within condition)." (NCT04259749)
Timeframe: There is one visit in this research: This variable is assessed at that visit, immediately after the experimental manipulation.

Interventionproportion of participants (Number)
Status Quo.10
Flavors Banned.16
Flavors and Menthol Banned.25

[back to top]

Proportion of Participants Susceptible to Smoking Cigarettes After Shopping in the StoreLab (Non-flavored)

"Self-report items: Do you think you will try an unflavored cigarette (unflavored = cigarettes without menthol or mint) anytime soon?, Do you think you will smoke an unflavored cigarette (unflavored = cigarettes without menthol or mint) anytime in the next year?; and If one of your best friends offered you an unflavored cigarette (unflavored = cigarettes without menthol or mint), would you smoke it?. Responses to each item are made on a 1 (Definitely Not) to 10 (Definitely Yes) scale and the three items were summed for a total scale score. The total scale score was dichotomized: those who scored a '3' were recoded as '0' (not susceptible) and any scores greater than '3' were coded as '1' (susceptible). Proportion of susceptible participants was the outcome (number susceptible over the total number of participants within condition)." (NCT04259749)
Timeframe: There is one visit in this research: This variable is assessed at that visit, immediately after the experimental manipulation.

Interventionproportion of participants (Number)
Status Quo.18
Flavors Banned.23
Flavors and Menthol Banned.33

[back to top]

Proportion of Participants Susceptible to Smoking Cigarettes After Shopping in the StoreLab (Menthol)

"Self-report items: Do you think you will try a cigarette flavored with menthol or mint anytime soon?, Do you think you will smoke a cigarette flavored with menthol or mint anytime in the next year?; and If one of your best friends offered you a cigarette flavored with menthol or mint, would you smoke it?. Responses to each item were made on a 1 (Definitely Not) to 10 (Definitely Yes) scale and the three items were summed. The total scale score was dichotomized: those who scored a '3' were recoded as '0' (not susceptible) and any scores greater than '3' were coded as '1' (susceptible). Proportion of susceptible participants was the outcome (number susceptible over the total number of participants within condition)." (NCT04259749)
Timeframe: There is one visit in this research: This variable is assessed at that visit, immediately after the experimental manipulation.

Interventionproportion of participants (Number)
Status Quo.13
Flavors Banned.19
Flavors and Menthol Banned.33

[back to top]

Proportion of Participants Susceptible to Using Smokeless Tobacco After Shopping in the StoreLab (Menthol-flavored)

"Self-report items: Do you think you will try smokeless tobacco flavored with menthol, mint, spearmint, or wintergreen soon?, Do you think you will use smokeless tobacco flavored with menthol, mint, spearmint, or wintergreen anytime in the next year?; and If one of your best friends offered you smokeless tobacco flavored with menthol, mint, spearmint, or wintergreen, would you use it?. Responses to each item were made on a 1 (Definitely Not) to 10 (Definitely Yes) scale and the three items were summed. The total scale score was dichotomized: those who scored a '3' were recoded as '0' (not susceptible) and any scores greater than '3' were coded as '1' (susceptible). Proportion of susceptible participants was the outcome (number susceptible over the total number of participants within condition)." (NCT04259749)
Timeframe: There is one visit in this research: This variable is assessed at that visit, immediately after the experimental manipulation.

Interventionproportion of participants (Number)
Status Quo.27
Flavors Banned.39
Flavors and Menthol Banned.43

[back to top]

Proportion of Participants Susceptible to Using Smokeless Tobacco After Shopping in the StoreLab (Sweet-flavored)

"Self-report items: Do you think you will try smokeless tobacco flavored with fruit soon?, Do you think you will use smokeless tobacco flavored with fruit anytime in the next year?; and If one of your best friends offered you smokeless tobacco flavored with fruit, would you use it?. Responses to each item were made on a 1 (Definitely Not) to 10 (Definitely Yes) scale and the three items were summed. The total scale score was dichotomized: those who scored a '3' were recoded as '0' (not susceptible) and any scores greater than '3' were coded as '1' (susceptible). Proportion of susceptible participants was the outcome (number susceptible over the total number of participants within condition)." (NCT04259749)
Timeframe: There is one visit in this research: This variable is assessed at that visit, immediately after the experimental manipulation.

Interventionproportion of participants (Number)
Status Quo.09
Flavors Banned.10
Flavors and Menthol Banned.20

[back to top]

Proportion of Participants Susceptible to Using Smokeless Tobacco After Shopping in the StoreLab (Non-flavored)

"Self-report items: Do you think you will try unflavored smokeless tobacco soon?, Do you think you will use unflavored smokeless tobacco anytime in the next year?; and If one of your best friends offered you unflavored smokeless tobacco, would you use it?. Responses to each item were made on a 1 (Definitely Not) to 10 (Definitely Yes) scale and the three items were summed. The total scale score was dichotomized: those who scored a '3' were recoded as '0' (not susceptible) and any scores greater than '3' were coded as '1' (susceptible). Proportion of susceptible participants was the outcome (number susceptible over the total number of participants within condition)." (NCT04259749)
Timeframe: There is one visit in this research: This variable is assessed at that visit, immediately after the experimental manipulation.

Interventionproportion of participants (Number)
Status Quo.06
Flavors Banned.07
Flavors and Menthol Banned.12

[back to top]

Proportion of Participants Susceptible to Using Electronic Nicotine Delivery Device (ENDS) After Shopping in the StoreLab (Menthol-flavored)

"Self-report items: Do you think you will try a vaping product flavored with menthol or mint soon?, Do you think you will use a vaping product flavored with menthol or mint anytime in the next year?; and If one of your best friends offered you a vaping product flavored with menthol or mint, would you use it?. Responses to each item were made on a 1 (Definitely Not) to 10 (Definitely Yes) scale and the three items were summed. The total scale score was dichotomized: those who scored a '3' were recoded as '0' (not susceptible) and any scores greater than '3' were coded as '1' (susceptible). Proportion of susceptible participants was the outcome (number susceptible over the total number of participants within condition)." (NCT04259749)
Timeframe: There is one visit in this research: This variable is assessed at that visit, immediately after the experimental manipulation.

Interventionproportion of participants (Number)
Status Quo.27
Flavors Banned.39
Flavors and Menthol Banned.43

[back to top]